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1. Introduction
In the 1970s and 1980s the role of L-glutamate as the major excitatory neurotransmitter in the
central nervous system (CNS) was accepted. In fact, it is believed that 70% of the excitatory
synapses in the CNS are utilizing L-glutamate as neurotransmitter. The rising interest in
excitatory amino acids function has led to the identification and cloning of several subtypes of
metabotrobic and ionotropic glutamate receptors and glutamate has proved to play a dual role
in the brain. Glutamate and its receptors are involved in physiological processes like learning
and memory as well as in neurodegenerative diseases. Since the synthesis of N-methyl-D-
aspartate by J.C. Watkins in the 1960s, and subsequent pharmacological studies by a number
of groups, NMDA receptors have emerged to play a key role in neuronal excitation and
toxicity. The present work has focussed on heterologous expression of recombinant NMDA
receptors in mammalian cell lines and the development of functional in vitro test systems for
compound testing.
1.1  Glutamate receptors within the CNS
Glutamate receptors are found throughout the mammalian brain. The longest known and best–
studied glutamate receptors are ligand gated ion channels, also called ionotropic glutamate
receptors, which are permeable for cations. They have traditionally been classified into three
broad subtypes of receptors based on the discovery of selective agonists: α–amino–3–
hydroxy–5-methyl-4-isoxazole propionate (AMPA) receptors, kainate (KA) receptors, and N–
methyl–D–aspartate (NMDA) receptors.
AMPA receptors (GluR1–4) are mainly located on the postsynaptic membrane. They form
voltage–independent ligand gated channels and are mediating the fast glutamatergic
neurotransmission. Under participation of the widely distributed GluR2 subunit, AMPA
receptors exhibit a high permeability for sodium and potassium and only a weak calcium
permeability. If GluR2 is removed from heteromeric assemblies, the resulting receptors
display a substantial calcium permeability. Thus, GluR2 dominantly determines the channel
conductance and calcium permeation. GluR2 (as well as KA receptor subunits GluR5 and 6)
contains an arginine residue within the channel forming region, whereas the other three
subunits carry a glutamine residue in the corresponding position (Q / R site). Site-directed
mutagenesis revealed that the distinct channel properties are indeed determined by this
arginine or glutamine residue  (Burnashev et al., 1992a; Hume et al., 1991). Even moreIntroduction
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surprising was the finding that a glutamine codon (CAG) is encoded at the Gln / Arg position
in the genomic sequence for all subunits (AMPA and kainate) whereas an Arg codon (CGG)
is found in cDNAs of the GluR2 (as well as in GluR5 and 6)(Sommer et al., 1991). This
alteration was explained by an RNA editing mechanism, the enzyme–directed,
posttranscriptional modification of RNA transcripts.
Native, postsynaptic NMDA receptors form highly regulated channels underlying a variety of
modulations, e.g. block by extracellular magnesium at resting potentials, simultaneous
stimulation by L-glutamate and glycine, slow depolarisation and modulation by polyamines,
histamine, protons and zinc ions. They are supposed to contribute to higher brain functions as
synaptic plasticity, learning and memory function. Depending on their subunit composition,
the resulting channels are highly permeable for calcium as well as for sodium and potassium.
For further details see chapter 1.2.
Only very little is known about KA receptors (GluR5 to 7). Similar to AMPA receptors they
show only weak permeability for calcium and seem to play a role in presynaptic regulation.
Beside these ionotropic receptors, a group of G–protein coupled receptors has been cloned,
also called metabotropic glutamate receptors (mGluR1 to 8). They seem to have modulatory
effects upon excitatory neurotransmission. The subtypes of mGluR1 and mGluR5 are coupled
to phospholipase C and lead to an intracellular release of calcium from the endoplasmatic
reticulum via IP3. In contrast mGluR2–4 and mGluR6–8 are coupled to adenylate cyclase
negatively modulating activity of voltage dependent calcium channels. Antagonists at
mGluR1 and mGluR5 as well as agonists at mGluR2–4 and mGluR6–8 have been
demonstrated to be neuroprotective in ischemic animal models.
The cross–talk of these different receptors in glutamatergic neurotransmission has
implications for brain function. Summerizing, the AMPA receptors evoke fast, voltage
independent synaptic responses and in turn promote the activation of voltage dependent
NMDA receptors. The metabotropic subtypes exert long lasting actions through the activation
and inhibition of intracellular signals.
1.2  Structure and function of the NMDA receptor Channel
As this work is focussed on the expression of NMDA receptors, their structure and function is
introduced in the following sections.Introduction
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1.2.1  Molecular diversity, nomenclature and primary structure
The most important result from molecular cloning studies was the elucidation of the diversity
of the NMDA receptor channel (Ikeda et al., 1992; Ishii et al., 1993; Kutsuwada et al., 1992;
Meguro et al., 1992; Monyer et al., 1992; Moriyoshi et al., 1991; Yamazaki et al., 1992). The
identified subunits have distinct distribution throughout the brain, distinct properties and
modulation sites. This implies that NMDA receptors are different in their molecular
architecture and function, depending on the brain regions and developmental stages (Mishina
et al., 1993; Monyer et al., 1992).
Gene Species protein
Size (aa)
MW
(kDa)
References
NR1 rat 920 103 (Moriyoshi et al., 1991)
mouse (ζ1) 920 (Yamazaki et al., 1992)
human 920 (Karp et al., 1993; Le Bourdelles et al., 1994;
Planells-Cases et al., 1993)
NR2A rat 1442 163 (Monyer et al., 1992)
mouse (ε1) 1442 (Meguro et al., 1992)
human 1464 (Hess et al., 1996; Le Bourdelles et al., 1994)
NR2B rat 1456 162 (Monyer et al., 1992)
mouse (ε2) 1456 (Kutsuwada et al., 1992)
human 1484 (Adams et al., 1995; Hess et al., 1996)
NR2C rat 1218 134 (Monyer et al., 1992)
mouse (ε3) 1220 (Kutsuwada et al., 1992)
human 1233 (Lin et al., 1996)
NR2D rat 1329 141 (Ishii et al., 1993)
mouse (ε4) 1296 (Ikeda et al., 1992)
human 1336 (Hess et al., 1998)
NR3A
(NMDAR-L)
rat 1115 (Sucher et al., 1995b)
Tab. 1 Cloned NMDA receptors
The identified NMDA receptor subunits (see tab.1) share a 22 to 26% homology in amino
acid sequence with AMPA or KA receptors and are classified into three subfamilies
designated as NR1, NR2 (for mouse receptors GluRζ and GluRε) and the recently detected
NR3. There are four on separate genes encoded members for the NR2 (GluRε) subfamily
(NR2A-NR2D / GluRε1-GluRε4), whereas only one member is known for NR1 (GluRζ)Introduction
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except for the seven splice variants. The amino acid sequence identity among the NR1 and
NR2 subfamilies is approximately 26%. Within the NR2 subfamily a homology of 42 to 56%
is found (Hollmann and Heinemann, 1994). The amino acid sequence identity between human
receptors and cDNAs from mouse and rat is 95 to 100%.
For NR1 subunits eight splice forms from NR1-1a to NR1-4b have been described. The
alternative splice variants differ by the presence or absence of three nucleotide cassettes into
the NR1 sequence (see tab. 2). The first N-terminal cassette inserts 21 predominant basic
amino acids after residue 190. This cassette is present in splice forms NR1b / 2b / 3b / 4b. Its
absence in NR1-1a / 2a / 3a / 4a is one requirement for polyamine modulation of receptors.
Deletion of C–terminal cassette 2 removes 37 amino acids after residue 863. Deletion of
cassette 3 removes 38 amino acids and the stop codon, resulting in a new 22 amino acid
carboxy terminal end. The most common transcripts in brain contain cassette 2 and / or 3, but
not cassette 1 (NR1-1a to NR4a).
Tab. 2 Presence and absence of N–terminale and C–terminale cassettes in the different
splice variants of the NR1 subunit and related nomenclature after Nakanishi (Nakanishi et al.,
1992) and Zukin & Bennett (Durand et al., 1993).
Nakanishi Zukin & Bennett cassette 1
(N-term.)
cassette 2
(C-term.)
cassette 3
(C-term)
NR1-1a NR1011 -++
NR1-2a NR1001 --+
NR1-3a NR1010 -+-
NR1-4a NR1000 ---
NR1-1b NR1111 +++
NR1-2b NR1101 +-+
NR1-3b NR1110 ++-
NR1-4b NR1100 +--
The recently discovered subunit NR3A (formerly termed NMDAR-L or chi-1) is expressed
primarily during brain development. NR3A seems to be a regulatory NMDA receptor subunit
during brain development since genetic knockout of NR3A in mice results in enhanced
NMDA responses and increased dendritic spines in early postnatal cerebrocortical neuronsIntroduction
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(Das et al., 1998). Under co-expression with NR1 / NR2 subunits in Xenopus Oocytes, NR3A
attenuates NMDA receptor currents but has no effect when tested with non-NMDA receptors
or expressed alone (Sucker et al., 1995a).
1.2.2 Heteromeric  channels
Native NMDA receptors are thought to consist of an association between multiple distinct
subunits. Many differences in the functional properties of NMDA receptors are observed in
electrophysiological and pharmacological studies with recombinant receptors depending on
the used subunits to generate the glutamate gated ion channels. Although it was found that in
Xenopus laevis oocytes expression of only one single splice variant of the NR1 subunit
generates a functional ion channel regulated by glutamate and glycine (Durand et al., 1992;
Moriyoshi et al., 1991) and expression of single NR2 subunits will not, in mammalian cell
lines functional channels are not detected upon single NR1 expression (McIlhinney et al.,
1996). For mammalian cell lines functional recombinant receptors most similar to native
NMDA receptors are obtained by co–expression of both NR1 and NR2 subunits. This
observation leads to the conclusion that native NMDA receptors are heterooligomeric proteins
assembled using NR1 and NR2 subunits in currently unknown ratios and stoechiometries
(although there seems to be some evidence for a tetrameric structure (Laube et al., 1998)).
This is supported by the reported localization models of the distinct glutamate and glycine
binding sites on NR2 and NR1, respectively. The major determinants for glutamate binding
are localized in the N–terminal extracellular domain and the M3-M4 loop region of the NR2
subunit (Laube et al., 1997). Similar features were found for the glycine binding site localized
on the NR1 subunit (Hirai et al., 1996b; Kuryatov et al., 1994; Laube et al., 1997; Wood et al.,
1997).
All these results were obtained from recombinant receptor expression systems. Using
immunoprecipitation and quantitative immunoblot analysis of subunits NR1 / NR2A / NR2B,
it was found that the majority of NMDA receptor complexes in the adult rat cerebral cortex
contains at least three different subunits (Luo et al., 1997). A smaller fraction was composed
of only two subunits, NR1 / NR2B or NR1 / NR2A and no complexes were found that
contained NR2A / NR2B and do not contain NR1. As well, fractions of unassembled NR2A
and NR2B were detected.Introduction
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1.2.3 Transmembrane  topology
Alternative models of the transmembrane topology of ionotropic glutamate receptors have
been proposed for NR1 (Moriyoshi et al., 1991) and AMPA / KA receptors (Hollmann et al.,
1994) (Bennett and Dingledine, 1995). The currently accepted consensus model for ionotropic
glutamate receptor subunits (Hirai et al., 1996b) is shown in fig. 1. It consists of a three
transmembrane structure (M1 / M3 / M4) with an extracellular located N–terminal region and
an intracellular C–term. The M2 domain forms an intramembrane reentry loop which
contributes to the channel pore region. The M3–M4 loop has an extracellular location. For
NMDA receptors, a contribution of the M3–M4 loop to the glycine binding site at NR1 and
the glutamate binding site at NR2 has been reported (Laube et al., 1997).
Fig. 1 Transmembrane topology of ionotropic glutamate receptors
NMDA receptors recognition sites are displayed in fig. 2. The co–agonists L-glutamate and
glycine (or D-serine) bind to recognition sites on distinct subunits. The binding site for L-
glutamate or the specific agonist N–methyl–D–aspartate is located on subunit NR2 whereas
the binding domain of glycine or D–serine has a distinct location on subunit NR1. Under
resting membrane potentials the channel is blocked by extracellular magnesium. Polyamines
such as spermine or spermidine are positive modulators if the contributing NR1 splice variantIntroduction
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is lacking the N–terminale cassette. At higher concentration levels polyamines can either
block the receptor channel. Open channels mediate influx of sodium and calcium ions as well
as efflux of potassium. Synthetic compounds such as MK801, ketamine, dextromethorphan,
phencyclidine and memantine block the open channel in a non-competitive manner. Channel
opening is either blocked by competitive antagonists like 2–amino–5–phosphono–pentanoic
acid (AP5), 4–(3–phosphonopropyl)piperazine–2–carboxylic acid (CPP) for the glutamate
recognition site or by glycine site antagonists such as 5,7–dichloro–kynurenic acid (DCKA)
or L–701,324. Splice variants of NR1 provide phosphorylation domains for protein kinase C
(PKC). Phosphorylation on serine residues decreases receptors inhibition by calmodulin. Zn
2+
negatively modulates receptor activity in a voltage-dependent and independent manner. In
addition, receptors are influenced by redox agents and protons. More details concerning the
mentioned recognition sites are given in the following sections.
Fig. 2 Recognition sites of the NMDA receptorIntroduction
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1.2.4  Channel pore region
The putative channel forming region consists of the membrane domain M2 (see fig. 1). High
permeability for calcium ions and sensitivity to channel block by extracellular Mg
2+ are
mediated by an asparagine residue within the M2 domain of NR1 and NR2 (Burnashev et al.,
1992b). This asparagine is in a position homologous to the so called Q / R site of the AMPA /
KA receptors (see section 1.1), that is occupied by either glutamine or arginine and that
controls divalent cation permeability of the AMPA / KA receptors. Replacement of either
glutamine or arginine with asparagine led to altered AMPA channels with a high permeability
for calcium compared to magnesium (Burnashev et al., 1992a). Replacement of the respective
asparagine in NR1 (N598Q) reduced calcium permeability in NR1 (N598Q) / NR2A
assemblies. Substitution of the homologous asparagine in NR2A (N595Q) led to reduced
magnesium block in NR1 / NR2A (N595Q) assemblies (Mori et al., 1992) (Sakurada et al.,
1993). This suggests that the asparagines of both subunits form the selectivity filter of the
NMDA receptor for both magnesium and calcium ions. These findings are of a special
relevance since the high calcium permeability and the voltage dependent block by
extracellular magnesium are thought to be important for the function of NMDA receptors in
mediating long term changes in synaptic plasticity. In addition, it was found that substitution
of asparagine 598 in NR1 strongly reduced the sensitivity to blockade by ketamine and
phencyclidine (Yamakura et al., 1993a) whereas the sensitivity to MK801 was only slightly
affected. For MK801 resistance asparagine mutations in both subunits were required. Hence,
these results suggest a common recognition site for open channel blockers and magnesium
within the channel forming region M2.
1.2.5  Ligand binding regions
Besides saturating concentrations of L–glutamate, maximum activation of NMDA receptor
channels requires co–agonism of glycine. This effect of glycine was first observed in mouse
brain neurons (Johnson and Ascher, 1987). D–alanine and especially D–serine were found to
mimic the effects of glycine (Kleckner and Dingledine, 1988). Site-directed mutagenesis of
the NR1 subunit revealed that aromatic residues at positions 390, 392, and 466 localized in a
domain preceding the M1 membrane segment are crucial determinants of glycine binding.
Glutamate efficacy was little affected by mutations at these positions (Kuryatov et al., 1994).
Mutations to aspartate 481 and lysine 483 produced receptors with up to 160-fold lower
affinities for glycine, as well as other agonists and partial agonists, without affectingIntroduction
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maximum current size or the degree of agonist efficacy (Wafford et al., 1995). Contribution
of the M3–M4 loop to the glycine recognition site was shown by substitution of the
phenylalanine residues at positions 735 and 736. Mutation of both residues caused a >100-
fold decrease in glycine affinity (Hirai et al., 1996a). Interestingly the mutated residues in
both domains (M1 preceding domain and M3-M4 loop) correspond to positions forming the
binding site of homologous bacterial amino acid-binding proteins, in particular the glutamine-
binding protein from E. coli and LAOBP (leucine alanine ornithine binding protein). These
findings have suggested a phylogenetically conserved amino acid–binding fold.
It should be noted that NR2 subunits contribute to the affinity of glycine. Homomeric NR1
receptors exhibit Ki values for glycine from 1 to 5µM whereas heteromeric receptors display
Ki values in the nanomolar range (Grimwood et al., 1995).
The location of the glutamate binding site on the NR2B subunit has recently been
demonstrated (Laube et al., 1997). The glutamate site is located in homologous regions
compared to the glycine site on NR1. Mutation of residues within the N-terminal domain and
the loop region between membrane segments M3 and M4 significantly reduced the efficacy of
glutamate in channel gating. 
Homology-based molecular modelling of the glutamate and glycine binding domains are
indicating that the NR2B and NR1 subunits use similar residues to ligate the agonist´s α–
aminocarboxylic acid groups, whereas differences in side chain interactions and size of
aromatic residues determine ligand selectivity. In the model of the NR1 subunit ligated to
glycine, the carboxyl group of glycine interacts with arginine 505 and threonine 500, whereas
the amino group is hydrogen bonded to glutamine 387 and the backbone carbonyl group of
proline 498. These binding residues are very similar to those of L-glutamate in NR2B, where
the α–carboxyl group interacts with arginine 493 and threonine 488 and the amino group of
L-glutamate is hydrogen bonded to glutamate 387 and the backbone carbonyl group of serine
486. The γ–carboxyl group of L-glutamate forms a salt bridge with arginine 493 and can
interact with lysine 463 and arginine 667.
1.2.6 Phosphorylation  domain
In neurons and transfected Hek 293 cells, phosphorylation domains have been detected on the
C–terminal domain of NR1 (Tingley et al., 1993). PKC phosphorylation occurred on several
distinct sites on the NR1 subunit. Splice variants differed in the extent to which they could be
potentiated by activators of protein kinase C (PKC) from 3- to 20-fold. Presence of the N-
terminal insert and absence of the C-terminal sequences increased potentiation by PKCIntroduction
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(Durand et al., 1993). These results demonstrate that alternative splicing of the NR1
messenger RNA regulates its phosphorylation by PKC, and that mRNA splicing is a
mechanism for regulating the sensitivity of glutamate receptors to protein phosphorylation.
Using the yeast two-hybrid system, it was found that calmodulin interacts with the C–
terminus of the NR1 subunit and inactivates the channels in a calcium-dependent manner.
Protein kinase C (PKC)-mediated phosphorylation on serine residues of NR1 decreases its
affinity for calmodulin (Hisatsune et al., 1997). This suggests that PKC-mediated
phosphorylation of NR1 prevents calmodulin from binding to the NR1 subunit and thereby
inhibits the inactivation of NMDA receptors by calmodulin.
However, it has been reported that the NR1 subunit is not responsible for the potentiation by
PKC activator 12-O-tetradecanoylphorbol 13-acetate (TPA) treatment in Xenopus oocytes
(Yamakura et al., 1993b). Treatment with TPA potentiated the response to GluRζ1 / GluRε1
and GluRζ1 / GluRε2, but not in GluRζ1 / GluRε3 and GluRζ1 / GluRε4 assemblies
(Kutsuwada et al., 1992; Mori et al., 1993). Functional analysis of chimeric receptors
demonstrated that the C–terminal region of GluRε2 is responsible for the potentiation of
GluRζ1 / GluRε2 receptors by treatment with TPA.
Additionally, protein-tyrosine kinases (PTKs) and protein-tyrosine phosphatases (PTPs) are
highly expressed in the central nervous system. They represent key enzymes in signal-
transduction. They are involved in the regulation of neurotransmitter receptors. Some
evidence was found that in the CNS tyrosine phosphorylation regulates the function of
NMDA receptors (Wang and Salter, 1994).
1.2.7 Allosteric  modulation  regions
NMDA receptor channel activity is influenced by various allosteric modulators. Modulating
effects of protons, polyamines, histamine, redox agents, Zn
2+ and Mg
2+ ions are described in
the next sections.
1.2.7.1 Proton  inhibition
Sensitivity of NMDA receptors in cerebellar neurons to protons has been described (Traynelis
and Cull-Candy, 1990). NMDA receptor responses was selectively inhibited by protons, with
a 50% inhibitory concentration of pH 7.3 that was close to physiological pH 7.4, implying
that NMDA receptors are not fully active under normal conditions. (S)-AMPA and kainate
responses remained unchanged at similar pH levels. Proton inhibition was voltage-insensitive
and did not result either from fast channel block, a change in channel conductance, or an
increase in the 50% excitatory concentration (EC50) of aspartate/NMDA or glycine. Instead,Introduction
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protons seemed to decrease markedly the opening frequency of NMDA channels. Studies with
recombinant receptors revealed that the proton sensitivity of NMDA receptors depends on the
contributing splice variants of NR1 (Traynelis et al., 1995). Splice variants lacking the N–
terminal cassette (exon 5) such as NR1-1a are much more sensitive to proton inhibition (IC50
pH 7.3) compared to those containing exon 5 (IC50 pH 6.8).
1.2.7.2  Modulation by polyamines
Polyamines such as spermine, spermidine and putrescine are endogenous compounds in the
CNS, although their function in the brain is largely unknown. These compounds modulate
NMDA receptor activity by at least three distinct mechanisms, maybe occurring at distinct
recognition sites. (i) Under subsaturating concentrations of glycine, polyamines are increasing
receptor’s affinity for the co–agonist (glycine–dependent stimulation). (ii) Under saturating
glycine concentrations they potentiate receptor’s response (glycine–independent stimulation).
In Xenopus oocytes glycine-independent stimulation is seen at homomeric receptors with NR1
splice variants lacking the exon 5, such as NR1-1a and at heteromeric receptors containing
NR1-1a and NR2B but not at NR2A, NR2C and NR2D (Williams et al., 1994). Because the
potentiation occurs at homomeric NR1-1a receptors as well as in heteromeric NR1-1a / NR2B
receptors the polyamine binding site for this kind of modulation may be located at NR1
subunit. Using amino acid sequence identity analysis, the NR1 subunit was compared to
known sequences of bacterial polyamine binding proteins (PotD and ESAT) (Kashiwagi et al.,
1996b). Aspartate residue 669 located in the extracellular M3-M4 loop of NR1-1a was found
to control sensitivity to spermine and to protons. In the N–terminal region, residues glutamate
342 and 339 of NR1-1a have been implicated in the control of polyamine stimulation
(Williams et al., 1995). Glutamate 201, located in the N–terminal region of NR2B, was found
to contribute to the glycine–independent stimulation (Gallagher et al., 1997). Meanwhile, it
was suggested that the glycine–independent stimulation by polyamines at heteromeric NR1-
1a / NR2B receptors is caused by the relief of proton inhibition through shielding receptor’s
proton sensor (Traynelis et al., 1995). (iii) At higher concentrations (200-300µM) polyamines
block NMDA receptors in a voltage dependent manner and reduce the receptor affinity for L-
glutamate (Rock and MacDonald, 1992; Williams et al., 1995). These different effects of
polyamines may involve at least three distinct polyamine recognition sites at the receptor.Introduction
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1.2.7.3  Modulation by histamine
Histamine is a neuromodulator in the brain, and the hippocampus is one of the brain regions
that is innervated by histaminergic neurons. It has been reported that glutamate enhances
histamine release through NMDA receptors located at histaminergic nerve terminals (Okakura
et al., 1992). When applied to cultured hippocampal neurons, histamine selectively increased
the amplitude of the component of synaptic transmission that was mediated by NMDA
receptors (Bekkers, 1993). In a subpopulation of rat cortical neurones, histamine potentiated
NMDA-induced ion currents by slowing the kinetics of onset of desensitization (Zwart et al.,
1996).  These results suggest that histamine may modulate processes involving NMDA
receptors, such as the induction of long-term potentiation. In voltage-clamp records of
recombinant NMDA receptors expressed in Xenopus Oocytes, histamine potentiated
responses to NMDA (EC50 = 10 µM) at heteromeric NR1 / NR2 receptors containing splice
variants of the NR1 subunit that lack the amino-terminal insert (exon 5), together with the
NR2B subunit but not the NR2A or NR2C subunit. This effect of histamine was not blocked
by classical histamine receptor antagonists (Williams, 1994b).
1.2.7.4 Redox  modulation
Disulfide–reducing agents such as dithiothreitol (DTT) or endogenous glutathion (GSH)
potentiate NMDA receptor evoked currents in cultured neurons (Aizenmann et al., 1989). In
contrast thiol oxidizing agents such as 5,5´-dithiobis–2–nitrobenzoic acid (DNTB) inhibit
NMDA–evoked currents, but not completely. Interestingly, potentiation of NMDA–mediated
currents is not modified by N–ethyl–maleimide (NEM) which irreversibly alkylates cysteine
residues (Tang and Aizenman, 1993). Studies with recombinant receptors expressed in
Xenopus oocytes showed that homomeric assemblies consisting of subunit NR1 are not
significantly redox modulated (Omerovic et al., 1995). In contrast, heteromeric receptors are
modulated by sulfhydryl redox agents (Sullivan et al., 1994). Unexpectedly, two cysteines
(cysteine 744 and 798) in the NR1 subunit were identified to be required for redox modulation
of NMDA induced currents in oocytes expressing NR1 / NR2B, NR1 / NR2C or NR1 / NR2D
receptors. Mutation of these two cysteines also eliminated potentiation by spermine and
shifted the IC50 for proton inhibition and the EC50 for NMDA.
Redox modulation of heteromeric NR1 / NR2A receptors appeared to be different from that of
the other heteromeric receptors. NR1 / NR2A channels exhibit a reversible component of
potentiation in addition to the persistent one found with all other heteromeric assemblies
(Kohr et al., 1994). In heteromeric expressed NR1 / NR2A channels in Hek 293 cells DTT
rapidly potentiated L-glutamate-activated whole-cell currents. A part of the currentIntroduction
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potentiation disappeared upon washout (reversible component). The remaining potentiation
(persistent component) was abolished by an oxidizing agent (DNTB). In cells expressing the
NR1 / NR2B, NR2C, or NR2D channels DTT elicited only a slowly developing, persistent
potentiation and increased the deactivation time course. In these, but not in NR1 / NR2A, the
DTT effect was rendered insensitive to reoxidation by alkylation. Reduced glutathione
mimicked the DTT effects only in the NR1 / NR2A receptor. Hence, distinct NMDA receptor
assemblies differ profoundly in their responses to sulfhydryl redox agents.
As the reversible component of redox potentiation only occurs at NR1 / NR2A receptors and
the used reducing agents have also chelating abilities, the relief of tonic zinc inhibition of
NR1 / NR2A was proposed as mechanism for this reversible kind of potentiation by reducing
agents.
1.2.7.5  Inhibition by zinc
Zinc has been shown to be present in synaptic vesicles in a number of glutamatergic vesicles
and is co-released with L-glutamate during presynaptic neurotransmitter release (Xie and
Smart, 1991). In addition, zinc ions have been proposed to allosterically modulate native
NMDA receptors. Zinc inhibits NMDA receptors at two independent sites (Christine and
Choi, 1990; Legendre and Westbrook, 1990). A low affinity zinc site is located inside the
channel pore and binding of zinc to this site causes a voltage–dependent open channel block,
similar to the one exerted by magnesium. A high–affinity site is located outside the channel
on extracellular domains and causes voltage–independent inhibition of NMDA receptors.
These two effects were initially described for zinc concentrations in the micromolar range and
this fits well to the estimated zinc concentrations in the synaptic cleft following glutamate
release. Using recombinant receptors expressed in Xenopus oocytes and Hek 293 cells, the
subunit specificity of these two effects was examined (Paoletti et al., 1997). The comparison
of NR1-1a / NR2A and NR1-1a / NR2B receptors shows that the voltage-dependent inhibition
is similar in both types of receptors but that the voltage-independent inhibition occurs at much
lower zinc concentrations in NR1-1a / NR2A receptors (IC50 in the nanomolar range) than in
NR1-1a / NR2B receptors (IC50 in the micromolar range). The high affinity of the effect
observed with NR1-1a / NR2A receptors was attributed mostly to the slow dissociation of
zinc from its binding site. By analyzing the effects of zinc on varied combinations of NR1
(NR1-1a or NR1b) and NR2 (NR2A, NR2B) it was shown that both subunit families
contribute to the voltage-independent zinc inhibition (NR1-1a>NR1-1b and NR2A>NR2B).
Further it was observed that the addition of low concentrations of heavy metal chelators
(EDTA or tricine) markedly potentiates the responses of NR1-1a / NR2A receptors, but not ofIntroduction
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NR1-1a / NR2B receptors. This result suggests that traces of a heavy metal (probably zinc)
contaminate standard solutions and tonically inhibit NR1-1a / NR2A receptors. Chelation of
zinc even could account for the reversible component of redox potentiation produced by
reducing compounds like DTT or glutathione (Paoletti et al., 1997). 
Recently, it has been reported that tyrosine kinase Src potentiates NMDA receptor currents by
reducing the tonic zinc inhibition (Zheng et al., 1998). Src only acted on receptors assembled
from NR2A subunits and a restricted group of NR1 splice variants (Kohr and Seeburg, 1996).
In addition, zinc is known to be cytotoxic due to entry into the cell. Cell death in neurons
induced by exposure to zinc is increased by glutamate and can be reduced by NMDA receptor
antagonists (Koh and Choi, 1994). This suggests that zinc entries into neurons via NMDA
receptors, which appear to be both blocked by and permeable to zinc.
1.2.7.6  Effects of magnesium
Extracellular Mg
2+, which blocks NMDA channels in a voltage-dependent manner and
increases the receptors affinity for glycine, has been shown to potentiate NMDA responses at
saturating glycine concentrations. This potentiation, induced by millimolar concentrations
(EC50 = 3mM) of Mg
2+, is not mimicked by Ca
2+ and Ba
2+ and is voltage independent. The
potentiation is variable in native receptors of cultured mouse central neurons; in recombinant
receptors, this potentiation is only seen in receptors containing the NR2B subunit and
prevented by NR1 splice variants containing the N-terminal insert. Mg
2+ also induces a shift
of the pH sensitivity of NMDA receptors. These effects of Mg
2+ are quite similar to those of
spermine and suggest that Mg
2+ may be the physiological agonist acting at the subunit-
specific spermine site (Paoletti et al., 1995).
1.3 Distribution  within  the  CNS
Distribution of the NMDA receptor channel subunit mRNAs in the adult rodent brain was
examined by in situ hybridisation analysis (Akazawa et al., 1994; Ishii et al., 1993;
Kutsuwada et al., 1992; Monyer et al., 1992; Moriyoshi et al., 1991; Watanabe et al., 1992;
Watanabe et al., 1993; Watanabe et al., 1994a; Watanabe et al., 1994b; Watanabe et al.,
1994c; Watanabe et al., 1994d; Watanabe et al., 1994e). In adult rodents NR1 subunit mRNA
is distributed throughout the brain (fig. 3A) consistent with its role as the key–subunit of
NMDA receptors. NR1 subunits containing cassette 1 (exon 5) are found in most brain
regions with higher levels in the thalamus, midbrain, cortex, CA3 hippocampus and
cerebellum. Although, it should be mentioned that the most common NR1 transcripts have a
deletion of cassette 1. Cassette 2 shows high expression levels in the striatum, septum,Introduction
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cerebral cortex, hippocampus and cerebellar granule cells. The expression of NR1 transcripts
containing cassette 3 is very similar to the cassette 2 distribution with high concentrations
found throughout the cerebral cortex, hippocampus, cerebellum, striatum and septum.
The NR2A (ε1) subunit is distributed widely in the brain (fig. 3B) with higher expression
levels in the cerebral cortex, the hippocampus region and cerebellum, especially in cerebellar
granula cells. In contrast, the NR2B (ε2) subunit is only expressed in the forebrain with higher
expression levels in the cerebral cortex, hippocampus region, the septum, caudate–putamen,
the olfactory bulb  and the thalamus (fig. 3C).  The NR2C (ε3) subunit mRNA is found
predominantly in the cerebellum (fig. 3D). Higher levels of NR2D (ε4) expression are
appearing in early developmental, peri– and neonatal stages. In the adult brain lower levels of
mRNA are found in the thalamus, brainstem and the olfactory bulb (fig. 3E).
Fig. 3 Horizontal sections of the adult mouse brain with
distinct NMDA receptor subunit expressing regions (for details
see text above).
(A) oligonucleotide probes, that recognizes all NR1 splice variants.
(B)–(E) oligonucleotide probing specific for NR2A (B), NR2B (C),
NR2C (D) and NR2D (E).
Abbreviations: AC, anterior cingulate cortex; Cb, cerebellum; CPu,
caudate-putamen; Cx, cortex; Hi, hippocampus; MB, midbrain; OB,
olfactory bulb; S, septum; Th, thalamus (taken from Watanabe et al.,
1993).
It should be added, that expression of NMDA receptors is not absolutely restricted to the
brain. NMDA receptor subtypes NR1 and NR2D were briefly detected in rat and human
osteoblasts and osteoclasts, suggesting that glutamate is also involved in the signalling
pathway between bone cells and may be an important local regulator of bone cell functions.Introduction
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(Patton et al., 1998) (Chenu et al., 1998). NMDA (and non-NMDA) receptors have been
identified in pancreatic islets (Inagaki et al., 1995) modulating insulin secretion and in
unmyelinated axons in the skin (Carlton et al., 1995) suggesting that peripheral glutamate
receptors are involved in the mediation of pain.
1.4 Pharmacological diversity of native and recombinant NMDA
receptors
The NR1 and NR2 subunits represent the molecular basis for the pharmacological
heterogeneity of native NMDA receptors. It is thus significant that some of the
pharmacological properties (provided by radioligand binding studies), that distinguish
subtypes of native receptors, correlate to the presence of identified NMDA receptor subunits.
It seems, that the presence of NR2C subunits contributes to the distinct pharmacological
properties of cerebellar NMDA receptor subtypes. For example, NMDA receptor agonists
quinolinate and homoquinolinate as well as competitive antagonists bind with a lower affinity
in the cerebellum than in the forebrain (Beaton et al., 1992; Yoneda and Ogita, 1991). In was
found that, relative to NR1 / NR2A and NR1 / NR2B receptors, oocyte-expressed NR1 /
NR2C receptors had a lower affinity for both D-CPP-ene (D-3-(2-carboxypiperazin-4-yl)-1-
propenyl-1-phosphonic acid) and homoquinolinate (Buller et al., 1994). Allosteric modulation
sites of NMDA receptors in the cerebellum differ also from those in the forebrain region. The
binding of [
3H]-MK801 to NMDA receptors in the cerebellum appears to be less sensitive to
polyamine modulation (Reynolds and Palmer, 1991). This finding is consistent with a higher
amount of NR1 splice variants containing the 5´-insert expressed in the cerebellum.
Forebrain NMDA receptors can be subdivided in quantitative autoradiographic studies by
their relative affinity for agonists and antagonists. In the lateral thalamus, NMDA receptors
exhibit a higher affinity for antagonists than do NMDA receptors in the medial striatum with
unchanged rank order. Vice versa, receptors in the medial striatum have higher affinities for
agonists than do receptors from the lateral thalamus. Therefore, these populations have been
described as “antagonist“– and “agonist“–preferring receptor populations. The distribution of
NR2A mRNA is very similar to that of antagonist preferring receptors determined by [
3H]-
CPP autoradiographic studies (Buller et al., 1994), whereas NR2 subunit mRNA expressed in
the medial striatum is predominantly NR2B. Again studies of NMDA receptor subunits
expressed in Xenopus oocytes revealed the higher affinity of NR1 / NR2B assemblies forIntroduction
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agonists compared to antagonist preferring NR1 / NR2A receptor channels (Kutsuwada et al.,
1992). The reported EC50 values of the different NMDA receptor channels are given tab. 3:
Tab. 3 Reported diversity of agonists efficacy at distinct NMDA receptor channels 
EC50 values are effector concentrations for half-maximum response in electrophysiological records at
transfected Xenopus Oocytes (taken from Kutsuwada et al., 1992).
heteromeric channels
    Affinity for agonists EC50 [µM]
     L-glutamate               glycine
NR1–ζ1 / NR2A–ε1 1.7 2.1
NR1–ζ1 / NR2B–ε2 0.8 0.3
NR1–ζ1 / NR2C–ε3 0.7 0.2
NR1–ζ1 / NR2D–ε4 0.4 0.1
It should be emphasized, that beside these distinct native receptor populations, the majority of
NMDA receptors e.g. in the cortex consist of three different subunits (NR1, NR2A, NR2B)
(Luo et al., 1997) exhibiting pharmacological properties that are between those of NR1 /
NR2A and NR1 / NR2B assemblies.
Regarding recombinant receptors other pharmacological diversities are apparent. Some
functional diversities between recombinant NMDA receptor channels have already been
discussed in other sections, such as glycine–independent potentiation by polyamines of NR1-
1a / NR2B receptors (see 1.2.7.2), reversible component of redox modulation of NR1 / NR2A
channels (see 1.2.7.4) and high affinity voltage–independent zinc inhibition of NR1 / NR2A
receptors (see 1.2.7.5). Concerning the voltage–dependent block by magnesium, NR1 / NR2A
and 2B channels are more sensitive compared to NR1 / NR2C and 2D receptors. Open
channel blocker MK801 has even a higher affinity to NR1 / NR2A and 2B, whereas ketamine
and phenylcyclidine exhibit only slight variations in receptor affinity. Expression of
heteromeric NR1 / NR2 receptors in Hek 293 cells led to cell death depending on the subunit
composition (Chazot et al., 1994). Co–expression of NR1-1a / NR2A resulted in 100 % cell
death of transfected cells whereas transfection of NR1-1a / NR2C subunits apparently did not
result in significant cell death. In contrast co–transfection of all three subunits again resulted
in cell death. The rate of dying cells depended on the transfected ratio of subunits. Increasing
the proportion of NR2C to NR2A cDNA led to decreasing cell death rates.Introduction
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These results may be explained by the decreased calcium permeability of NR1 / NR2C
channels. However it has been reported that these two receptors have similar calcium
permeability (Monyer et al., 1994), but higher conductance states of NR1 / NR2A (and 2B)
receptors (Stern et al., 1992) may account for the higher cell death rate.
As mentioned in section 1.2.6, treatment with the PKC activator TPA potentiated the response
of NR1 / 2A and 2B receptors expressed in Xenopus oocytes but did not alter response of NR1
/ NR2C and 2D channels (Kutsuwada et al., 1992; Mori et al., 1993).
Compounds such as ifenprodil and haloperidol were identified to selectively inhibit NMDA
receptors containing the NR2B subunit (Chenard and Menniti, 1999). These compounds
exhibit a selectivity by inhibition of NMDA receptor responses in forebrain neurons
compared to neurons from cerebellum. More recent compounds such as CP–101,606 or Ro
25,6981 have similar abilities. Some findings, e.g. the displacement of high affinity [
3H]-
ifenprodil binding by spermine and spermidine (Carter et al., 1989; Carter et al., 1990),
indicate an interaction with the binding site involved in glycine–independent polyamine
stimulation.
Recently, glycine site antagonist CGP 61594 was shown to have some selectivity for the
NR2B subtype (Honer et al., 1998).Introduction
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1.5  Physiological and pathophysiological implications
1.5.1 Glutamatergic  neurotransmission
In brain, L-glutamate is synthesized in the nerve terminals from two sources: from glucose via
the Krebs cycle and transamination of α–ketoglutarate and from glutamine that is synthesized
in glial cells, transported into nerve terminals and locally converted by glutaminase into L-
glutamate. In the glutamate containing nerve terminals, glutamate is stored in synaptic
vesicles. Upon depolarization of the nerve terminal, it is released by a calcium–dependent
exocytotic process. At the post synaptic membrane, L–glutamate interacts with its distinct
receptors. Activation of fast depolarizing AMPA receptors causes the loss of the voltage–
dependent magnesium block within the NMDA receptor channel pore and together with its
co–agonist glycine (or D-serine), L–glutamate evokes strong calcium and sodium inward
currents. Besides the binding to ionotropic receptors, L–glutamate can activate metabotropic
glutamate receptors coupled either to PLC or to adenylate cyclase. The action of synaptic
glutamate is terminated by a high affinity uptake process via plasma membrane glutamate
transporters on presynaptic nerve terminals or on glial cells. The glutamate, taken up into glial
cells, is then converted by glutaminase into L-glutamine and transported into the neighboring
nerve terminals, where it serves as precursor for L-glutamate. In astrocytes, glutamine can
also be oxidized into α–ketoglutarate which is in turn actively transported into the neuron to
replace the α–ketoglutarate lost during the synthesis of neuronal L–glutamate.
1.5.2  Long term potentiation
The term “long–term potentiation“ (LTP) refers to a long lasting enhancement of synaptic
transmission (10 minutes to days depending on testing conditions) after a high–frequency,
high–intensity period of afferent pathway activation. The effect is measured as increased
amplitudes of excitatory postsynaptic potentials (EPPs). The transductive mechanism of
electrophysiological changes at the synaptic level has become a candidate to link learning and
cellular changes in vivo. This special form of enhanced synaptic transmission is exerted by
glutamatergic pathways and takes place in the hippocampal formation known to be involved
in functions like memory and learning. The possible involvement of NMDA receptors into
learning process raised following the finding of Collingridge et al., that NMDA receptor
activation is a critical step in the induction of hippocampal LTP (Collingridge et al., 1983). It
was assumed, that synaptic alterations mediated by NMDA receptors are underlying memory.Introduction
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Competitive antagonists like AP5 or open channel blocker MK801 offer now the
pharmacological tools to block this kind of synaptic plasticity and investigate effects upon
learning and memory. Besides this, there are possible interactions or synergisms between
NMDA receptors and mGluRs in the induction of LTP. Calcium influx via NMDA receptors
causes activation of kinases and facilitates the activation of mGluRs. Stimulation of PLC
coupled mGluRs results in the generation of diacylglycerol and inositol–1,4,5–triphosphate
(IP3) which in turn is involved in the activation of kinases and the release of calcium from
intracellular stores (endoplasmatic reticulum). Additionally, activation of mGluRs facilitates
the activation of the NMDA receptor system.
1.5.3 Clinical  implications
Several therapeutic applications have been proposed for drugs modulating excitatory amino
acid systems. In the next sections the most important proposed targets will be described.
1.5.3.1 Epilepsy
A very early observation related to the application of excitatory amino acids to the brain was
their ability to evoke convulsions and epilectic seizures (Hayashi, 1954). Therefore, some
forms of clinical epilepsy may be related to an excessive sensitivity of NMDA receptor
mediated responses. 
NMDA receptor antagonists show anticonvulsive activity in a number of seizure models. In
kindled rats, representing a model for complex partial seizures, non-competitive and
competitive NMDA receptor antagonists have only a weak efficacy at doses producing
significant motor side effects (Löscher, 1993). This was later confirmed in clinical trials with
the competitive L–glutamate antagonist D–CPP–ene (SDZ EAA–494) being poor
anticonvulsant in epileptic patients with complex seizures in doses causing side effects like
impaired concentration, sedation, depression, ataxia and amnesia (Sveinbjornsdottir et al.,
1993). These results suggest that these compounds will not be clinically useful antiepileptics
against partial and secondarily generalized seizures. 
In contrast, systemically active glycine site antagonists like L-701,324 have been reported to
prevent audiogenic seizure in DBA/2 mice (Carling et al., 1997; Kulagowski et al., 1994). A
series of tricyclic pyrido-phtalazine-diones inhibited pentylenetetrazol-, NMDA- and
maximum electroshock-induced convulsions in mice (Parsons et al., 1997a). Besides their
higher efficacy, glycine site antagonists seem to provide a more acceptable side effect profile
since they induce less behavioural effects like motor incoordination and ataxia and failed toIntroduction
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induce psychotomimetic and neuropathological changes like PCP or MK801 (Leeson and
Iversen, 1994).
1.5.3.2 Schizophrenia
Compounds such as phenylcyclidine, ketamine and MK801 as well as competitive antagonists
evoke psychotomimetic activity in patients. Hence, a glutamatergic hypothesis of
schizophrenia has been developed, suggesting hypofunction of some glutamatergic systems in
certain brain regions which may be responsible for the expression of symptoms (Javitt and
Zukin, 1991). This hypothesis is supported by the finding that the glutamate release from
synaptosomes of schizophrenia patients is decreased (Sherman et al., 1991). Application of
NMDA receptors glycine site partial agonists like D–cycloserine improved some of the
schizophrenic symptoms in animals and patients (Toth and Lajtha, 1986; Waziri, 1988).
Additionally, it has been demonstrated that glycine site antagonists block the activation of the
mesolimbic dopamine systems induced following amphetamine administration in the rat
(Bristow et al., 1995).
1.5.3.3 Anxiety
Results from anxiety animal models indicate that competitive NMDA receptor antagonists
show anxiolytic response, but are different in many respects from benzodiazepines (Liebmann
and Bennett, 1988). Additionally, antagonists acting as non competitive open channel blocker
or glycine site antagonists exhibit potential anxiolytic activity (Kehne et al., 1995; Kehne et
al., 1991). For glycine site antagonists inconsistent results have been reported. Although
anxiolytic activity has been demonstrated for compounds like DCKA (Kehne et al., 1991), D-
cycloserine or (R)-HA-966 (Anthony and Nevins, 1993) other high affinity glycine site
antagonists like L-701,324 and MRZ 2/576 failed to be effective (Karcz-Kubicha et al., 1997).
Since observed the anxiolytic efficacy of glycine antagonists was far weaker than that of
benzodiazepines, it seems that glycine antagonists currently are not considered to be new
powerful tools in anxiolytic therapy.
1.5.3.4  Acute neurodegenerative diseases
Ischemic damage to the central nervous system by stroke or trauma is a very prominent
target in excitatory amino acid research. Glutamate or similar agonists induce neuronal cell
death by excessive activation of NMDA receptors. This term called excitotoxicity is involved
in many types of acute neurodegenerative disorders (for chronic neurodegenerative diseases
see 1.5.3.5). Brain microdialysis studies indicate that the concentrations of extracellular L–
glutamate rises rapidly upon the induction of ischemic situations or traumatic brain injuriesIntroduction
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(Andine et al., 1991; Lees, 1993; Meldrum and Garthwaite, 1990). The concentration of co–
agonist glycine is also increased (Globus et al., 1988). Energy deficits seem to be involved in
excitotoxic effects of glutamate as they cause high intracellular sodium concentrations leading
to a reversal of sodium dependent glutamate uptake and in consequence to a presynaptic non–
vesicular release of glutamate (see fig. 4). 
Depolarisation of the postsynaptic membrane (e.g. via fast depolarizing AMPA receptors) and
subsequent massive calcium influx via NMDA receptors results in the activation of different
calcium dependent enzymes such as NO-synthase, phospholipase A2, protein kinase C,
ornithine–decarboxylase, proteases and endonucleases. Some resulting metabolites such as
polyamines or arachidonic acid may in turn trigger the activation of NMDA receptors.
Damage of calcium buffering mitochondria causes the release of apoptosis inducing factors
like AIF or cytochrome C activating the apoptotic cascade or radicals from the respiratory
chain leading to plasma membrane damage and necrosis.
Numerous preclinical studies indicate the efficacy of glutamate antagonists in various animal
models of acute ischemic damage (Bordi et al., 1997; Bullock et al., 1990; Warner et al.,
1995).
1.5.3.5  Chronic neurodegenerative diseases
Excitotoxicity mediated by L–glutamate may even be involved in chronic neurodegenerative
disorders. It has been proposed that the neurodegeneration of the substantia nigra
dopaminergic pathways in Parkinson’s disease depend to some extent to glutamate evoked
excitotoxicity. NMDA receptor antagonists prevent substantia nigra neurons from undergoing
cell death due to application of MPP
+ (Camins et al., 1997; Turski et al., 1991), a
dopaminergic neurotoxin (inhibitor of complex I of the respiratory chain) used in animal
models to induce Parkinson’s disease. In fact, the NMDA channel blockers amantadine and
memantine have been used for the symptomatological treatment of Parkinson’s disease.
Related to Parkinson’s disease are disorders like amyotrophic lateral sclerosis (ALS) and
Alzheimer type dementia with respect to loss of neurons in discrete brain areas such as
neurones in cortex and motoneurons in the spinal cord or cholinergic neurons of the basal
forebrain, respectively. Some evidence for an involvement of the glutamatergic pathway in
Alzheimer’s disease was given by the loss of NMDA binding sites in the cortex and
hippocampus of post mortem brains (Greenamyre, 1986). The treatment of the resulting
cognitive deficits with glycine site agonists like D–cycloserine was proposed. But this is
probably not a valid approach since the positive effects of D–cycloserine disappeared after
repetitive administration (Randolph et al., 1994). Recently, it was found that a ß-amyloidIntroduction
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fragment (25-35) inhibited [
3H]-glycine binding and stimulated [
3H]-MK801 binding but only
when glycine concentrations were low (Cowburn et al., 1997). This suggests an enhancement
of NMDA receptor function mediated by glycine recognition site agonism. Therefore, a
neuroprotective potential of glycine antagonists is likely.
Fig. 4 Simplified scheme of processes involved in glutamate mediated excitotoxicity
There is also an excitotoxic hypothesis for the pathogenesis of ALS. It was first proposed on
the basis of data that showed changes in glutamate levels in plasma, cerebrospinal fluid and
post mortem brain tissue (Allaoua et al., 1992). Further more, an impaired glutamate uptake in
vesicular preparations from post mortem spinal cord and motor cortex of ALS patients was
shown (Rothstein et al., 1992). Additionally, the vesicular transmitter release inhibiting
compound riluzole (sodium channel blocker) has been shown to be neuroprotective and to
slightly extent survival in ALS.
The acquired immunodeficiency syndrome is often accompanied by neurological symptoms
including dementia (AIDS dementia). It was suggested that the gp 120 coat protein of HIV-1
might indirectly stimulate NMDA receptors causing L–glutamate induced cell death (Toggas
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et al., 1996; Wu et al., 1996). These findings suggest that clinically tolerated NMDA receptor
antagonists may be useful in the prevention of neuronal damage in HIV-1-infected patients.
Huntington's disease is a dominantly inherited, progressive neurodegenerative disorder
caused by selective neuronal death in the basal ganglia. The pathophysiology is as yet
unknown, but evidence suggests that the neurotoxicity may result from endogenous
substances acting at excitatory amino acid receptors (DiFiglia, 1990). 
The low non-competitive NMDA receptor antagonist remacemide and its metabolite
remacemide des–glycine (FPL 12495) block also voltage dependent calcium channels
(VSCCs). Remacemide has been used in clinical trials to improve Huntington´s disease
(Kieburtz et al., 1996). As glycine levels in Huntington´s disease patients have been reported
to be increased (Reilmann et al., 1997), glycine site antagonists may have some therapeutical
benefit.
1.5.3.6 Chronic  pain
The involvement of glutamatergic pathways and NMDA receptors in the development of
chronic pain is now well established. Besides the increased sensitivity of primary afferent
nociceptors, hyperalgesia depends on NMDA receptor mediated central changes in synaptic
excitability. Ketamine, which is a widely used dissociative anaesthetic, offers good analgesic
properties (Klepstad et al., 1990). Since there is evidence for the presence of NMDA (and
non-NMDA) receptors in small, unmyelinated sensory nerve terminals in the skin (Carlton et
al., 1995), peripheral NMDA receptors may also contribute to the development of chronic
pain (Warncke et al., 1997; Zhou et al., 1996). Other NMDA receptor antagonists such as
MK801, ACEA 1011 (Vaccarino et al., 1993) L-701,324 (Laird et al., 1996), memantine
(Carlton and Hargett, 1995), amantadine (Pud et al., 1998) or CPP (Kristensen et al., 1994),
were shown to exert analgesic effects, too. All these preclinical data suggest that NMDA
receptor antagonists will find clinical use in the treatment of chronic pain.
1.5.3.7  Drug and ethanol dependence, tolerance and abuse
One major obstacle with the use of opioids, especially morphine, is the development of
tolerance with respect to the antinociceptive effects. Unfortunately, tolerance does not refer to
the side effects like the development of respiratory depression and reduction of intestinal
motility. Beside the development of tolerance, drug abuse is another important therapeutic
challenge associated to the chronic use of these compounds. In various studies, NMDA
receptor antagonists and partial antagonists block the development of tolerance to opiates and
inhibited withdrawal signs and motivational aspects of drug abuse (Popik and Skolnick, 1996;Introduction
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Tiseo and Inturrisi, 1993; Trujillo, 1995; Trujillo and Akil, 1991). Ethanol inhibits NMDA
receptors with affinity in the low-millimolar range by decreasing the affinity of glycine. After
prolonged abuse, this inhibition seems to cause an upregulation of NMDA receptors (Hu et
al., 1996) (Chandler et al., 1999), whose activity is responsible for the occurrence of ethanol
withdrawal seizures (Hoffman et al., 1995). Hence, NMDA receptor antagonists have been
shown to normalize withdrawal syndromes in ethanol dependence, too (Danysz et al., 1992).
1.5.3.8 Side  effects
There are some typical side effects of excitatory amino acid modulating drugs like neuronal
vacuolization, psychotomimetic effects and amnesia which are discussed in this section.
Neuronal vacuolization and damage was first observed after postischemic treatment of rats
with high affinity non-competitive NMDA receptor antagonists like MK801 (Olney et al.,
1989). Only specific brain areas are affected and under low doses vacuolization is temporary.
High doses may cause necrosis. As reason for this vacuolization, the activation of metabolic
activity and the lysosomal proteolytic system of neurons has been proposed (Hetman et al.,
1997). These changes have been suggested to be a class specific effect but also competitive
antagonists have been shown to induce some vacuolization (Hargreaves et al., 1993) whereas
the effect seems to be absent with glycine site antagonists (Hawkinson et al., 1997).
This side effect has been studied in rat and mice and there is some evidence for species
differences in susceptibility to and location of vacuolization induced by NMDA receptor
antagonists (Auer, 1994; Raboisson et al., 1997). Therefore, the importance of this side
effect is certainly unknown.
As mentioned above (1.5.3.2) PCP exhibit psychotomimetic effects. It has been mainly used
in psychiatric research and in drug abuse (“angel dust“). Psychotomimetic effects have also
been seen with other NMDA receptor antagonists such as ketamine, MK801 and competitive
antagonists (Krystal et al., 1994; Loscher and Honack, 1991; Willetts et al., 1990). Glycine
site antagonists seem to exert minor psychotomimetic effects (Kretschmer et al., 1997). If
these effects should be caused in general by blockade of the NMDA receptor channel, then
their use is restricted to acute indications.
Systemical application of competitive and non competitive NMDA receptor antagonists at
anti-epileptic and neuroprotective doses typically results in some impairment in motor
behaviour, ataxia and hyperactivity (Loscher and Honack, 1991; Murata and Kawasaki,
1993). For systemic administration of full glycine site antagonists ataxia / myorelaxation
seem to be the major side effect (Baron et al., 1997; Parsons et al., 1997b).
Since the activation of NMDA receptors seems to play an important role in the induction ofIntroduction
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LTP (see 1.5.2) neuroprotective agents completely blocking NMDA receptor channels also
induce  amnesic effects. However, impairment of memory may depend on compounds
blocking mechanism. The low affinity, voltage–dependent open channel blocker memantine,
which has been used in Germany since the early 1980s as both an anti-parkinson agent and an
antispastic agent in a variety of chronic neurological diseases including multiple sclerosis, has
been shown to act neuroprotective (Kornhuber et al., 1994) in an use–dependent manner.
Pathological activity is blocked while physiological activity is unchanged. This is achieved
with a high voltage–dependency and a fast channel blocking kinetic (Parsons et al., 1993a). In
contrast MK801, which offers only weak voltage–dependency compared with slow kinetics
blocks both forms of NMDA receptor activation. 
Maintenance of normal synaptic transmission under pathophysiological conditions may also
be achieved using glycine–site antagonists. As shown in fig. 5 the co–agonist glycine is
potentiating both, peak response to NMDA application (representing physiological response)
and the desensitisation plateau (representing the pathophysiological phase). However, the
effect of glycine in potentiating peak response is five fold lower than that for plateau
responses (Parsons et al., 1993b). Hence, rising concentrations of glycine during ischemic
periods predominantly inhibit the physiological receptor desensitization and induce long–term
neurotoxic NMDA receptor activation. Abolishment of the desensitization inhibition by
glycine antagonists may therefore prevent pathophysiological activation under preservation of
physiological peak response and hence, leading to drugs with improved side effect profiles.
Fig. 5 Desensitization  of  neurons
response to NMDA depends on glycine
concentration.
NMDA (200µM) response of a single cell in the
presence of rising glycine (53nM, 120nM, 350nM,
1020nM) concentrations. (taken from Parsons et al.,
1993b).Introduction
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It should be added that glycine full antagonists vary in their ability to induce glycine –
sensitive desensitization. The quinolone derivate L-701,324 reveal only little desensitization
whereas compounds such as 7-chloro–kynurenic acid or DCKA showed 10 fold higher
potencies against plateau responses (Karcz-Kubicha et al., 1997; Molnar and Erdo, 1996).
1.6  NMDA receptor agonists and antagonists
1.6.1  Agonists and competitive antagonists
A major feature of NMDA receptor agonists (and antagonists) is the necessity of three
ionizable groups. Compounds lacking the amino group or one or both acidic groups failed to
show any activity. The α-carboxyl residue seems to be of certain importance since the α-
phosphonyl analogue of L-glutamate has low receptor affinity. In addition, an optimal
separation of the two acidic groups of either two (aspartate length) or three (glutamate length)
carbons is needed for high affinity agonists.
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Fig. 6 Structures of NMDA receptor agonists.
Ki values (determined for displacement of [
3H]-CGS 19755) for (S)-Glu, (S)-Asp, NMDA, (R/S)-TetGly
and trans-ACBD are taken from Lunn et al., 1992. Ki value of L-CCG IV was determined by
displacement of [
3H]-CPP (Kawai et al., 1992) (Ki for reference compounds: NMDA = 15.0 µM; (S)-Glu
= 0.327 µM).Introduction
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Among the open chain agonists, the (S)-enantiomer of glutamate (L-glutamate) has the
highest affinity and (R)- and (S)-glutamate show the widest enantiomeric difference. (S)
isomers of agonists of glutamate chain length are more active than the corresponding
analogues of aspartate chain length.
Alkylation of the α-amino group is usually detrimental to the activity of the compounds
except the N-methylation of (R)-aspartate (NMDA). NMDA has the same affinity as the
parent compound. Many potent and selective NMDA receptor agonists represent cyclic
structures. The (R/S)-TetGly has twice the affinity of (S)-glutamate (92 nM vs. 172 nM) and
is a potent neurotoxic and convulsant compound. In this structure, the tetrazole group acts as
an isosteric replacement for CH2-COOH. Higher homologues such as ω-tetrazole substituted
aspartate or glutamate have lower affinity. Other highly active and specific compounds
incorporate a tri- or tetracyclic ring in the interacidic carbon chain. In these series glutamate
analogues which mimic a folded rather than an extended conformation of (S)-glutamate such
as trans-ACBD and L-CCG-IV showed enhanced activity. The (2S, 3R, 4S)-CCG is one of
the highest affinity NMDA receptor agonists with a 10 fold increased affinity compared to
(S)-glutamate (Kawai et al 1992). The same phenomenon is seen with the corresponding
cyclobutane analogue ACBD where the trans isomer has substantially higher affinity than the
cis isomer (cis-trans ratio of Ki values = 80).
Competitive NMDA receptor antagonists are typically higher homologues of glutamate /
aspartate where the number of atoms in the chain separating the α–carbon and the ω–acidic
group is either three (AP5–length) or five (AP7–length). In most compounds the enantiomer
with the (R) configuration at the α–terminus has the highest affinity, the R/S potency ratio
being usually 10–50. Compounds include AP5, AP7, CPP, CPPP, CPP–ene, CGS 19755,
CGP 37849, MDL 100,453, MDL 100,925 and quinoxaline (structure I and II) derivates.
Concerning the ω–acidic terminus, the rank order of potency for NMDA antagonism is PO3H2
> tetrazole > COOH > SO3H.
AP5 and AP7 can be regarded as lead compounds for the development of competitive
glutamate antagonists, since almost all following structures derived from these two open
chain antagonists. Other compounds have been synthesized that have substituents
incorporated in the interacidic group chain. Besides the (cyclic) piperazines with AP7-length,
compounds with a C-4 keto group like MDL 100,453 or MDL 100,925 or the methyl
substituted CGP 37849 showed an increased affinity. The latter compounds can be regarded
as substituted AP5.Introduction
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Chronologically, CPP and then CGS 19755 were the first compounds reported to have higher
affinity than AP5 and AP7 as competitive NMDA antagonists. These piperazine and
piperidine compounds can be regarded as cyclic AP7 and AP5 analogues, respectively. In the
piperidine group the AP5–length compound CGS 19755 and AP7–length compound CPPP
have near equal affinity but CGS 19755 shows higher in vivo potency. In the 4–substituted
piperazines, however, peak activity is seen in the AP7–length compounds CPP and CPP-ene.
In a reported quinoxaline series of NMDA-receptor antagonists the AP6-length analogues
with a 6,7-dichloro substitution (structure I) (Baudy et al., 1993) or 6,7 annealed phenyl
moiety (structure II) showed highest affinity. These compounds represent two of the most
potent competitive NMDA-receptor antagonists with Ki values of 3.4 and 6.5 nM,
respectively.
Fig. 7 Structures of competitive antagonists at the glutamate binding site of the NMDA
receptor (Collingridge and Watkins, 1994)
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The strong increase in affinity of these bulky compounds may be caused by the use of a large
hydrophobic pocket within the binding site. In addition to its high affinity, the 6,7-dichloro
compound is of particular interest, since an IC50 value of 0.6µM has been reported for the
displacement of [
3H]-glycine binding. This presumably results from its close structural
similarity to the quinoxalinediones and 6,7-dichlorokynurenate.
1.6.2  Glycine site agonists and antagonists
The action of glycine on NMDA receptors is mimicked by other small neutral amino acids,
notably by (R)-serine (D-serine) and (R)-alanine. These (R)-α-amino acids act as
enantioselective agonists with submicromolar affinities (McBain et al., 1989). Glycine and
(R)-serine are present in the CNS at micromolar levels (Matsui et al., 1995) and uptake
mechanisms have been described for both. For glycine, cloning studies revealed the existence
of GLYT1, a Na
+ and Cl
- dependent uptake transporter specific for glycine (Smith et al.,
1992), expressed in glia cells and colocalized with NMDA receptors (Fedele et al., 1993).
Glycine uptake via GLYT1 was demonstrated to efficiently regulate local glycine levels
(Supplisson and Bergman, 1997). Intracerebroventriculary (i.c.v.) injected (R)-serine
accumulates in glial cells (Wako et al., 1995), suggesting the existence of a (R)-serine uptake
mechanism in astrocytes (Schell et al., 1995). There are indications that the reversal of the
described uptake mechanisms play a major role in increasing the concentration of these amino
acids near the synaptic cleft. Since both amino acids, (R)-serine and glycine exhibit
heterogeneous and partially complementary distribution within in the CNS (Schell et al.,
1997) it remains elusive whether glycine and / or (R)-serine represent the native co-agonist(s)
of NMDA receptors.
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Fig. 8 Structure of compounds acting as agonists and partial agonists at the glycine
recognition site of the NMDA receptorIntroduction
37
Exogenous full and partial agonists derived from α-amino acid structures. Cyclic amino acids
ACPC and ACBC contain cyclopropane and cyclobutane residues, respectively. In vitro,
ACPC represents a partial agonist (Watson and Lanthorn, 1990) with an intrinsic activity of
approximately 90%. However, in vivo ACPC showed antidepressive, anxiolytic and
neuroprotective effects with good penetration to the CNS. ACBC, with its bigger ring and
much lower affinity and intrinsic activity, has not been studied extensively. (R)-HA-966 has
been recognised as a partial agonist (Foster and Kemp, 1989) with a very low efficacy (<10%
of glycine) and anticonvulsant action in vivo, whereas the (S)-enantiomer does not bind to the
glycine recognition site of the NMDA receptor. The structurally related aminohydroxamate
(R)-cycloserine, which has been formerly used as an antibiotic for the treatment of
tubercolosis, is a systemically active partial agonist with high affinity for NR1 / NR2C and
NR2D assemblies and higher efficacy than HA-966.
Kynurenic acid was the first glycine site antagonist after the discovery of glycine as a co-
agonist of the NMDA receptor (Birch et al., 1988). Optimization strategies led to a 7-chloro
substitution, which enhances the affinity for the glycine site by 70-fold (Kemp et al., 1988).
This substitution is usually found in all subsequently developed high affinity compounds.
Further improvement of affinity led to the 5,7-dichloro derivate known as DCKA (Baron et
al., 1990). The development of dihydrokynurenate series led to the highly potent phenylurea
derivate L-689,560 (Foster et al., 1992). Further reported kynurenic acid derived compounds
were a cyclic hydrazide (M 241,247) and the recently reported pyrido-phthalazine-dione MRZ
2/576 (Parsons et al., 1997b). These two latter tricyclic compounds are glycine site
antagonists with only moderate potency, but provide a relative good penetration into the CNS.
This is in contrast to the other kynurenic acid derived high affinity antagonists which are
inactive in vivo due to poor brain penetration and bioavailability in the CNS, although they
provide optimized affinities in the nanomolar level.
The essential features of the kynurenic acid pharmacophore are also present in the indole-2-
carboxylic acids. The potency of the propanoic acid derivate MDL 29,951 (Salituro et al.,
1992) is comparable to the corresponding DCKA. Unfortunately, like kynurenic acids, most
of these compounds show poor bioavailability and are active after i.c.v. administration only
(Baron et al., 1992). MDL 105,519 which has an IC50 for the displacement of [
3H]-glycine
binding of 10nM, is widely used as tritiated radioligand of the glycine recognition site (Baron
et al., 1996). GV 150526A (Gavestinel) belongs to a series of 2-carboxyindole derivates in
which chain substitutions at position 3 increased affinity to the low nanomolar range.
However, Gavestinel is active against convulsions in mice after i.v. and peroral administrationIntroduction
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(Di Fabio et al., 1997) and is currently under  development by Glaxo Wellcome for the
treatment of stroke.
Quinoxaline derivates derived form the finding, that CNQX and DNQX, which were the first
antagonists at AMPA non-NMDA receptors, had also substantial affinity for the glycine
recognition site of the NMDA receptor (Randle et al., 1992). ACEA 1021 has been reported
to have improved affinity and selectivity (Woodward et al., 1995) and was active in various
models of glutamate induced pathogenesis (Lutfy and Weber, 1996; Takaoka et al., 1997;
Warner et al., 1995). The tricyclic quinoxalinedione compound 20-g (Nagata et al., 1994)
incorporates structural features from the bulky 4-position of the tetrahydrochinoline L-
689,560 leading to comparable affinities. The in vivo data of this compound are in common
with those of kynurenate and indole classes. Based on the structural features of the kynurenic
acids and the quinoxalinediones, a putative model of the binding pocket was developed
(Leeson and Iversen, 1994), which is given in fig. 9 .
Fig. 9 Pharmacophore for glycine site antagonists after Leeson and Iversen, 1994
The pharmacophore contains a H-bond donor and acceptor moiety, a size limited hydrophobic
region, and on the opposite site of the pharmacophore a bulk tolerance and a size limited
acidic region. Based on this pharmacophore 2-quinolone derivates have been synthesized. The
2-quinolones lack the carboxylic group (pKa ∼4) present in indole-2-carboxylic acids and
kynurenic acid derived compounds, whose dissociation was thought to be detrimental to brain
penetration. Instead, the compounds hold the acidic function within the fused heterocyclic
ring, delocalized to the 2-carbonyl and leading to an increased pKa value of ∼5.
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Fig. 10 Structures of glycine site antagonists
Affinities are expressed as IC50 values from displacement of [
3H]-glycine (taken from Leeson and
Iversen, 1994 and Danysz and Parsons, 1998). IC50 of MRZ 2/576 was determined by displacement of
[
3H]-MDL 105,519 (Parsons et al., 1997b).
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A series of 4-hydroxy-2-quinolone represents a class of glycine antagonists with consistent
bioavailability and in vivo activity. The potency of this series of compounds depends on the
nature of the 3-substituent. A breakthrough in systemic activity was found in the 3´-aryloxy-
3-phenyl derivates. Compounds L-701,324 and L-705,022 (Kulagowski et al., 1994) are two
of the most potent glycine antagonists with high in vitro and in vivo potency, yet described.
Bioavailability problems of most glycine site antagonists arise from poor penetration into the
brain due to ionization of acidic groups or a rapid transport out of the brain mediated by the
organic acid transporter in the choroid plexus. However, the bioavailability in the CNS was
found to be improved by co-application of probenecid which seems to inhibit drugs outflux
via the mentioned organic acid transporter (Moroni et al., 1988; Parsons et al., 1997a;
Santamaria et al., 1996). Another bioavailability problem rises from the binding to plasma
proteins (Rowley et al., 1997b). It was proposed that on one hand, the affinity at the glycine
site increases with lipophilicity. But on the other hand, increased lipophilicity also leads to an
enhanced binding to plasma proteins (e.g. albumin) limiting the amount of free compound to
diffuse across the blood-brain barrier. This hypothesis was supported by the finding that
warfarin increased in vivo potency of some high affinity compounds in vivo (Rowley et al.,
1997a).
Another approach to influence the activity of NMDA receptors via the glycine binding site is
the use of the L-kynurenine pathway of L-tryptophane in a prodrug concept (Moroni et al.,
1988; Russi et al., 1992; Schwarcz, 1993; Stone, 1993). Via this pathway, L-kynurenine is
transformed into the antagonistic kynurenic acid and the agonistic quinolinic acid. Central
injection of 4-chloro-L-kynurenine led to the in vivo formation of its metabolite 7-chloro
kynurenic acid in neuroprotective quantities (Wu et al., 1997). As advantage of this prodrug
system, the facilitated penetration of substituted kynurenines via large amino acid transport
systems is proposed. Another approach is the inhibition of the kynurenine-3-hydroxylase, a
key enzyme in the formation of the agonistic quinolinic acid. Blockade of kynurenine-3-
hydoxylase should lead to decreased quinolinic acid levels whereas the endogenous kynurenic
acid levels should be increased by facilitating metabolism. An applied compound in this
approach is FCE 28833A [(R/S)-3,4-dichlorobenzoylalanine] (Speciale et al., 1996). But
unfortunately, since kynurenic acid represents a glycine antagonist with only weak affinity,
the estimated antagonist levels after high dose treatment were more than 1000 fold lower than
the respective Ki value of kynurenic acid (15µM) (Kessler et al., 1989).Introduction
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Fig. 11 Kynurenine pathway of L-tryptophane
1.6.3 Non-competitive  antagonists
Non-competitive antagonists include the dissociative anaesthetics phencyclidine and ketamine
(Ketanest
®), the morphinan dextromethorphan (NeoTussan
®), the adamantanes memantine
(Akatinol-Memantine
®) and amantadine (PK-Merz
®), the dibenzocycloalkenimine MK801
and the substituted guanidine CNS 1102, which has been reported to be neuroprotective in
vitro and in vivo. PCP was developed in the 1950s as an anaesthetic agent and has been used
in psychiatric research as a model of schizophrenia. It is also encountered as a drug of abuse
(“angel dust“). Ketamine is an analogue of PCP with lower affinity for the NMDA receptor
ion channel. It is a racemic compound widely used for anaesthesia. Like PCP it induces
catalepsy and psychotomimetic effects. Dizocilpine (MK801) is the agent with the highest
affinity for the NMDA receptor ion channel. It was the first drug consistly shown to be
neuroprotective (Park et al., 1988). Unfortunately, induced hallucinations and histological
changes in brain of rats (Horvath et al., 1997) led to safety concerns. Aptiganel (CNS 1102 /
Cerestat) is a diarylguanidine with high affinity for the NMDA receptor ion channel (Reddy et
al., 1994).
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Fig. 12 Structures of non-competitive NMDA receptor antagonists
Clinical trials with this compound in phase I reported symptoms of sedation and central
nervous excitation (Muir et al., 1994; Muir et al., 1997). Even in phase III studies with
aptiganel, increased systolic blood pressure and an excess of CNS effects were both observed
(Dyker et al., 1999). Dextromethorphan has been used as an antitussive for many years before
its recognition as a low-affinity open channel blocker of NMDA receptors. A Clinical trial
(phase II) in amyotrophic lateral sclerosis did not result in an improvement in 12-month
survival (Gredal et al., 1997). The low-affinity non-competitive NMDA antagonists
memantine and amantadine have been used as antiparkinson, antidementia and antispastic
agents since the early 1980s. They were recognised as NMDA ion channel blockers well after
their introduction to clinical practice.Introduction
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Fig.  13 Use- and voltage-dependency of non-competitive NMDA receptor antagonists
Patch clamp studies at hippocampal neurons (taken from Parsons et al., 1993a).
The described compounds differ in their kinetics for NMDA receptor binding. The low-
affinity compounds memantine and ketamine bind to NMDA receptors strongly use-
dependent similar to magnesium. In contrast, MK801 and PCP showed much slower kinetics
(see fig. 13-A). (Parsons et al., 1993a). Even the voltage-dependence of memantine resembles
that of magnesium, whereas the blockade by PCP and MK801 is weak (see fig. 13-B).Introduction
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1.6.4  NR2B specific compounds
This class of compounds is selective for the subtypes of NMDA receptors containing the
subunit NR2B. CGP 61594 is a competitive glycine antagonist, which was shown to have
some selectivity for the NR2B subtype (Honer et al., 1998). Ifenprodil is the prototype of
NR2B selective NMDA receptor antagonists (Williams, 1993b) but exhibits also affinity to
α1 adrenergic, serotonin and sigma receptors (Chenard et al., 1991). High potency and
selectivity for the NR2B subtype was found in single enantiomers from erythro and threo
ifenprodil (Avenet et al., 1996). Eliprodil was the first ifenprodil analogue to be described
with NMDA antagonist properties. This compound is equipotent at α1 adrenergic receptors
and showed some calcium channel blocking activity (Biton et al., 1994). Nevertheless,
clinical trials with this compound as a neuroprotectant for stroke and traumatic brain injury
were performed. Haloperidol is an antipsychotic drug with affinity for dopamine and sigma
receptors. Electrophysiological studies concluded that haloperidol specifically inhibits NR2B
containing NMDA receptors (Coughenour and Cordon, 1997).
Fig. 14 Structures of NR2B selective NMDA receptor antagonists
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1.6.5 Immunological  approach
Recently, it has been reported, that a humoral autoimmune response targeting the NR1
subunit of the NMDA receptor has antiepileptic and neuroprotective effects (During et al.,
2000). Oral genetransfer of mouse NR1 to intestinal, antigen presenting lamina propria cells
was performed using an adeno-associated virus (AAV) vaccine and induced the generation of
antibodies against a range of NR1 epitopes. Serum from AAVNMDAR1-immunized rat
showed specific binding to peptides that correspond to functional domains within the
extracellular NH2-terminal side of M1 and the M3-M4 loop containing critical residues for
glycine binding. In a model of kainate induced epilepsy one month following vaccination the
status epilepticus frequency was significantly reduced by ~ 68% and prevented even seizure
induced neurotoxicity. In an endothelin-1 model of experimental stroke the total infarct
volume of AAVNMDAR1-immunized rats was reduced by ~ 70%. In contrast to
administration of NMDA receptor antagonists, vaccination did not result in an impairment of
motor behaviour. Besides the lack of this typical side-effect, the most promising feature of
this approach seem to be an “on demand delivery“ of neuroprotective agent. Under
physiological conditions, vaccinated animals showed low levels of NMDAR1 antibodies in
the cerebrospinal fluid (CSF). After kainate treatment, a tenfold increase in CSF levels of
NMDAR1 autoantibodies was observed. Since glutamate itself has been reported to alter the
blood-brain-barrier (BBB) permeability (Mayhan and Didion, 1996), the authors conclude,
that increased glutamate levels after an cerebral insult may lead to a local increase of BBB
permeability, resulting in an facilitated passage of antagonistic autoantibodies from the
periphery into the CNS. The observed neuroprotection by autoantibodies against NR1 is
consistent with the results of a human study in Russia, which showed the presence of NMDA
receptor autoantibodies in the serum of patients after stroke (Gusev et al., 1996). A
neurological recovery occurred only in individuals with significant antibody titers whereas a
poor prognosis or death was correlated to the absence of NMDA receptor autoantibodies. The
described approach suggests the possibility of prophylactic vaccination for patients with a
high risk of stroke or other cerebral insults and difficult forms of epilepsy as well as a direct
treatment of stroke patients with NMDA receptor antibodies.Introduction
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1.7  Apoptosis and necrosis – modes of cell death
Cell death can occur by either of two distinct mechanisms, apoptosis or necrosis. The term
apoptosis or programmed cell death characterizes a structurally distinctive mode of cell death,
responsible for the loss of cells within living tissues (Kerr et al., 1972). In contrast, necrosis
occurs when cells are exposed to extreme variance from physiological conditions,
 e. g. hypothermia or hypoxia.
Necrotic cell injury is initiated by the damage of the plasma membrane. The leakage of the
plasma membrane causes an impairment of the cell’s ability to maintain homeostasis, leading
to an influx of water and extracellular ions. Intracellular organelles, most notably the
mitochondria, and the entire cell swell and rupture (cell lysis). Due to the ultimate breakdown
of the plasma membrane, the cytosolic contents including lysosomal enzymes are released
into the extracellular fluid. Therefore, in vivo, necrotic cell death is often associated with
extensive tissue damage and an intense inflammatory response.
The main morphological features of apoptosis are cell shrinkage, accompanied by blebbing
from the surface, and culminating in separation of the cell into a cluster of membrane–bound
vesicles (apoptotic bodies). Besides a usually intact organellar structure, the nucleus
undergoes a characteristic chromatin condensation resulting in densely heterochromatic
regions. Changes in surface molecules ensure that in vivo apoptotic cells are immediately
recognised and phagocytosed by macrophages, microglia or other phagocytes. Due to this
removal, no inflammatory response is elicited. In vitro, the apoptotic bodies as well as the
remaining cell fragments ultimately swell and finally lyse. This terminal in vitro phase has
been termed “secondary necrosis“.
“Physiological“ apoptosis is responsible for cell death in development, normal tissue turn
over, negative selection in the immune system, the mediation of cell killing by TNF and the
prevention of tumours and carcinogenesis. Furthermore it accounts for many cell deaths
following exposure to cytotoxic compounds, viral infections, hypoxia / stroke and in chronic
neurodegenerative processes including Alzheimer’s or Parkinson’s disease.
Several key elements of the apoptotic pathway have been described: (i) Death receptors, like
the CD-95 (Fas / APO-1) and the TNFR1 receptor ligand systems. After binding of the
respective ligand (FasL / TNFα) and a subsequent trimerization of the receptors, an
intracellular recruitment of “death domain“ containing factors (FADD or TRADD/FADD) is
described, leading to the activation of caspase 8 (Nagata, 1997). (ii) Protease cascades have
been characterized, in which caspases (cysteinyl- aspartate-specific proteases) play a pivotalIntroduction
47
role in the initiation (caspase 9 and 8) and execution of apoptosis (caspase 3) by the cleavage
of target proteins such as poly(ADP-ribose)polymerase (PARP) (Nicholson et al., 1995) or
ICAD / DFF45 (inhibitor / chaperone of caspase-3 activated DNase CAD (Enari et al., 1998).
Caspase-3 activation seems to be required for nuclear apoptosis and DNA fragmentation
(Janicke et al., 1998). (iii) During apoptosis mitochondrial permeability is altered. Caspase
activator cytochrome C is released from mitochondria (Andreyev et al., 1998; Yang and
Cortopassi, 1998). Together with dATP, cytochrome C (Apaf-2) promotes the caspase
activation in the cytosol by binding to Apaf-1 (Zou et al., 1997) (mammalian homologue of
CED 4 in C. elegans) and therefore activating Apaf-3 (caspase 9)(Li et al., 1997). Another
pathway is the release of proapoptotic AIF (apoptosis inducing factor) (Susin et al., 1996).
AIF is a caspase-1-like protease (inhibited by z-VAD.fmk) capable of activating a caspase-3-
like protease to induce nuclear apoptosis. The release is mediated by mitochondria undergoing
permeability transition. Permeability transition is a phenomenon characterized by the opening
of pores in the inner membrane of mitochondria (Bernardi et al., 1998). These pores are
inducted by the disruption of the inner membrane potential (∆ψm) e.g. by elevated
intracellular calcium or protonophores (FCCP).
Although apoptosis and necrosis are considered as distinct forms of cell death, there is
increasing evidence that classical apoptosis and necrosis represent only the extreme ends of a
continuum of possible types of cell death. In some cases, both forms share common steps
since the execution of apoptosis in neurons and lymphoid cells depends on intracellular ATP
levels and can be switched to necrosis by depletion of ATP (Ankarcrona et al., 1995; Leist
and Nicotera, 1997; Leist et al., 1999; Nicotera et al., 1998). This suggests, while initial
events may be common to both types of cell death (e.g. overstimulation of NMDA receptors
in neurons), certain metabolic conditions (maintenance of mitochondrial function and ATP
levels) would be required to activate downstream switches which direct cells to the execution
of apoptosis. Since glutamate induced neuronal cell death requires mitochondrial calcium
uptake (Stout et al., 1998a) and the resulting mitochondrial dysfunction is a primary event in
glutamate induced neurotoxicity (Schinder et al., 1996), mitochondrial function and
intracellular ATP-levels seem to be critical factors that determine the mode of neuronal death
in excitotoxicity. Correspondingly, it is not surprising that both modes of cell death can be
found in experimental stroke models (Charriaut-Marlangue et al., 1996). In the ischemic core,
necrosis is the predominant form of cell death whereas in the less severely compromised
penumbra or border regions a delayed apoptotic cell death occurs. Aim of the study
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2. Aim of the study
After the cloning of the rodent NMDA receptor subunits (Ikeda et al., 1992; Ishii et al., 1993;
Kutsuwada et al., 1992; Monyer et al., 1992; Moriyoshi et al., 1991) these cDNAs have been
used in heterologous transient expression systems like Xenopus oocytes for
electrophysiological studies (Le Bourdelles et al., 1994; Monyer et al., 1992; Wafford et al.,
1993) or mammalian cells for radioligand binding studies (Cik et al., 1993; Grimwood et al.,
1995; Laurie and Seeburg, 1994; Lynch et al., 1994). Cloning of human cDNA clones (Karp
et al., 1993; Le Bourdelles et al., 1994; Planells-Cases et al., 1993) (Grimwood et al., 1996b;
Hess et al., 1996; Hess et al., 1998; Lin et al., 1996) now allows studies at recombinant
human NMDA receptors. Since it has been reported that expression of NMDA receptors in
the nonneuronal cell line Hek 293 leads to cell death (Anegawa et al., 1995) the establishment
of a cell death based in vitro test system was intended. As expression system we favoured
nonneuronal cell lines, stably transformed with recombinant NMDA receptors, since
comparable cell lines have proved to be robust and reliable expression systems (Grimwood et
al., 1996b; Uchino et al., 1997; Varney et al., 1996).Results – transient expression
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3. Results
3.1 Transient expression of rat NR1-1a, mouse NRε ε ε ε1 and mouse
NRε ε ε ε3 in Hek 293 cells
Human embryonal kidney cells (Hek 293) have widely been used for the heterologous,
transient expression of recombinant NMDA receptors in mammalian cells. These cells were
immortalized by exposure to shared fragments of adenovirus type 5 DNA (Graham et al.,
1977). A portion of the adenovirus genome is expressed in these cells including the
adenovirus E1a and E1b proteins. E1a proteins have been shown to inhibit the immediate
early region (IE) of the SV40 promotor through a mechanism of enhancer repression but do
not inhibit the IE region of the human cytomegalovirus (HCMV) promotor (Gorman et al.,
1989). In contrast E1b proteins transactivate the IE region of HCMV. Hence, the HCMV
promotor is superactivated in HEK 293 cells. The expression of the rat NR1-1a, mouse NRε1
and mouse NRε3 containing pCIS constructs is therefore under the control of the
constitutively active HCMV promotor.
As already mentioned, cell death after heterologous expression of recombinant NMDA
receptors has been reported (Anegawa et al., 1995). To examine the effects of rat NR1-1a co–
transfected with mouse NRε1 or NRε3 on cell viability, 3 x 10
6 cells were plated in 10 cm cell
culture dishes. After 48 hours, transfection was performed using the calcium phosphate
precipitation method (Chen and Okayama, 1987) with 10µg total DNA. Cells were
transformed with pCIS (control) and with either pCIS NR1-1a / pCIS NR2A–ε1 (1:3 ratio) or
pCIS NR1-1a / pCIS NR2C–ε3 (1:3 ratio). Transfections were carried out in triplicates. 24
hours after transfection, cells were removed from the plates with a cell culture rubber,
centrifuged and cell death was determined by trypan blue exclusion. Transfection of NR1-1a /
NRε1 led to a 4-fold increase in cell death (28.2 ± 3.7 %) compared to pCIS transfected
population (7.3 ± 2.5 %). In contrast, subunits NR1-1a / NRε3 did not affect the cell death
rate significantly (8.7 ± 2.1 %). To confirm that the observed cell death resulted from the
expression of functional NMDA receptors and not from unspecific toxic effects of different
transfected constructs, the ability of the competitive antagonist (R/S)-AP5 (150µM) to prevent
cell death was tested. 150µM APV reduced cell death to 16.5 ± 1.5 % representing aResults – transient expression
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reduction of approximately 50% compared to positive control. These results are in good
agreement with former studies (Anegawa et al., 1995; Cik et al., 1993). Cik et al. reported a
cell mortality rate of 21.7 ± 3% for the co–transfection of rat NR1-1a and NRε1 (ratio 1:3) 20
hours post–transfection. The presence of AP5 (200µM) reduced cell death rate to 8.3 ± 2.6%.
Anegawa et al. reported a 48 hour cell death rate of approximately 57.9 ± 5.2 % for rat NR1-
1a / NR 2A expression and an unchanged cell death rate for rat NR1-1a / NR2C. The
observed cell death under transient co–expression of NR1-1a and NR2A subunits might be
caused by the activation of functional NMDA receptors and subsequent influx of calcium
ions. Transfection was carried out in DMEM medium which contains 4 mM glutamine known
to produce high glutamate levels within the cell culture medium. Additionally, supplemented
fetal calf serum (10%) may contribute to higher concentrations of L–glutamate and glycine.
Fig. 15 Transient expression of NMDA receptor subunits in Hek 293 cells leads to cell death
dependent on subunit composition. Expression of NMDA receptor subunits NR1-1a and NR2A
(NRε1) led to an increased cell death 24 hours post transfection which could be partially reduced with
the competitive antagonist (R/S)-AP5 at a concentration of 150µM. Increased cell death was not
observed after transfection of subunits NR1-1a / NR2C (NRε3) compared to pCIS control vector
transformed populations.
Due to the use of calcium phosphate precipitation method the concentration of free calcium in
the cell culture medium is increased. Block of opened channels by magnesium, present in
DMEM medium in active concentrations (0.7mM), might be reduced as the resting membrane
potential of Hek 293 is in the range of –15 to –50mV (Cik et al., 1993). Therefore, activation
of functional NMDA receptors is likely to occur. Elevated intracellular calcium levels mayResults – transient expression
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then damage calcium buffering mitochondria resulting in increased cell death rates.
The absence of increased mortality under co–transfection of NR1-1a / NR2C agrees with
findings from other groups (Anegawa et al., 1995; Chazot et al., 1994). This may be explained
by a decreased calcium permeability of this expressed NMDA receptor subtype. In fact,
higher NMDA-induced currents in Xenopus oocytes expressing NR1 / NR2A compared to
NR1 / NR2C have been reported (Monyer et al., 1992).Results – generation of cell lines
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3.2 Generation of cell lines stably expressing human NR1-1a /
NR2A and NR1-1a / NR2B
3.2.1 General  considerations
Compared to transient expression systems, cell lines stably expressing human recombinant
NMDA receptors have been proved to represent a more reliable, convenient and robust
heterologous expression system (Grimwood et al., 1996a; Uchino et al., 1997; Varney et al.,
1996). They offer some advantages, since the expression level does not depend upon
transfection efficiency limiting parameters such as purity and batch homogeneity of used
DNA and other critical transfection conditions, e.g. pH of transfection buffer and medium,
cell cycle and growth state of cultures (Graham and Van der Eb, 1973). Furthermore, these
stable cell lines offer the possibility of a high throughput screening of compound libraries to
discover compounds selectively acting on specific NMDA receptor subtypes.  For these
reasons, the generation of cell lines stably expressing different recombinant NMDA receptor
subtypes was intended.
Since expression of recombinant NMDA receptors in non neuronal cell lines is known to
induce cell death, an inducible expression system should be preferred. The mammalian
expression vectors pMSGNR1-1a, pMSGNR2A and pMSGNR2B (see fig. 16) represent
suitable expression systems, since the expression of the NMDA receptor subtypes is under the
control of the mouse mammary tumor virus (MMTV) promotor. The transcription of cloned
genes is stimulated by the addition of glucocorticoid hormones, such as dexamethasone, to the
cell culture medium. The hormonal stimulation of the MMTV promotor activity is mediated
by intracellular glucocorticoid receptors (Lee et al., 1981). These receptors are involved in the
regulation of gene transcription by the nuclear translocation of the steroid–receptor complex
and the subsequent association with the DNA which favours the binding of RNA polymerase
II and the transcription of the encoded gene. Hence, the cell lines intended to be transfected
with these constructs should possess glucocorticoid receptors. Therefore we chose the mouse
L(tk-) fibroblasts as host cells (American Type Culture Collection CCL1.3)
Two transfection strategies were followed to obtain L(tk-) fibroblasts expressing functional
NMDA receptors. As mentioned before, functional recombinant NMDA receptors consist of
the assembly of NR1 and NR2 subunits. Hence, one transformation strategy was the co–
transfection of either pMSGNR1-1a / pMSGNR2A or pMSGNR1-1a / pMSGNR2B. TheResults – generation of cell lines
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second strategy intended the co-transfection of pCISNR1-1a, containing the NR1-1a subunit
of the rat constitutively expressed by human CMV promotor, and inducible pMSGNR2A or
pMSGNR2B. It has been reported that the cell surface expression of the human NMDA
receptor subunit NR1-1a requires the co–expression of the NR2 subunit (McIlhinney et al.,
1996). Hence, the combination of these constructs should also lead to stable cell lines
expressing functional NMDA receptors upon dexamethasone addition.
Fig. 16 Constructs used for stable transfection of L(tk-) cells. In pMSG vectors the expression of
cDNAs encoding the human NMDA receptor subunits NR1-1a, NR2A and NR2B is under the control of
the dexamethasone inducible MMTV promotor. The SV40 splicing and polyadenylation sites provide
RNA processing in mammalian cells whereas the E. coli neomycine resistance gene driven by the
SV40 early promotor allows selection of transformants growing in media containing G418 antibiotics.
Ampicillin resistance gene allows selection in E. coli strain (DH5α). The pCIS vector contains the
cDNA encoding the rat NR1-1a subunit whose expression is driven by the constitutive expressing
enhancer–promotor sequence of the immediate early gene of the human cytomegalovirus (CMV). The
vector also contains Poly A site and ampicillin resistance gene for prokaryotic selection. For eukaryotic
selection the G418
+ resistance of the cotransfected pMSGNR2A or 2B vectors was used.
3.2.2  Transfection and cell cloning
To avoid increasing concentrations of L–glutamate within the cell culture medium due to
hydrolysis of L–glutamine, L(tk-) cells were grown in MEM medium (lacking L–glutamine)
supplemented with 2 mM alanylglutamine (Glutamax I 
® by Gibco), known to have a higher
stability in the cell culture medium. MEM medium was further supplemented with 10% heat
inactivated fetal calf serum (FCS), 0.5 mM sodium pyruvate, 100 U/ml penicillin and 100
µg/ml streptomycin. In the following, this medium is designated as growth medium.
Transfections were performed using the calcium phosphate precipitation method (for detailsResults – generation of cell lines
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see experimental procedures 5.1). In brief, 20µg of total DNA were used for the transfection
of 5x10
5 cells. Co–transfection of NR1 and NR2 constructs was performed in an 1:5 ratio. 48
hours after transfection cells were exposed to increasing concentrations of geneticine (final
2mg/ml). To avoid selection due to NMDA receptor background expression, 100µM ketamine
were included. After 4 weeks of selection, pool cultures were cloned using limiting dilution in
96 well plates (0.3 cells per well). After 10 to14 days, various numbers of clones were
obtained (see tab. 4).
Tab. 4 Number and code of clones obtained from limiting dilution
co–transfected vectors Code Number of clones
pMSGNR1-1a & pMSGNR2A L12 62
pMSGNR1-1a & pMSGNR2B L13 16
pCISNR1-1a & pMSGNR2A L42 48
pCISNR1-1a & pMSGNR2B L43 45
3.2.3 Clone  screening
The obtained clones were monitored for NMDA receptor activity by detection of cell death 24
hours after induction of NMDA receptor expression. Cell toxicity assays were carried out in
growth medium containing 5% FCS and 1µM dexamethasone using the CytoTox 96
®
cytotoxicity assay. This assay is based on the determination of lactate dehydrogenase (LDH)
activity from cell culture supernatants. LDH represents a stable cytosolic enzyme, that is
released into the cell culture medium upon cell lysis. To control response to NMDA receptor
antagonists, the open channel blocker ketamine was included into clone screening at a final
concentration of 500µM. To examine, whether mortality of clones could be triggered under
increased agonist concentrations effects of 100µM L-glutamate and glycine were also tested.
In brief, clones from 96 well plates were subdivided into 4 wells. Three wells were treated
with either growth medium containing 5% FCS and 1µM dexamethasone or additionally
500µM ketamine or 100µM L-glutamate and glycine for 24 hours. The fourth well was
maintained for further cultivation. Celltoxicity was determined after 24 hours. Clones
showing highest cell death rates and response to ketamine inhibition were preselected. Results
of preselected clones are given in table 5.Results – generation of cell lines
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Tab. 5 Results of preselected clones from cytotoxicity clone screening
clone
                                      Cytotoxicity [%]
growth medium           500µM ketamine    100µM L-glu / gly
L12-B6 32.7 18.4 47.8
L12-B10 20.0 8.5 27.3
L12-D3 28.4 15.5 40.8
L12-D8 27.5 14.4 37.7
L12-D9 20.9 9.8 27.9
L12-E3 44.0 26.6 60.7
L12-E6 24.6 13.7 35.3
L12-E10 26.3 15.0 32.3
L12-F8 27.4 15.0 27.7
L12-G5 65.2 7.7 81.4
L12-G10 75.6 5.3 82.9
L13-C1 19.5 8.5 20.1
L13-C5 41.1 39.9 64.0
L13-E5 26.6 14.3 33.7
L13-E6 45.3 27.3 58.7
L13-F6 17.0 7.2 17.3
L42-C6 33.4 25.8 67.2
L42-D9 19.2 13.2 69.3
L42-E1 94.7 n.d. 95.5
L42-F5 62.1 42.7 72.4
L42-G6 52.9 21.9 47.8
L42-G8 23.3 6.0 20.3
L43-B9 23.6 9.8 24.6
L43-C4 28.7 23.8 38.2
L43-C10 22.0 20.10 25.4
L43-C11 31.6 12.3 26.1
L43-E8 26.1 10.2 33.4
L43-F8 15.6 10.0 20.9
L43-G4 18.3 11.2 18.7Results – generation of cell lines
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All preselected clones were frozen. Clones marked in tab. 5 were chosen for further
pharmacological monitoring. Reproducibility of screening results and responsiveness of
clones to various competitive and non–competitive antagonists were examined. The results of
this second clone screening are given in fig. 17. 
Four of twelve clones were dropped, since they showed neither upregulation of cell death
upon exposure to dexamethasone (L13–E5, L42–D9, L43–B9) nor accurate response to the
distinct antagonists or high unspecific cell death (L12–G5).
Clones L12–B6, L12–E3 and L12–G10 displayed an upregulation of cell death after treatment
with 1µM dexamethasone in a range of approximately 35 to 55%. In contrast, cell mortality
without dexamethasone was not increased (<10%), although 100µM L-glutamate and glycine
were present. This indicates a lack of functional NMDA receptors in the absence of
dexamethasone. The open channel blocker ketamine (100µM) and MK801 (100µM) as well
as the competitive antagonist (R/S)–AP5 (100µM) and glycine site antagonist DCKA
(100µM) reduced cell death to control levels. Response to antagonists acting at distinct
recognition sites of the NMDA receptor channel complex demonstrated the functionality of
expressed NMDA receptors in these three cell lines. It also shows, that cell death occurring
after heterologous expression of NMDA receptors in non-neuronal cell lines is caused by their
functional assembly within the plasma membrane, since the cell penetration of the hydrophilic
compound (R/S)–AP5 is unlikely and its recognition site has been determined to be
extracellularly located (Laube et al., 1997). Addition of 100µM L-glutamate and glycine to
dexamethasone failed to significantly increase the cell mortality. This could be explained by
saturated concentrations of agonists within the incubation medium (MEM cont. 10% FCS).
Anegawa et al. (1995) reported L–glutamate levels of ~180 µM determined in MEM (10%
serum) from cell cultures 24 hours post transfection. Although this medium contained L–
glutamine it is likely that supplemented serum already provides high concentrations of L–
glutamate and glycine. This hypothesis is confirmed later on, as it was shown that cell death is
strictly dose dependent on L–glutamate in the absence of serum. Even the second transfection
strategy combining constitutively expressing pCISNR1-1a construct and dexamethasone
inducible pMSGNR2A vector led to clones (L42–C6, L42–E1, L42–F5) which showed an
increased cell mortality upon exposure to dexamethasone compared to control.Results – generation of cell lines
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Fig. 17 Screening of selected clones 
Clones, cultured in growth medium containing 5% FCS, were exposed to (a) 1µM dexamethasone, (b)
1µM dexamethasone and 100µM L–glutamate / glycine, (c) 100µM L-glutamate / glycine w/o dexa-
methasone (control), (d) 1µM dexamethasone and 100µM ketamine, (e) 1µM dexamethasone and
100µM (R/S)-AP5, (f) 1µM dexamethasone and 100µM MK801, (g) 1µM dexamethasone and 100µM
DCKA. Cell death was measured after 24 hours.
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Fig. 17 Screening of selected clones (continued) 
Clones, cultured in growth medium containing 5% FCS, were exposed to (a) 1µM dexamethasone, (b)
1µM dexamethasone and 100µM L–glutamate / glycine, (c) 100µM L-glutamate / glycine w/o dexa-
methasone (control), (d) 1µM dexamethasone and 100µM ketamine,(e) 1µM dexamethasone and
100µM (R/S)-AP5, (f) 1µM dexamethasone and 100µM MK801, (g) 1µM dexamethasone and 100µM
DCKA. Cell death was measured after 24 hours.
The observed NMDA receptor mediated cell death was in the range of 35 to 85%. Control
levels of L42–C6 and L42–F5 were comparable to those of L12–clones (<10%), whereas
L42–E1 displayed a higher rate of unspecific cell death (20%). Similar to L12–clones, L42–
cells, exposed to selective NMDA receptor antagonists, displayed a viability comparable to
control cells (except the treatment of L42–E1 with 100µM (R/S)–AP5 which was slightly
increased to control). The similarity between the pharmacological profiles of L12– and L42–
clones demonstrates the possibility of functional assemblies between subunits cloned from rat
and human. This is predicted by the great amino acid sequence identity between rat and
human NR1 subunits (95 to 100%). 
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L42–clones showed no increased mortality while stimulated in growth medium lacking
dexamethasone. This is quite remarkable, since the rat NR1-1a subunit is under the control of
the constitutive expressing human CMV promotor and should be expressed even in
dexamethasone free medium. Cell death in L42-cells only occurred after exposure to
dexamethasone and subsequent induction of subunit NR2A expression. This fact supports the
finding of McIlhinney et al., who reported that successful surface expression of recombinant
NMDA receptors in heterologous cell systems depends on the co–expression of both NR1 and
NR2 subunits. Single NR1 expression does not yield to functional receptors (McIlhinney et
al., 1996).
Unfortunately, the rat NR1-1a / human NR2B expressing clone L43–E8 showed only
unspecific increase in cell death upon exposure to dexamethasone since cell death was not
significantly decreased by NMDA receptor antagonists. Since even control levels were
increased, this clone was dropped. In contrast, clone L13–E6 expressing subunits hNR1-1a
and hNR2B, both under the control of the MMTV promotor, displayed an increase in cell
mortality after induction of receptor expression with dexamethasone which was blocked by
application of open channel blockers ketamine and MK801. No or only slight response was
observed to 100µM (R/S)AP5 and DCKA. Since heterologous NMDA receptors consisting of
subunits NR1-1a and NR2B are supposed to exhibit an agonist preferring status, the lacking
response to competitive antagonists is caused by a reduced affinity of these compounds. As
shown later, we demonstrate that a competitive antagonism at the glutamate and glycine
recognition sites takes place under defined agonist concentrations.
From these results it can be summarised, that the co-transfection of inducible vectors
pMSGNR1-1a and pMSGNR2A or pMSGNR2B as well as the co-transfection of constitutive
expressing pCISNR1-1a (rat) and inducible pMSGNR2A led to cell lines stably expressing
functional recombinant NMDA receptors. These cell lines provide a functional in vitro test
system for competitive antagonists and channel modulating compounds based on the
prevention of cell death mediated by heterologous NMDA receptor expression. For further
characterization by RT–PCR analysis, immunoblotting, immunocytochemistry and calcium
imaging, clones L12–G10 and L13–E6 were chosen.Results – characterization of clones
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3.3  Characterisation of clones L12-G10 and L13-E6
For further characterization of selected clones L12–G10 and L13–E6 RT-analysis,
immunoblotting and immunocytochemistry of subunit NR1-1a and calcium imaging were
performed. The results of these experiments are given in the next four sections. 
It should be added, that the immunological characterization was restricted to NR1 subunits
since it has been suggested that heterologously expressed NMDA receptor subunits are
assembled in the endoplasmatic reticulum and that co-synthesis of the subunits is necessary
for their successful cell surface targeting and functionality (McIlhinney et al., 1998). In
addition a C–terminal truncation of NR2 subunits was reported which complicates the
immunological detection of NR2 subunits; so far all commercially available antibodies were
directed against a C–terminal polypeptide region.
3.3.1 RT-PCR  analysis
RT-PCR analysis of NMDA receptor mRNA, isolated from clones cultured for 12 hours in
growth medium containing 2µM dexamethasone and 100µM ketamine, was performed for
clone L12-G10 and L13-E6. Isolated RNA was reverse transcribed into cDNA using d(T)12-18
priming. Reverse transcription of mature and immature transcripts was followed by PCR with
primers corresponding to the distinct transfected cDNAs. As control for successful RNA
isolation, amplicons from PCR with beta–actin priming were subjected to agarose gel
electrophoresis. As shown in fig. 18, RT–PCR analysis revealed the transcription of
transfected subunits in both clones. For clone L12–G10, amplicons in the predicted size of
654 bp (NR1-1a) and 480 bp (NR2A) were detected (fig. 18-A). Clone L13–E6 displayed the
predicted 654 bp signal for NR1-1a and 501 bp for NR2B (fig. 18-B). Transcripts of the
predicted size were also detected in uninduced cells but not in untransfected wildtype cells
(fig. 18-C). To estimate the induction of transcription by dexamethasone, densitometric
volume analysis was applied resulting in a 5-fold increase for hNR1-1a transcripts and a 2.3-
fold increase for hNR2A in L12-G10. For clone L13-E6, ratios of 4.8 for hNR1-1a and 3.5 for
hNR2B were calculated, respectively. This finding indicates an upregulation of mature
transcripts for both transfected subunits. Hence, it is likely that exposure to glucocorticoids
induces a co–synthesis of the NR1 and the NR2 subunits necessary for their functional
assembly and cell surface targeting.  The observed background transcription in uninduced
clones does obviously not lead to detectable amounts of protein (see section 3.3.2).
Additionally, uninduced cells cultured in growth medium lacking ketamine for more than 24Results – characterization of clones
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hours appeared healthy and no increased cell death rate could be detected, whereas
dexamethasone treated cultures did undergo cell death.
Fig. 18  RT-PCR analysis
To verify the transcription of human NMDA
receptor cDNA in transfected clones RT-PCR
analysis was performed. Cells were cultured
for 12 hours in growth medium ± 2µM
dexamethasone. Amplicons in the predicted
size for hNR1-1a (654 bp), hNR2A (480 bp)
and hNR2B (501 bp) were determined for the
respective cell lines (A–B). Under treatment
with dexamethasone clones showed an
increase in transcription rate. Densitometric
volume analysis leads to a 5-fold increase for
hNR1-1a transcripts and a 2.3-fold increase
for hNR2A in L12-G10 cells. For clone L13-
E6 ratios of 4.8 for NR1-1a and 3.5 for NR2B
were calculated. In wildtype L(tk-) cells no
transcripts for hNR1-1a, hNR2A or hNR2B
were detected (C).
3.3.2 Immunoblotting
Western blot analysis was performed using a monoclonal affinity purified mouse anti-NR1
antibody which was directed against the N–terminal region of rat NR1 (amino acids 1 – 564).
L12-G10, L13-E6 and WT-cells were cultured in growth medium ± 4µM dexamethasone and
100µM ketamine for 24 hours. Aliquots of solubilized membrane fractions (40µg) were
subjected to gel electrophoresis. As positive control 5µg of rat brain membrane protein were
probed. 
In both clones a ~116 kDa polypeptide was recognised (fig. 19) which is in good agreement
with the estimated molecular mass of rat NR1 transiently expressed in the human embryonal
kidney cell line Hek 293 (Chazot et al., 1992), unglycosylated human NR1-1a (103.5 kDa)
and the detected NR1 subunits in rat brain membranes. The slightly increased molecular
weight compared to rat NR1 could be caused by different glycosylation. The observed lower
molecular weight bands may be either proteolytic fragments or unglycosylated forms of the
protein. In control lanes, no protein was detected neither in uninduced clone cultures nor in
wildtype cells.Results – characterization of clones
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Fig. 19 Immunoblots  of
induced, uninduced clones and
wildtype cells
Cells were cultured for 24 hours in
growth medium containing 4µM
dexamethasone and 100µM ketamine.
Aliquots of solubilized membrane
protein (40µg) were probed with N–
terminal directed monoclonal mouse
anti–NR1 antibody. As positive control
5µg rat brain membrane were loaded.
Fig.  20 Time course of hNR1-1a protein expression in L12–G10 and L13–E6 cells
Clones were cultured in growth medium containing 4µM dexamethasone and 100µM ketamine for the
indicated time intervals. Aliquots of solubilized membrane protein (60µg) were loaded and NR1-1a
subunit protein was detected with N–terminal directed monoclonal mouse anti–NR1 antibody (positive
control 5µg rat brain membrane).
To examine the time course of hNR1a expression, cells were cultured in growth medium
containing 4µM dexamethasone and 100µM ketamine and harvested after 0, 8, 16, 24, 32 and
48 hours. Aliquots of solubilized membrane protein (60µg) were probed (see fig. 20). As
positive control, 5µg of rat brain membrane protein were subjected to gel electrophoresis.
Surprisingly, both clones revealed a maximum protein amount after 8 hours of treatment with
dexamethasone. Between 16 and 48 hours declining amounts of NR1 were detected.
In summary, results from immunoblotting revealed the expression of a 116 kDa protein
detected with the monoclonal mouse anti–NR1 antibody. The size of the protein is consistent
with the predicted molecular weight from the deduced amino acid sequence (103.5 kDa) and
the size from the NR1 subunits detected in rat brain membranes. The maximum amount of
protein is expressed between 8 and 16 hours after induction of receptor expression. This time
course is consistent with the results from the RT–PCR analysis which revealed only 5 fold
increase of hNR1-1a transcripts compared to background expression after 12 hours and mayResults – characterization of clones
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also account for the lack of specific [
3H]-MK801 binding at membranes from cells
differentiated with dexamethasone / ketamine for 24 to 72 hours.
3.3.3 Immunocytochemistry
To investigate the cellular localization of the expressed recombinant NMDA receptor
subunits, confocal laser microscopy was applied after immunofluorescence labelling with Cy–
3 coupled rabbit anti–goat serum. As primary antibody we choose a polyclonal goat anti-NR1
serum which was directed against an intracellularly located C-terminal epitope of the NR1
subunit. The monoclonal mouse anti-NR1 antibody directed against the N–terminal region of
NR1, which was used for immunoblotting, could not be used due to unspecific binding to
L(tk-) cells. 
Cell lines, grown on cover slides, were permeabilized and fixed with ice cold methanol /
acetic acid (90:10). Receptors were labelled with goat anti–NR1 serum (1:500) and rabbit
anti–goat serum (1:200) conjugated with Cy3 fluorescence dye. Fluorescence images were
obtained by confocal laser microscopy.
As shown in fig. 21, strong fluorescence signals were observed within the plasma membrane
indicating the cell surface targeting of the expressed NR1 subunits. Specificity of staining was
verified by the lack of fluorescence signals from immunostained wildtype cells.
In contrast to other ion channels, e.g. AMPA or P2X receptors, which assemble to functional
homo–oligomeric channels if expressed as single subunits, NMDA receptors seem to be
different. As mentioned above, it has already been shown, both for transient and for stable
heterologous transfection of recombinant NMDA receptor subunits, that  cell surface
expression of the NR1-1a subunit is found only in cells expressing both NR1 and NR2A
subunits (McIlhinney et al., 1996). Same authors reported intracellular inclusions of NR1-1a
subunits within the endoplasmatic reticulum of NR1-1a transfected COS cells which were lost
when NR2A was co–transfected with NR1-1a (McIlhinney et al., 1998). This suggests that the
two subunits are first associated in the ER. This hypothesis was supported by the co–
precipitation of NR2A with NR1-1a in cells where normal transport out of the ER was
blocked by Brefeldin–A (which disrupts transfer of proteins from the ER to the golgi
apparatus within minutes after its addition to cells).Results – characterization of clones
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Fig.  21 Immunofluorescent staining of subunit NR1-1a in permanently transfected cell
clones.  Cells were differentiated with 2µM dexamethasone for 24 hours. After fixation and
permeabilisation cultures were immunofluorescence labelled with primary goat anti–NR1 (1:500) and
Cy3–conjugated rabbit anti–goat IgG (1:200) and imaged by confocal laser microscopy (ex 550nm;
em 598nm). Fluorescence and phase contrast images of the following cultures are presented: L12–E3
(A, B), L12–G10 (C, D), L13–E6 (E, F), L42–C6 (G, H), L43–E8 (I, J), wildtype (K, L)
This requirement of NR1-1a association to NR2 for full surface expression in mammalian
cells may not be valid for neurons, but there is some evidence that cell surface expression and
functional channel formation of native NMDA receptors is regulated by the synthesis of the
NR2 subunit family. Immunohistochemical studies found substantial NR1 immunoreactivity
in neuronal cell bodies (Petralia et al., 1994b). Using NR2A/NR2B specific antibody same
authors reported higher levels of dendritic staining than for cell body staining (Petralia et al.,
1994a).
Supported by these findings it is most likely, that the fluorescence signals at the cell surface,
detected by immunofluorescence labelling of NR1-1a subunits, result from functional hetero–
oligomeric channels.Results – characterization of clones
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3.3.4 Calcium  imaging
To confirm the functionality of expressed ion channels, calcium imaging was performed using
the calcium sensitive fluorescence dye fluo-4 acetoxymethylester and confocal laser
microscopy. Cells were plated in growth medium containing 4µM dexamethasone and 100µM
ketamine for 16 to 20 hours. For dye loading cultures were treated with 1µM fluo-4
acetoxymethylester. Removal of ketamine enables calcium influx via NMDA receptor
channels after stimulation with agonists. A set of functional experiments was performed with
both clone L12–G10 and L13–E6. 
Stimulation of clone L12–G10 with 100µM L–glutamate and glycine led to a rapid increase in
intracellular calcium ([Ca
2+]i) concentration as indicated by increasing fluorescence signal
intensity (fig. 22-B to D). As control, an increase in [Ca
2+]i was elicited by 10µM ionomycin
(fig. 22-A). Application of NMDA receptor specific open channel blockers abolished the
increased [Ca
2+]i. After exposure to 200µM ketamine (fig. 22-C) or 10µM MK801 (fig. 22-D)
fluorescence signal intensity was reduced to starting levels. Receptors were also stimulated by
the co–application of 200µM N-methyl-D-aspartate (NMDA) (fig. 22-E) or 1000µM L-
aspartate with 100µM glycine (fig. 22-F). NMDA stimulation was inhibited by 10µM MK801
(fig 22-E). Addition of 100µM L-glutamate did not trigger response to 1000µM L-aspartate
(fig. 22-F) indicating already saturated conditions after L–aspartate application.
For clone L13–E6, a similar set of experiments was performed. Control experiments revealed
the stability of fluorescence signals over the experimental interval in the absence of L–
glutamate (fig. 23-A). Calcium influx was then elicited by the addition of 10µM ionomycin.
In functional experiments with 100µM L–glutamate and glycine, a steep increase in [Ca
2+]i
via stimulated NR1-1a / NR2B receptors was observed (fig. 23-B to D). Similar to L12–G10
cells increased [Ca
2+]i was abolished by the addition of 100µM ketamine (fig. 23-C) or 10µM
MK801 (fig. 23-D). An increase of L–glutamate concentration to 200µM did not trigger peak
level of fluorescence signal (fig. 23-E) which may be explained by either saturated agonist
levels or by saturation of fluorescence dye by calcium. Subsequent application of competitive
antagonist (R/S)–AP5 (400µM) reduced the increased [Ca
2+]i to approximately 50%. Figure
23-F demonstrates the calcium response of native glutamate receptors from mouse CGC cells
to 100µM L–glutamate (data provided by E. Fava, Inst. for Molecular Toxicology, University
of Konstanz). It should be noted that this increase in [Ca
2+]i is caused by the activation of
distinct glutamate receptors and therefore represents the sum of calcium influx via NMDA
receptors and release of calcium from intracellular stores via phospholipase C coupled
mGluR1 / 5 stimulation.Results – characterization of clones
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Fig. 22 Increase in intracellular calcium concentration via hNR1-1a / hNR2A expressed
in L12–G10 cells 
Cells were plated on coverslips in growth medium containing 4µM dexamethasone and 100µM
ketamine for 16 to 20 hours. For dye loading, the cultures were treated with 1µM fluo-4
acetoxymethylester in original medium at 37°C. To remove ketamine, cells were washed 3 times. All
experiments were performed in CSS pH 7.8 containing 50mM KCl, 1.8mM CaCl2 and 100µM glycine.
Presented data are mean values (n=6): (A) control (10µM ionomycin); application of 100µM L–
glutamate (B-E), 200µM ketamine (C), 10µM MK801 (D and E), 200µM N-methyl-D-aspartate (E) and
1000µM L-aspartate (F).Results – characterization of clones
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Fig. 23 Increase in intracellular calcium concentration via hNR1-1a / hNR2B expressed
in L13-E6 cells and via native NMDA receptors in CGC cells. Clones were plated on coverslips in
growth medium containing 4µM dexamethasone and 100µM ketamine for 16 to 20 hours. For dye
loading, the cultures were treated with 1µM fluo-4 acetoxymethylester in original medium at 37°C. To
remove ketamine, cells were washed 3 times. All experiments were performed in CSS containing
50mM KCl, 1.8mM CaCl2 and 100µM glycine. Presented data are mean values (n=6): (A) control
(10µM ionomycin). Application of 100µM L–glutamate (B-D), 200µM ketamine (C), 10µM MK801 (D),
200µM L–glutamate and 400µM (R/S)–AP5 (E). CGC cells were stimulated with 100µM L–glutamate
(F). CGC cell data were provided by E. Fava (Inst. for Molecular Toxicology, University of Konstanz).
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3.4  Cell death based in vitro assays
3.4.1  LDH assay mixture
For economic reasons, a lactate dehydrogenase (LDH) assay mixture which is suitable for the
performance of cell culture cytotoxicity assays was developed. 
The developed assay is based on the same principle as the CytoTox 96
® assay which was
successfully used in clone screenings. LDH is a stable cytosolic enzyme that is released into
the cell culture medium upon cell lysis. Released LDH activity in cell culture supernatants is
quantitatively measured with a coupled enzymatic assay resulting in the conversion of a
tetrazolium salt (INT) into a red formazan product. The formation of formazan is stopped
through a pH shift by the addition of acetic acid. The amount of color formed, measured at
490nM, is proportional to the number of lysed cells. The general chemical reactions are as
follows: Oxidation of L–lactate to pyruvate (catalysed by LDH) results in the generation of
NADH which in turn reduces the tetrazolium salt to the red colored formazan (catalysed by
diaphorase). The LDH-assay mixture was freshly prepared before each assay and contained
approximately 1% sodium L-lactate, 0.1% NAD
+, 75mM phosphate buffer (PB) pH 7.4,
0.08% BSA, Diaphorase (18 U / ml) and 0.4 % INT (for details see experimental procedures
5.4.1). 
Initial studies with the developed LDH
assay mixture displayed linear kinetics
for the LDH dependent formation of
formazan (fig. 24).
Fig.  24 Time course of formazan
formation
50µl aliquots of samples which contained 5,
10, 25, 50 and 100 mU LDH (from rabbit
muscle in 0.1M phosphate buffer pH 7.4)
were incubated with 50µl assay mixture and
absorbance was recorded at the indicated
intervals.Results – cell death based in vitro assays
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A plot of the obtained slopes (∆absorbance / ∆time) against spiked LDH activity (fig. 25-A)
shows, that the rate of formazan formation varies with the LDH activity. The plot represents a
function, that fits to the classical Michaelis-Menten equation (r = 0.998):
V = Vmax* [S]/([S] + KM)
Hence, the provided amount of reduced NADH as a required substrate of diaphorase, is
directly proportional to the added LDH activity. All other substrates are included in saturated
concentrations under the described conditions. A Lineweaver-Burk plot of the obtained data
allowed the estimation of a pseudo Michaelis constant of the used diaphorase for LDH (fig.
25-B), which was in the range of approximately 17 mU LDH / 50µl. From these data we
conclude that, for the used activity of diaphorase (18 U / ml mixture), the time dependent
formation of formazan is almost linearly proportional to LDH activity, if the sample contains
less than 10mU LDH / 50µl.
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Fig. 25 Michaelis-Menten kinetics
(A) Slopes from graphs in fig. 1 dependent on the added LDH activity fitted to the Michaelis Menten
equation. (B) Lineweaver-Burk plot of data in (A). The interception on the horizontal axis represents –
KM
-1.Results – cell death based in vitro assays
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LDH activity [mU] / 50µl
in growth medium (5% FCS)
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Also in MEM containing 5% FCS, the amount of formed formazan is directly proportional to
the spiked LDH activity (fig. 26). The high interception of ~ 0.2 derived from LDH within
the supplemented FCS and is decreased to ~ 0.08 under the use CSS in the differentiation
model. Formazan containing solutions exhibited a high stability over a period of 90 min if
stored under light protection, since the parameters of the standard curve only slightly
decreased under maintenance of linearity (fig. 26).
Fig. 26 Linearity
and stability of LDH
dependent formazan
formation
Indicated LDH activity
(0, 2.5, 5, 7.5mU) from
rabbit muscle was
spiked to growth
medium containing 5%
FCS. The resulting
solutions were
measured as triplicates.
Absorbance was
recorded immediately
after the addition of
stop solution (t = 0) or
after a 90 min storage
under light protection
(t = 90).
To demonstrate the accuracy and precision of the developed assay, we quantified quality
control samples (QCs; n = 9) which contained 7, 4.5 and 1.5mU LDH / ml growth medium
(5% FCS). The amount of LDH activity within the samples was recalculated using a standard
curve (0 – 7.5mU LDH). For both, precision and accuracy, we obtained satisfying results with
coefficients of variation < 4% and relative errors < 3% (fig. 27).Results – cell death based in vitro assays
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Fig. 27 Accuracy  and  precision
of developed LDH assay
QCs containing 1.5, 4.5 and 7mU LDH /
ml growth medium (5% FCS) were
assayed (n = 9) and the amount of added
LDH was recalculated using a standard
curve (0 - 7.5mU LDH).
To obtain a suitable total LDH activity < 10mU / 50µl cell culture supernatant, 15x10
3 L(tk-)
cells were seeded overnight prior to receptor induction and the incubations were performed in
a final volume of 200µl / well.
3.4.2 Cell  culture  models
Two models for the in vitro testing of compounds have been developed. Both models are
based on the determination of cell death mediated by NMDA receptor activity using the
quantification of released LDH from cell culture supernatants.
The first model, designated as induction model, is characterized by the simultaneous
induction of NMDA receptor expression by addition of dexamethasone and application of
increasing concentrations of NMDA receptor antagonists under sterile conditions at 37°C and
5% CO2. As shown in fig. 28, induction of NMDA receptor expression leads to a steep
increase in LDH release, as a parameter for the extent of NMDA receptor induced
cytotoxicity. The increased LDH release started approximately 10 hours after receptor
induction and reached a plateau after 20 hours. The addition of 50mM potassium triggered
this L-glutamate mediated cytotoxicity whereas uninduced cultures remained unaffected. ThisResults – cell death based in vitro assays
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effect of potassium indicates a dependency of receptor activity upon membrane
depolarisation.
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Fig. 28 LDH release after the induction of NMDA receptor expression
L12-G10 cells were exposed to MEM medium containing 5% FCS and 5 or 55mM potassium in the
presence or absence of 4µM dexamethasone. LDH release was assayed after 0, 12, 16, 20, 24, 36
and 48 hours.
According to the time course of LDH release, cell death is quantified 20 to 24 hours after
receptor induction. Due to the long incubation period and distinct growth of sister cultures, an
individual cell amount should be taken into account. Therefore, to quantify the percentage of
LDH release due to NMDA receptor activity, also the remaining cytosolic LDH activity in
surviving cells was determined. This method exhibits some limitations due to the need of 5%
FCS within the incubation medium. FCS is added to guarantee normal growth and low levels
of unspecific cell death. Besides different growth factors, FCS contains high amounts of free
amino acids. Therefore, addition of L–glutamate or glycine for stimulation of expressed
NMDA receptors is not necessary. In turn, the application of this method is therefore
restricted to NMDA receptor antagonists. This method was applied for the characterization of
a series of thieno[2,3-b]pyridinones acting as glycine site antagonists.Results – cell death based in vitro assays
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The induction model was improved for the testing of compounds (agonists and antagonists)
under more defined conditions. The developed model is designated as differentiation model.
Fig. 29 Scheme of developed excitotoxicity models
In this design, NMDA receptors are pre-expressed by treatment with dexamethasone for 20 to
24 hours under sterile conditions. To avoid cell death, clones are exposed to 100µM ketamine
during this period. For the testing of compounds, NMDA receptor activity is enabled by
removal of ketamine and subsequent incubation in a controlled salt solution containing
defined concentrations of agonists, antagonists or modulators such as protons or polyamines.
Sterile conditions are not further required. The time course of LDH release is given in fig. 30.
After stimulation with 30µM L-glu / gly, NR1-1a / 2A expressing L12-G10 cells showed a
steep increase in LDH release, starting 5 min after the beginning of NMDA receptor
stimulation and reaching their maximum cell death rate after 20 min, already. In contrast,
NR1-1a / 2B expressing clone L13-E6 exhibited a more delayed cell death with a maximum
cell death rate after 40 to 50 min.Results – cell death based in vitro assays
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Fig. 30 Time course of LDH release in the differentiation model
L12-G10 (NR1-1a / NR2A) and L13-E6 (NR1-1a / NR2B) cells were differentiated for NMDA receptor
expression in growth medium containing 4µM dexamethasone and 100µM ketamine for 24 hours.
After removal of the induction medium cells were stimulated in CSS (pH 7.6  for L12-G10 or pH 8.0 for
L13-E6) containing 1.8mM Ca
2+, 50mM potassium and 30µM L-glu / gly). LDH-release was assayed
after the indicated intervals.
This slower increase in cell death could be explained by a reduced calcium permeability of
NR1-1a / NR2B receptors. In contrast to the onset of cell death, the final amount of
cytotoxicity is comparable in both clones with cell death rates of 50 to 60% after 90 min of
stimulation. According to these data, cells are incubated for 60 to 90 min at 37°C. Cell death
is quantified by the determination of released LDH from test wells and total LDH from
control wells released by addition of detergent. Due to the brief incubation period, differences
in total cell amount do not occur and cytosolic LDH is not taken into account. Compared to
the induction model, the amount of samples is therefore reduced to 50%.
The differentiation model was applied to the pharmacological characterization of the clones
L12–G10 and L13–E6.Results – cell death based in vitro assays
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3.4.3  Structure - in vitro activity relationship of a series of thieno[2,3-b]pyridinones
A series of glycine site antagonists was used to demonstrate the usefulness of the created cell
lines in drug screening and optimization of pharmacophores. The pharmacophore of the tested
compounds is based on the structure of the 2-quinolone derivate L-701,324 (Kulagowski et
al., 1994), one of the most potent antagonists at the glycine recognition site of the NMDA
receptor yet described, with both high in vitro and in vivo activity. L-701,324 combines
structural features present in 7-chlorokynurenic acid and quinoxaline-2,3-dione derivates (see
fig. 31) which were compounds early shown to have affinity for the glycine binding site
(Kemp et al., 1988) (Kleckner and Dingledine, 1989). The special feature of 2-quinolone
derivates is the lack of the carboxylic acid function which is believed to improve the
bioavailability within the CNS. Instead, the anionic function, which is necessary for high
affinity, is restored as a vinylogous acid in tautomeric forms of the 4-hydroxyquinolin-2(1H)-
one. The series of tested thieno[2,3-b]pyridin-6(7H)one compounds are derived from
quinolones by bioisosteric replacement of the benzene nucleus with a thiophene (C. R. Noe et
al, unpublished). Synthesis strategies of the thienopyridinones were driven by their ability to
displace [
3H]-glycine from rat hippocampal membranes (according to Berger, 1995). Hence,
due to the availability of binding data, this series represented a suitable trial set.
Fig. 31 Structure relationship between 2-quinolone and thieno[2,3-b]pyridinone derivatesResults – cell death based in vitro assays
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Compounds were characterized for their ability to prevent NMDA receptor mediated cell
death in L12-G10 cells expressing hNR1-1a / hNR2A. Cell death rates were determined in the
induction model. The obtained IC50-values as well as Ki-values from [
3H]-glycine binding are
given in tab. 6. Not for all compounds IC50-values  were obtained. The determination of
cytoprotective effects at higher concentration levels, for compounds such as 185, 323, 198
and 342 with lower affinity and increased lipophilicity, was not possible due to poor solubility
of compounds in the incubation medium. Another limitation was the unspecific toxicity of
some compounds (258, 234, 197) which occurred at concentrations > 50µM. Compound 186
exhibited no cytoprotective effects in concentrations up to 250µM. For high affinity
compounds, IC50-values obtained by cytotoxicity assays correlated well with the Ki values of
the binding assays. For the 9 compounds active in both settings, a correlation coefficient of
0.90 (P = 0.001) was observed. The obtained IC50-values in the cytotoxicity assay were
between 4 and 90µM, whereas compounds were about thousand times more potent in the
binding assay (Ki between 1 and 290nM). This discrepancy could be explained by high
glycine concentrations within the micromolar range, since the used induction medium
contained 5% FCS. According to its low activity in [
3H]-glycine displacement (Ki=290nM),
the 2-, 3-unsubstituted compound 256 exhibited a very low efficacy in cytoprotection of L12-
G10 cells (IC50=89.2µM). In radioligand studies, it was found that the introduction of a 2-
chloro residue as well as a 3-alkyl residue leads to strongly increased affinity (see compounds
256 vs. 257 and 237 vs. 238). This increased affinity is also evident in our in vitro
cytotoxicity model. Compared to compound 256 (R1=H / R2=H), introduction of a
methoxymethyl residue at C-3 in compound 237 enhanced the cytoprotective efficacy (IC50 =
55.8µM). Introduction of a 2-chloro residue in compound 257 enhanced the cytoprotective
efficacy to a higher degree (IC50=15.4µM). For compound 257 (R1=H / R2=Cl), results from
cytotoxicity assays revealed a six-fold increase in cytoprotective potency compared to
unsubstituted compound 256 (R1=H / R2=H) and a four-fold increase compared to the C-3
methoxymethyl substituted compound 237 (R1=meOme / R2=H). These results correspond to
the data from radioligand binding studies which showed a 30-fold increased affinity for 2-
chloro substitution compared to unsubstituted compound 256 and a four-fold increased
affinity compared to compound 237 (R1=meOme / R2=H). For the combination of both
subtitution principles, the cytoprotective efficacy was further enhanced by the introduction of
i-propyl (compound 191; IC50=5.2µM) and i-butyl (compound 204; IC50=7.9µM) residues but
not by n-propyl (compound 233; IC50 = 15.9µM) or tert-butyl (compound 199; IC50=15.5).Results – cell death based in vitro assays
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These compounds exhibited the highest cytoprotective potency of all tested thienopyridinone
derivates.
Tab.  6. Results of the pharmacological
characterization of 5-(3-phenoxyphenyl)-thieno[2,3-
b]pyridin-6(7H)one derivates by radioligand binding
studies at rat brain membranes and cytotoxicity assays
at clone L12-G10
Compound R1 R2 Ki [
3H]-glycine
[nM]
IC50 [µM]
cytotoxicity assay
256 H H 290 (410; 169) 89.2 (97.52; 80.90)
237 methoxymethyl H 37 (24; 49) 55.8 (51.10; 60.54)
257 H Cl 10.4 (13; 7.8) 15.4 (14.33; 16.55)
233 n-propyl Cl 3.9±1.4 (3) 15.9 (20.54; 11.24)
199 tert.-butyl Cl 3.3±0.4 (3) 15.5 (13.28; 15.74; 17.61)
204 i-butyl Cl 2.0±0.2 (3) 7.9 (7.35; 8.46)
191 i-propyl Cl 1.5±0.5 (5) 5.2 (6.27; 4.12)
238 methoxymethyl Cl 0.99±0.65 (3) 15.7 (11.10; 20.32)
186 methyl H 261±213 (9) >250
323 ethyl H 32 >50 
b
258 i-butyl H 66 (38; 156;3.6) >50 
a
185 methyl Cl 21±12 (7) >200 
b
234 n-hexyl Cl 80±43 (5) >50 
a
197 cyclohexyl Cl >30000 >50 
a
198                2,3-thiopyrane 35±10 (3) >250 
b
342            2,3-cyclohexane 500 >30 
b
L-701,324
1) HC l 1.35±0.2 (4) 3.8 (3.45, 4.13)
Ki values were determined by M. Berger (Berger, 1995) and are expressed as mean ± ± ± ± SEM (n) or
as arithmetic mean of two experiments (n1,n2). Inhibition constants (IC50) in cytotoxicity assays
are expressed as mean of two experiments (n1,n2).
 
1)benzene analogous compound of thieno[3,2-b]pyridones with a chloride residue at C-7 of the
chinoline ring
a no effect; exceeding indicated concentrations led to unspecific cell death 
b no effect; insoluble at higher concentrationsResults – cell death based in vitro assays
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Fig.  32 Correlation between inhibition of NMDA receptor mediated cytotoxicity and
inhibition of [
3H]-glycine binding to rat brain membranes by L-701,324 and eight
thienopyridinones. Data points are marked with the corresponding residues R1/R2 from table 6.
Cytoprotective potencies of compounds 204 (R1=i-butyl / R2=Cl) and 191 (R1=i-propyl /
R2=Cl) are comparable to the cytoprotective efficacy of the quinolone analogue L-701,324
which showed an IC50-value of 3.8µM. In the series of 2-chloro substituted compounds,
introduction of a 3-methoxymethyl residue (compound 238) displayed the highest affinity in
[
3H]-glycine binding with a Ki value of 0.99nM. The increased affinity of this compound,
compared to n-propyl or tert-butyl substituted compounds 233 and 199, did not result in an
improved cytoprotective efficacy. The IC50-value of compound 238 was determined with
15.7µM corresponding to the IC50-values determined for compounds 257, 233 and 199. A
possible explanation for this discrepancy could be a different plasma protein binding of these
compounds. 
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To investigate the presence of binding to plasma albumin, the high affinity compound L-
701,324 and the low affinity compound 237 (R1 = methoxymethyl / R2 = H) (compound 238
was no more available!) were tested in the presence and absence of micromolar
concentrations of warfarin. This 4-hydroxycoumarin is known for its high binding rate to
plasma albumin (> 99%) and selectively competes for albumin binding site I. Although the
structure of warfarin is closely related to those of 2-quinolone derived glycine site
antagonists, it exhibited no cytoprotective effects in concentrations up to 300µM. As shown in
fig. 33-B 100 to 300 µM warfarin improved the efficacy of both compounds by approximately
2-fold. For L-701,324, the IC50 decreased from 4.2µM to 2.6µM in the presence of 100µM
warfarin. For compound 237, 300µM warfarin shifted the IC50-value from 58.3µM to
28.0µM. These data demonstrate, that binding to plasma albumin is present to a higher
degree. Due to supplementation with 5% FCS, the assay medium contains at least 0.5 to 1%
BSA. Since binding to plasma proteins limits the concentration of free antagonist in the
pharmacodynamic phase, a higher affinity could be compensated by decreased effective
concentrations of antagonist.
Summarizing, a 2-chloro residue, also present in the bioisosteric quinolone derivate L-
701,324, seems to represent the major determinant for both, high affinity and high
cytoprotective efficacy of this pharmacophore. This finding agrees with the proposed
structure-activity model of Kemp and Leeson (Kemp and Leeson, 1993) who postulated a
lipophilic pocket of the glycine binding site in this region. Compared to quinolones, in which
the introduction of one Cl is sufficient for optimal affinity, thienopyridinones need an
additional alkyl substituent (R1) vicinal to the chloro residue (R2) to reach high potency. The
size of the 3-alkyl residue seems to influence the potency of the high affinity compounds, too.
Radioligand binding data suggested a seven- to twenty-fold enhanced affinity for a C-3
methoxymethyl group (compounds 237 and 238) compared to methyl substituted compounds
(compounds 186 and 185). This increased affinity is also evident in the cytoprotective
efficacy of these compounds. The average IC50-value of the C–2 unsubstituted
methoxymethyl compound 237 was determined to 55.8µM, whereas no cytoprotective effects
were found for C-3 methyl substituted compound 186 up to 250µM. The same results were
obtained for the 2-chloro substituted analogues 238 (R1=methoxymethyl / R2=Cl;
IC50=15.7µM) and 185 (R1=methyl / R2=Cl; IC50>200). On the other hand, bulky alkyl
residues like n-hexyl (compound 234; IC50 >50) or cyclohexyl (compound 197; IC50 >50) led
to decreased potencies. Therefore, the size of the introduced residue is critical with anResults – cell death based in vitro assays
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Fig.  33-A   Inhibition of NMDA receptor mediated cell death by eight thieno[2,3-
b]pyridinone derivates and L-701,324.  Compounds were incubated for 24h in MEM w/o Mg
2+
containing 5% FCS, 55mM KCl and 4µM dexamethasone at 5% CO2. Cell death rate is expressed as
percentage of positive control. Hill coefficients were > 1 for all tested compounds.
Fig. 33-B Warfarin increases the potency of L-701,324 and compound 237
Compounds were incubated for 24h in MEM w/o Mg
2+ containing 5% FCS, 55mM KCl and 4µM
dexamethasone at 5% CO2 in the presence and absence of warfarin.Results – cell death based in vitro assays
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It should be noted, that the observed dose response curves displayed a very steep slope (see
fig. 33-A) and Hill coefficients > 1, which is a characteristic for the positive cooperativity of
ligand binding. Since more than one glycine recognition site is present in the heteromultimer
complex, this finding suggests, that the binding of one antagonist to a glycine recognition site
lowers the affinity of glycine at the remaining binding sites. 
3.4.4  Structure - in vitro activity relationship of quinoxaline-2,3-diones
Two 6,7-dihydro-1H,5H-pyrido[1,2,3-de]quinoxaline-2,3-diones (Nagata et al., 1994) were
tested for their cytoprotective efficacy. The structure of these glycine site antagonists derived
from the AMPA and NMDA receptor / glycine site antagonists CNQX and DNQX (see fig.
34). These compounds represent high affinity glycine antagonists (Nagata et al., 1994) with a
20-fold selectivity over AMPA receptors due to the substitution of one of the nitrogen atoms.
For the determination of IC50-values, hNR1-1a / hNR2A expressing L12–G10 cells were
exposed to the compounds in the induction model. Nagata et al. evaluated the affinity for the
glycine binding site of the NMDA receptor using a [
3H]-5,7-dichlorokynurenic acid binding
assay. The six-membered ring-fused tricyclic quinoxalinedione 18g displayed high affinity for
the glycine site. The Ki-value was determined to 9.9 nM. The corresponding anilide derivative
20g was reported to be 4-fold more potent than 18g (Ki = 2.6 nM) and as potent as the
tetrahydroquinolone derived compound L-689,560 (Leeson et al., 1992), one of the most
potent glycine antagonists so far reported, whose structural features in position 4 are
incorporated in these two compounds (fig. 34). The data obtained from the cytotoxicity assays
confirmed the described structure affinity relationship between compounds 18g and 20g. For
the anilide derivate 20g an IC50 -values of 4.7µM was determined. In contrast, the carboxylic
acid derivative 18g was less effective with an IC50-values of 17.2µM. From these data, an IC50
ratio of 3.7 is calculated which accurately fits to Ki-ratio of 3.8 obtained from the radioligand
binding studies.Results – cell death based in vitro assays
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Fig. 34 Structure – activity relationship of 6,7-dihydro-1H,5H-pyrido[1,2,3-de] quinoxaline-2,3-
dione derivates 20-g and 18-g
Ki-values for displacement of [
3H]-DCKA in rat brain membranes were taken from Nagata et al, 1994.
IC50-values represent the concentration for halfmaximum cytoprotection of L12-G10 cells in the
induction model.
3.4.5  Pharmacology of clones
Since the induction model is limited by the presence of glutamate and glycine containing
FCS, the further pharmacological characterization of clones was performed in the improved
differentiation model. This design offers the possibility of cell death based in vitro assays
under defined concentrations of agonists, antagonists and modulators.
Beside the determination of IC50-values for competitive and non-competitive antagonists, the
influence of modulators of the NMDA receptor complex, such as protons, polyamines,
histamine and protein kinase C were examined. We have also addressed the question whether
subunit specific antagonists like ifenprodil and haloperidol, exhibit a preference for distinct
clones expressing different NMDA receptor subtypes.
3.4.5.1  Cell death caused by NMDA receptors is pH dependent
It has been reported from electrophysiological studies, that native NMDA receptors are
sensitive to the extracellular proton concentration (Traynelis and Cull-Candy, 1990; Traynelis
and Cull-Candy, 1991). In these receptor preparations, protons inhibit the NMDA receptor
function by 50 percent at pH 7.3. Protons seem to mediate their NMDA receptor inhibition by
interactions with the NR1 subunit, and both polyamines and presence of NR1 exon 5
potentiate receptor function through relief of the tonic proton inhibition present at
physiological pH (Traynelis et al., 1995). Since the heteromultimeric channels expressed in
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our cell lines contain the splicevariant NR1-1a lacking the 5´-insert (exon 5), these cell lines
should be sensitive to proton inhibition. Therefore, the effects of various pH levels upon cell
death rate were investigated.
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Fig. 35 Proton inhibition of NMDA receptor mediated cell death at clone L12-G10 (A)
and L13-E6 (B) 
Clones were cultured in growth medium containing 4µM dexamethasone and 100µM ketamine for 20
hours. After removal of ketamine, clones were stimulated in CSS containing 400µM L-glutamate and
D-serine adjusted to pH levels between 6.8 and 8.0 for 90 min.
As shown in fig. 35, cell death rates of both clones depended on applied pH values. In clone
L12-G10 expressing subunits NR1-1a / NR2A, an IC50 of pH 7.2 was calculated. L13-E6
cells, expressing subunits NR1-1a / NR2B, showed a greater sensitivity to proton inhibition
with a halfmaximum inhibition at pH 7.5. These results correspond to data from
electrophysiological studies with NMDA receptor transformed Xenopus oocytes (Traynelis et
al., 1995). Traynelis et al. reported IC50-values for proton inhibition of pH 7.2 for NR1-1a /
NR2A expression and pH 7.3 for NR1-1a / NR2B receptors. Further experiments were
performed under the relief of proton inhibition (pH 7.6 for L12-G10 or 8.0 for L13-E6) unless
indicated differently.
3.4.5.2  Spermine triggers cell death in a subunit specific manner
Polyamines like spermine are known to modulate the activity of the NMDA receptor complex
by distinct mechanisms. One mechanism is the glycine independent stimulation. This
stimulation depends on NR subunit composition, since only receptors containing NR1 spliceResults – cell death based in vitro assays
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variants lacking the 5´-insert (such as NR1-1a) exhibit stimulation (Durand et al., 1993;
Gallagher et al., 1996). In addition, glycine independent stimulation is only seen at receptors
containing NR2B but not at NR2A-, NR2C-, NR-2D containing receptors (Kashiwagi et al.,
1996a; Williams et al., 1994). Under saturated concentrations of glycine, it was proposed that
polyamines act to shield the proton sensor, reducing the proton inhibition and therefore
potentiating the activity of NMDA receptors (Traynelis et al., 1995). To confirm this
hypothesis, the effect of 300µM spermine on proton inhibition was examined (fig. 36). After
20 hours of receptor induction and removal of ketamine, the cells were incubated in CSS
containing 100µM L-glutamate and glycine in the presence or absence (control) of 300µM
spermine at various pH values. Exposure of clone L13-E6 to spermine enhanced cell death
rate from pH 6.8 to 8.0. The relative extent of increased cell death by spermine depended on
the applied pH values. At pH 8.0, cell death at 300µM spermine was only slightly enhanced
compared to control. In contrast, the relative extent of triggered cell death increased strongly
if NMDA receptor activity in controls was reduced due to proton inhibition (pH 7.4 to 6.8).
Fig.  36 Proton and subunit dependent enhancement of cell death by spermine
Clones were cultured in growth medium containing 4µM dexamethasone and 100µM ketamine for 20
hours. After removal of ketamine, clones were stimulated in CSS containing 100µM L-glutamate and
glycine or CSS containing additional 300µM spermine. The pH of the incubation medium was varied
from pH 6.8 to 8.0.
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These findings suggest a partial relief of proton inhibition through the application of spermine
at NR1-1a / NR2B expressing L13-E6 cells. With clone L12-G10, no receptor stimulation by
spermine was observed. In contrast, a slight inhibition of cell death was detected.
3.4.5.3  Glycine site agonist D-serine enhances L-glutamate induced cell death
To demonstrate a coagonism at the L-glutamate and glycine binding sites of the expressed
NMDA receptors, increasing concentrations of D-serine, L-glutamate and L-glutamate plus
100µM D–serine or D–serine plus 100µM L–glutamate were applied to both clones (fig. 37).
During the application of D–serine at concentrations up to 100µM, both clones remained
healthy and no LDH release could be determined. In contrast, L–glutamate induced cell death
in both clones in a dose dependent manner. Maximum cell death rates of both clones were
enhanced by addition of 100µM D–serine. Co-treatment with increasing concentrations of D–
serine and 100µM L–glutamate exhibited a dose response to D–serine. But unexpectedly,
enhanced cell death was even observed under low D–serine concentrations (0.1µM). This
atypical dose dependency might be explained by glycine contamination due to the washing
procedure with the BSA containing wash solutions.
Fig. 37 Glycine site agonist D-serine enhanced L-glutamate mediated cell death
Differentiated clones were stimulated in CSS containing increasing concentrations of D-serine, L-
glutamate, L-glutamate with 100µM D-serine or D-serine with 100µM L-glutamate.
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This contamination may also account for the lower enhancement of maximum cell death by
co-application of 100µM D–serine and L–glutamate compared to single application of 100µM
L–glutamate at clone L13–E6. As shown later, this clone has a stronger preference for
agonists compared to clone L12–G10 reflecting the distinct pharmacological properties of the
transfected NR2 subunits. Hence, the determination of concentrations required for
halfmaximum cell death (EC50) for glycine site agonists D–serine or glycine were not
possible. The estimated EC50 for glutamate under saturated D-serine concentrations were
3.4µM (3.71µM, 3.12µM) for L12-G10 (fig. 37-A) and 2.7µM (2.80µM, 2.59µM) for L13-E6
(fig. 37-B).
3.4.5.4  Glutamate and glycine site antagonists inhibit NMDA receptor induced cell
death
The ability of competitive antagonists at the glutamate and glycine binding site of NMDA
receptors to prevent cells from undergoing cell death due to calcium overload was examined
(tab. 7). For glutamate antagonism, (R/S)-AP5 and (R/S)-CPP were tested. Both antagonists
prevented L12-G10 and L13-E6 cells from cell death. In both clones, (R/S)-CPP showed a 6-
to 10-fold higher potency than (R/S)-AP5. Comparing the potency of antagonists in both
clones there seems to be a dependency on receptor subunit composition which is in good
agreement with data from radioligand binding studies at recombinant receptors (Laurie and
Seeburg, 1994). The hNR1-1a / hNR2A expressing clone L12-G10 seems to be an antagonist
preferring clone. The IC50 ratios (L12-G10:L13-E6) for (R/S)-AP5 (0.14) and for (R/S)-CPP
(0.22) indicate a higher affinity of these antagonists to NR2A containing assemblies. The
same preference was found for glycine site antagonist DCKA with a IC50 ratio of 0.15.
Protection by 100µM DCKA was abolished in both clones by increasing concentrations of co-
agonists glycine and D-serine, respectively. No significant difference in the potency of both
co-agonists was observed. To abolish 50% of the cytoprotective effect of 100µM DCKA
(EC50) in L12-G10 cells, approximately 200µM of either glycine or D-serine were needed
whereas L13-E6 showed a higher preference for co-agonists with EC50 of 70µM for glycine or
103µM for D-serine. Similar results were obtained using (R/S)-CPP and L-glutamate or L-
aspartate. In L13-E6 cells the cytoprotective effect of 100µM CPP was abolished to 50% by
149µM L-glutamate or 1044µM L-aspartate whereas at clone L12-G10 EC50-values of
182µM and 1769µM for displacement of 30µM (!) (R/S)-CPP were determined. Comparing
efficacy of both agonists, L-glutamate is 7 to 10 fold more effective than L-aspartate.Results – cell death based in vitro assays
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Tab. 7.  Pharmacological properties of clones L12-G10 and L13-E6 expressing hNR1-1a /
NR2A and hNR1-1a / hNR2B, respectively (determined by cytotoxicity assays in the
differentiation model). For tests with ketamine and competitive antagonists, cells were stimulated in
CSS containing 30µM L-glutamate / glycine and increasing concentrations of compounds. Non-
competitive compounds ifenprodil and haloperidol were applied in CSS containing 100µM L-glutamate
and glycine. For agonist testing, the indicated concentration of antagonist was included and increasing
concentrations of agonist were applied to abolish the cytoprotective effects of the antagonists. All
concentrations were tested in triplicates. The ratios of respective IC50-values indicate ligand
preference for clone L12-G10 (<1) or for L13-G10 (>1).
3.4.5.5  Ifenprodil and haloperidol inhibit cell death selectively at NR2B expressing
L13-E6 cells in the absence of spermine
Ifenprodil and haloperidol are known to be non-competitive antagonists selective for NMDA
receptors containing the subunit NR2B. The mechanisms by which ifenprodil and haloperidol
inhibit the ligand gated ion channel are still unknown. One proposed mechanism is the
interaction with polyamine binding sites (Carter et al., 1990) in a competitive or more recently
reported in an allosteric way (Kew and Kemp, 1998). Initially, both compounds were tested
for their ability to protect clones from undergoing cell death in the absence of spermine. Both
L12-G10 cells  L13-E6 cells 
expressing NR1a/NR2A expressing NR1a/NR2B
Compound IC50 or EC50 IC50 or EC50 ratio
[µM] [µM]
Antagonists
  (RS)-APV 17.1 (14.4; 19.7)* 121.4 (115.2; 127.7)* 0.14
  (RS)-CPP 2.6* 12.0* 0.22
  DCKA 3.7* 24.6 (13.3; 36.0)* 0.15
  Ifenprodil >100 0.149 ± 0.019  >670
  Haloperidol >100 2.19 ± 1.55  >45
  Ketamine 14.4* 14.9* 0.97
Agonists
  glycine 192.8** 70.3** 2.7
  D-serine 206.9** 103.4** 2.0
  L-glutamate 182.1*** 148.6**** >1
  L-aspartate 1769.5*** 1043.9**** >1
* vs 30µM L-glutamate / glycine
** vs 100µM DCKA
*** vs 30µM (RS)-CPP
**** vs 100µM (RS)-CPPResults – cell death based in vitro assays
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compounds were cytoprotective to clone L13-E6 expressing subunits hNR1-1a / hNR2B (fig.
38-B). Ifenprodil strongly inhibits cell death with an IC50 of 149nM whereas haloperidol was
15-fold less effective (IC50 2.19µM). In contrast, cell death of clone L12-G10 remained
unaffected up to 100µM (fig. 38-A). Higher concentrations were not tested due to induction of
unspecific cell death. 
Since polyamines were not present under our standard settings, the mechanism of inhibition
by these NR2B specific antagonists seems not to be restricted to a competition at polyamine
binding sites. Hence, we wanted to elucidate whether spermine is able to abolish
cytoprotective effects of both antagonists in a competitive way. As polyamines have several
modes of action, e.g. potentiation by increasing the affinity for glycine or glycine independent
stimulation by reducing proton inhibition, the proposed direct competition of spermine and
NR2B specific antagonist should be best demonstrated under saturating glycine conditions
(100µM glycine). To exclude an abolishment of proton inhibition by spermine, experiments
were performed under relief of proton inhibition (pH 8.0).
Fig. 38  Subunit dependency of cytoprotective effects of ifenprodil and haloperidol and
interaction with spermine
Differentiated cells were stimulated in CSS containing 100µM L-glutamate and glycine under relief of
proton inhibition. (A) Effects at NR1-1a / NR2A expressing L12-G10 cells; (B) Effects at NR1-1a /
NR2B expressing L13-E6 cells in the presence and absence of 300µM spermine.
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As shown in fig. 38-B, spermine failed to abolish cytoprotective effects of haloperidol and
ifenprodil in a competitive way. The obtained dose response curves from controls and
spermine treated cells exhibited significant different slopes. At non-protective concentrations
of antagonist spermine increased the rate of cell death. In contrast, protective concentration
levels remained nearly unaffected. Therefore, an allosteric interaction of spermine with both
compounds is more likely.
3.4.5.6  Cell death is not triggered by histamine or activation of PKC
NT2 cells, representing a clonal line of human teratocarcinoma cells, exhibit NMDA receptor-
mediated excitotoxicity after terminal differentiation into NT2-N neurons (Munir et al., 1996).
Besides spermine and spermidine, histamine enhanced glutamate mediated excitotoxicity in a
dose-dependent manner consistent with expression of an NR1 / NR2B combination of
subunits. Examination of histamine effects on NMDA receptor-mediated ion current in
cultured rat cortical neurones showed that in a subpopulation of the neurones tested, histamine
(10-100 mM) enhanced the peak amplitude and slowed down the onset of desensitization of
the NMDA-induced ion currents, both in a concentration-dependent manner (Zwart et al.,
1996).
We have tested whether histamine triggers cell death in our recombinant cell lines (fig. 39),
too. At clone L12-G10, neither 10µM nor 30µM histamine significantly influenced L-
glutamate mediated cell death which was determined under relief of proton inhibition (pH
7.6). This is consistent with previous described findings which suggested that the NR1-1a /
NR2A combination of subunits is not sensitive to histamine stimulation (Williams, 1994a). At
NR1-1a / NR2B expressing L13-E6 cells, histamine also failed to enhance L-glutamate
dependent cell death. At non saturated glutamate concentration levels (0.1 to 1µM), cell death
rates were unchanged to control. In contrast, under saturated concentrations of L-glutamate
(10 to 30µM), 30µM histamine significantly decreased cell death rates compared to control by
approximately 10 to 20%. This unexpected inhibition by histamine is in contradiction with
results obtained from NT2-N cells and heterolgous expression in Xenopus oocytes as
mentioned above. But it is consistent with the finding that histamine affects NMDA receptors
in a pH-dependent manner. Whole cell records in the CA1 region of slices of rat hippocampus
showed that histamine enhanced the N-methyl-D-aspartate (NMDA) component of the
synaptic current at lowered pH (7.2) whereas at raised pH (7.6) it reduced them (Saybasili et
al., 1995). At a pH of 7.4 no effects were observed. Since we performed the reported cell
toxicity assays under relief of proton inhibition (pH 8.0 for clone L13-E6), our data supportResults – cell death based in vitro assays
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the finding of a histamine mediated inhibition of NR2B containing NMDA receptors at raised
pH levels. Contradictions to other observations may be caused by distinct pH conditions.
Fig. 39 Effects of histamine
Differentiated clones were stimulated with increasing concentrations of L-glu (0.1-30µM) in the
absence or presence of 10µM or 30µM histamine. Experiments were performed under relief of proton
inhibition (pH 7.6 for L12-G10 and pH 8.0 for L13-E6) and saturating glycine concentrations (100µM).
Since it has been reported that activation of PKC by 12-O-tetradecanoylphorbol 13-acetate
(TPA) treatment in Xenopus oocytes potentiated the response of NR1 / NRε1 and NR1 / NRε2
assemblies (Kutsuwada et al., 1992; Mori et al., 1993) we tested the ability of TPA to trigger
cell death in our cell culture models. L12-G10 and L13-E6 cells were stimulated with
increasing concentrations of L-glutamate in the presence and absence of 100nM TPA for 90
min (fig. 40). With both cell lines, treatment with TPA failed to affect L-glutamate induced
cell death. This finding suggests, that either the expressed receptors are highly phosphorylated
due to basal activity of PKC or a putative phosphorylation did not affect receptors activity due
to lack of calmodulin binding and inhibition.Results – cell death based in vitro assays
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Fig. 40 Activation of PKC did not trigger cell death
Differentiated clones were stimulated with increasing concentrations of L-glutamate (0.03-30µM) in the
absence or presence of 100nM TPA. Experiments were performed under relief of proton inhibition (pH
7.6 for L12-G10 and pH 8.0 for L13-E6) and saturated glycine concentrations (100µM).
3.5  Mechanism of cell death inhibition by cyclosporin A
The initial event in glutamate evoked excitotoxicity in neurons is an extensive entry of
extracellular calcium through overstimulated NMDA receptors. Although it is well accepted
that the subsequent intracellular accumulation of calcium plays a key role in the induction of
excitotoxicity, the calcium dependent pathogenetic target is still unknown.
In cerebellar granule cells (CGC), continuous glutamate exposure is characterised by a
transient elevation of cytoplasmatic free calcium followed by a decay to a plateau after
NMDA receptor desensitization. The plateau is maintained for a variable time (latent period)
until a secondary, irreversible increase in intracellular calcium occurs (Nicholls and Budd,
1998). The raised calcium levels during the latent period as well as the delayed calcium
deregulation do not depend on the presence of L-glutamate. Since the activity of calcium
pumps within the plasma membrane could not only account for the decay of intracellular
calcium to the plateau within the latent period, the involvement of calcium sequestering
cellular organelles is likely. The dominant organelles capable of sequestering large quantities
of calcium are the mitochondria. Meanwhile, it has been demonstrated that mitochondriaResults – inhibition of cell death by CsA
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accumulate large quantities of calcium during a toxic glutamate stimulus (White and
Reynolds, 1997) and that calcium efflux from mitochondria contributes to the delayed
calcium deregulation after glutamate removal (White and Reynolds, 1996). Therefore,
mitochondria are supposed to be the primary targets in glutamate induced excitotoxicity
(Schinder et al., 1996).
It is known that mitochondria can actively accumulate calcium into their matrix using the
electrical potential across the inner membrane as the driving force. This calcium transporting
system operates as a uniporter whose activity depends on the intracellular calcium
concentration with a set point of approximately 500nM as well as on the mitochondria
membrane potential. In the presence of phosphate, substantial amounts of calcium can be
taken up forming insoluble calcium phosphate complexes within the matrix. In the case of
glutamate induced excitotoxicity, sequestering of calcium is accompanied by a depolarisation
and finally by a disruption of the transmembrane potential ∆ψ which is detrimental for the
oxidative phosphorylation. The loss of ∆ψ is explained by a permeability transition (PT) state,
a phenomenon that is characterized by the opening of pores spanning the inner and outer
membrane of mitochondria. Since these pores are permeable to compounds up to 1500 kDa,
the opening of these PT pores allows the equilibration of protons and the release of respiratory
substrates, sequestered calcium and other cell death inducing factors like cytochrome C
(Kantrow and Piantadosi, 1997) and apoptosis-inducing factor (AIF) into the cytosol (Susin et
al., 1996). The molecular composition of the PT pores is not entirely known but the adenine
nucleotide translocator (ANT or ADC), the voltage dependent anion channel (VDAC), the
peripheral benzodiazepine receptor (Szabo et al., 1993) and matrix cyclophilin (Connern and
Halestrap, 1994; Crompton et al., 1992) are probable components of the PT pore. Similar to
NMDA receptors this channel seems to be inhibited by protons (Halestrap, 1991) (Szabo et
al., 1992) and sensitive to membrane potentials (Bernardi et al., 1993).
The immunosuppressant drug Cyclosporin A (CsA) has been reported to block pore
conductance and to inhibit the onset of mitochondrial PT at isolated mitochondria from liver
(Broekemeier et al., 1989; Davidson and Halestrap, 1990; Szabo and Zoratti, 1991) and heart
cells (Crompton et al., 1988; Halestrap et al., 1997). Cytoprotective effects of CsA were
shown in anoxic cultured hepatocytes (Broekemeier et al., 1992; Pastorino et al., 1993) and
for neurons in an ischemic animal model (Friberg et al., 1998) and CGC cells (Ankarcrona et
al., 1996). Also a delayed mitochondrial depolarization after treatment of cultured cortical
neurons with CsA has been reported (Nieminen et al., 1996).Results – inhibition of cell death by CsA
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It should be noted that beside its inhibitory effect upon the cyclophilin proportion of the PT
pore, CsA (in submicromolar concentrations) is also a known inhibitor of the Ca
2+/calmodulin
dependent Ser/Thr phosphatase calcineurin. Inhibition of calcineurin is also mediated by the
immuno-suppressive drug tacrolimus (FK506) in a submicromolar concentration range (10-
100nM). Calcineurin has been shown to regulate the activity of native NMDA receptor
channels at two different levels, gating and desensitization. FK506 has been shown to prolong
the duration of single NMDA receptor channel openings (Lieberman and Mody, 1994).
Inhibition of calcineurin by cyclosporin A (200-500nM) or FK506 (200-500nM) decreased
the glycine insensitive desensitization after synaptic stimulation of NMDA receptors on rat
hippocampal neurons (Tong et al., 1995). Thus, calcium entry through native NMDA
receptors in neurons is limited by calcineurin activity and inhibition of calcineurin by
cyclosporin A or FK506 results in a prolonged opening of channels. In contradiction,
inhibition of calcineurin by 100nM CsA or FK506 has been reported to prevent the
development of both early necrosis and delayed apoptosis in cerebellar granule cells
(Ankarcrona et al., 1996). Although CsA and FK506 are structurally unrelated compounds,
both bind to specific immunophilins (cyclophilin A and FKBP12). Inhibition of calcineurin
activity is then mediated by the binding of cyclosporin A / cyclophilin or FK506 / FKBP12
complexes.
As already shown, even heterologous expression of recombinant NMDA receptors in non-
neuronal cell lines leads to an increase in intracellular calcium concentration (Grant et al.,
1997) and subsequent cell death (Anegawa et al., 1995) depending on subunit composition.
To examine, whether even in heterologous expression systems the occurring excitotoxicity is
related to an early damage of mitochondria, the influence of the extracellular calcium
concentration upon intracellular ATP levels was investigated. Using the differentiation model,
L12-G10 were stimulated in CSS pH 7.6 containing 100µM L-glu / gly. The content of
calcium chloride was varied from 1.8µM to 0.1µM, respectively. Differentiated L12-G10
cells, treated with CSS pH 7.6 with 1.8mM Ca
2+ lacking L-glu / gly were used as control.
ATP levels were determined using a luciferase based bioluminescence assay. ATP levels were
assayed before and during stimulation with CSS (10, 20 and 30 min).Results – inhibition of cell death by CsA
94
time [min]
0 1 02 03 0
R
L
U
 
i
n
 
%
 
t
o
 
c
o
n
t
r
o
l
0
20
40
60
80
100
120
1.8 mM Ca
2+
0.1 mM Ca
2+
Fig. 41 Decrease of ATP levels after NMDA receptor stimulation is Ca
2+ dependent
Differentiated L12-G10 cells were stimulated in CSS pH 7.6 containing 100µM L-glu / gly, 1% BSA and
1.8 or 0.1mM Ca
2+, respectively (n = 3). Differentiated L12-G10 cells cultured in CSS pH 7.6 (1% BSA)
w/o L-glu / gly were used as control. ATP samples were taken prior to stimulation and after the
indicated time intervals. The ATP content of the samples was determined using a luciferase based
bioluminescence assay. The obtained relative light units (RLU) are proportional to the amount of ATP
within the samples. Results are expressed as RLU in % to control.
As shown in fig. 41, cultures stimulated in CSS containing 1.8mM Ca
2+ exhibited decreased
ATP levels whereas cultures stimulated in CSS with reduced Ca
2+ content maintained ATP
levels comparable to unstimulated control cultures. Although it cannot be excluded, that the
decreased ATP levels are caused by the loss of plasma membrane integrity, these data clearly
indicate the keyrole of Ca
2+ and its involvement in the observed excitotoxicity.
For further investigations on the role of mitochondrial Ca
2+ sequestration, CsA and FK506
were investigated for cytoprotective effects in a modified differentiation model. Clones,
cultured in induction medium containing 4µM dexamethasone and 100µM ketamine for 16 h,
were pre-treated with compounds for 4 hours followed by stimulation with L-glutamate and
glycine in the presence of immunophilin ligands. Stimulation of L12-G10 cells with
saturating agonist concentrations (400µM L-glu /gly) in the presence of CsA reduced cellResults – inhibition of cell death by CsA
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death by approximately 40% (fig. 42) with an IC50-values of 7.1µM. Similar results were
obtained for L13-E6 cells (IC50 of 7.1µM). Therefore, the cytoprotective effect of CsA seems
not to be subunit specific. FK605, known to inhibit calcineurin but not the PTP (Friberg et al.,
1998), did not exert significant cytoprotective effects in concentrations up to 30µM. Higher
concentrations induced unspecific toxicity. 
To examine whether plain pre-treatment of cells is sufficient for a cytoprotective effect, L12-
G10 cells, differentiated with 4µM dexamethasone and 100µM ketamine for 16 hours, were
loaded with CsA (0.3-30µM) for 4 hours in induction medium prior to stimulation with CSS
containing 100µM L-glutamate and glycine. As shown in fig. 42, cytoprotective effects
obtained by plain pre-treatment of cells are similar to those obtained by pre-treatment and
application during the stimulation interval. A prolonged pre-treatment of L12-G10 cells for 3h
with increasing concentrations of FK506 did not lead to significant cytoprotection.
Interestingly, these cytoprotective effects were only observed after a prolonged pre-treatment
of cells with CsA.
Fig. 42 Inhibition of cell death by
CsA
Cytoprotective efficacy of immunophilins
CsA and FK506 was tested (A) by pre-
treatment for  4 hours and presence
during stimulation period or  (B) by plain
pre-treatment with CsA (4 hours) or
FK506 (3 hours). L12-G10 cells were
stimulated in CSS with saturating
concentrations of L-glutamate and glycine
under relief of proton inhibition (pH 7.6).
As shown in fig. 43 the cytoprotective
effect decreases if the pre-treatment
interval is reduced. Maximum
cytoprotection is obtained after 4 hours and reduced the cell death rate by more than 60%. No
significant prevention of cell death was observed with a brief pre-treatment interval of 10
minutes. Pre-treatment with 30µM FK506 was less effective with a maximum reduction of
cell death by approximately 15% for pre-treatment intervals from one to three hours. After 4
hours of pre-treatment, cell death rate exceeded those of control cells due to unspecificResults – inhibition of cell death by CsA
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toxicity. Similar to CsA, a brief pre-treatment of 10 minutes failed to exert cytoprotection.
The need of a prolonged pre-treatment by CsA for maximum cytoprotective effects is
surprising and could not be explained by a delayed resorption of CsA to the cells since the
cyclic undecapeptide has a highly lipophilic structure. 
A possible explanation for this phenomenon could be effects on NMDA receptor expression.
Studies concerning functional expression of potassium channels in Xenopus oocytes have
shown  that a prolonged treatment (16h) of RNA injected oocytes with CsA selectively
reduces the functional expression of the transformed channels (Chen et al., 1998). Since the
protein synthesis was not impaired by CsA, these authors conclude that the functional
expression of these channels is facilitated by the peptidyl-prolyl isomerase cyclophilin. A
similar hypothesis was proposed from another group (Helekar et al., 1994) who also
demonstrated that functional surface expression of α7 neuronal nicotinic and a type 3
serotonin receptor is dependent on the activity of a cyclophilin.
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Fig. 43  Cytoprotection by CsA depends on the duration of pre-treatment intervals 
L12-G10 cells expressing NMDA receptors were loaded with 30µM CsA for the indicated intervals.
Ketamine and CsA were removed by washing. Cells were stimulated in CSS pH 7.6 containing 100µM
L-glutamate and glycine.Results – inhibition of cell death by CsA
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Surface receptor expression was reduced in channel and cyclophilin co-injected oocytes by a
treatment with 2 to 30µM CsA for 4 to 7 days. These authors concluded, that the oligomeric
assembly of neurotransmitter-gated ion channels is a multi-step process involving the
participation of cyclophilins. These immunophilins, which are present in the cytoplasm, the
endoplasmatic reticulum and the mitochondria, exhibit a peptidyl-prolyl isomerase activity
and assist in the folding of polypeptides similar to classical heat shock proteins (chaperones).
To determine whether the cytoprotective effects after prolonged pre-treatment with CsA are
caused by an inhibition of the PT pore or by a reduction of receptor surface expression, we
investigated the surface expression of the NR1 keysubunit by densitometric volume analysis
of immunoblots. L12-G10 cells were differentiated with 4µM dexamethasone and 100µM
ketamine for 14 hours and an additional differentiation interval of 6 hours in the presence or
absence of 30µM CsA. Plasma membranes were enriched by density centrifugation and
subjected to gel electrophoresis. For relative quantification of subunit NR1-1a protein
amounts of 8, 4, 2 and 1µg were probed with a mouse anti-NR1 (N-term) antibody. The
resulting immunoblots were analysed by densitometric volume analysis. As shown in fig. 44,
the amount of membrane bound NR1-1a receptor was drastically reduced to 28.5 % (29.76%;
27,32%) under treatment with 30µM CsA for 6 hours. 
To investigate, whether the reduced protein amount of NR1a is accompanied by decreased
mRNA levels, RT-PCR analysis was applied. L12-G10 cells were differentiated with 4µM
dexamethasone and 100µM ketamine for 9 hours and an additional differentiation interval of
4 hours in the presence and absence of 30µM CsA. Uninduced L12-G10 cells were used as
control. After 13 hours, total RNA was isolated and mRNA was transcribed into cDNA using
d(T)12-18 priming. Reverse transcription was followed by PCR with primers corresponding to
the transfected NMDA receptor subunits NR1a and NR2A (same Primers were used for the
detection of NMDA receptor mRNA; see chapter 3.3.1). Qualitative and quantitative template
homogeneity was verified by PCR with ß-actin primers. As shown in fig. 45, differentiation
with 4µM dexamethasone for 13 hours increased the transcription rate of subunit NR1a and
NR2A. These increased transcription levels were not affected by prolonged treatment with
30µM CsA. Hence, these results exclude an interference of CsA with the transcription of
transfected cDNAs and favour the suggested CsA mediated inhibition of the peptidyl-prolyl
isomerase cyclophilin as a mechanism for the reduced NMDA receptor expression.Results – inhibition of cell death by CsA
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Fig.  44 Prolonged treatment with cyclosporine A decreases expression of NMDA
receptor subunit NR1-1a
L12-G10 cells were differentiated with 4µM dexamethasone and 100µM ketamine for 14 hours and an
additional differentiation interval of 6 hours in the presence and absence of 30µM CsA. Plasma
membranes of cell lysates were enriched by density centrifugation and aliquots of solubilized
membrane protein (8, 4, 2, 1µg) were probed with N–terminal directed monoclonal mouse anti–NR1
antibody. Decreased NR1a amount in CsA treated cells was estimated by linear regression of
densitometric volume analysis data from controls.
Fig.  45 Prolonged treatment with cyclosporin A does not affect transcription rates of
transfected NMDA receptor subunits
L12-G10 cells were differentiated with 4µM dexamethasone and 100µM ketamine for 9 hours and an
additional differentiation interval of 4 hours in the presence of 30µM CsA. As control, uninduced L12-
G10 cells were used. Treatment with 4µM dexamethasone increased mRNA levels of NR1-1a and
NR2A. Additional treatment with 30µM CsA did not alter the amount of NR1-1a or NR2A transcripts.Results – inhibition of cell death by CsA
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Since functional NMDA receptors represent heteromultimers consisting of NR1 and NR2
subunits (Chazot et al., 1994) and the NR1 subunit represents a keysubunit necessary for
successful surface expression (McIlhinney et al., 1996), the described reduction of NR1-1a
expression by CsA may drastically alter the NMDA receptor mediated calcium influx. Hence,
the functionality of expressed NMDA receptors after CsA treatment was characterized by
fluo-4 calcium imaging. L12-G10 cells were differentiated with 4µM dexamethasone and
100µM ketamine for 15 hours and an additional differentiation interval of 5 hours in the
presence and absence of 30µM CsA.
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Fig.  46 Prolonged treatment with cyclosporine A leads to a loss of functional NMDA
receptors
Cells were differentiated on coverslips in growth medium containing 4µM dexamethasone and 100µM
ketamine for 15 hours and an additional differentiation interval of 5 hours in the presence or absence
of 30µM CsA. For dye loading, the cultures were treated with 1µM fluo-4 acetoxymethylester in original
medium at 37°C. To enable receptor activity, ketamine was removed by washing. All experiments
were performed in CSS pH 7.6. Thick lines represent the obtained mean values: (A) Stimulation of
control cells with 100µM L-glu / gly (n=16); (B) stimulation of CsA treated cells with 100µM L-glu / gly
(n=13); (C) stimulation of control cells with 30µM ionomycin (n=8); (D) stimulation of CsA treated cells
with 30µM ionomycin (n=17).Results – inhibition of cell death by CsA
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As shown in fig. 46-B, 100µM L-glu / gly failed to increase intracellular calcium levels in
CsA treated cultures, whereas intracellular calcium significantly increased in control cells
(fig. 46-A). Successful dye loading of CsA treated and untreated cells was demonstrated by
the application of 30µM ionomycin (fig. 46-C and D). 
From these data we conclude, that the observed cytoprotective effects exerted by prolonged
pre-treatment with CsA are predominantly caused by an interaction with the NMDA receptor
expression. Since we could exclude an influence on the transcription rate of transfected
cDNAs, another possibility could be the suggested inhibition of the peptidy-prolyl isomerase
activity of immunophilin by CsA which will lead to the observed reduction of plasma
membrane bound NR1-1a subunit and therefore prevent the formation of functional NMDA
receptors. The influence of CsA upon the surface expression of NR2 subunits was not
investigated. But since it has been shown, that heterologously expressed NMDA receptor
subunits are assembled in the ER and that co-synthesis of the subunits is necessary for their
successful cell surface  targeting (McIlhinney et al., 1998), a reduction of cell surface
expressed NR2 subunits seems to be likely.  As shown in fig. 43, CsA failed to exert
cytoprotective effects after a brief equilibration interval of 10 min.
These investigations were performed under the relief of tonic proton inhibition (CSS pH 7.6)
leading to highly permeable channels. It should be added that, in contrast to these results,
cytoprotective effects were evident under partial proton inhibition of NMDA receptors (CSS
pH 7.0). Under these modified conditions, a brief pre-treatment with 30µM CsA for 10 min
reduced cell death by approximately 40% compared to control (fig. 47). FK506 (30µM) was
only slightly effective and displayed a mean reduction of ~7% compared to control. From
these results a calcineurin mediated cytoprotection of CsA could be excluded due to the lack
of significant cytoprotection exerted by FK506. 
But so far, we cannot clearly distinguish between the assumed inhibition of PT and a
reduction of NR1 subunit expression by inhibition of cyclophilin A. Hence, the participation
of mitochondrial damage after stimulation of heterologously expressed NMDA receptors
remains elusive and instead of CsA, the use of more specific PT inhibitors like bongkrecic
acid or inhibitors of mitochondrial calcium sequestration like ruthenium red or protonophores
should be favoured in further investigations.Results – inhibition of cell death by CsA
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Fig.  47 Inhibition of cell death by brief pre-treatment with 30µM CsA prior to NMDA
receptor stimulation (under proton inhibition)
NMDA receptors expressing L12-G10 cells were loaded with 30µM CsA for 10 min prior to stimulation
in CSS pH 7.0 containing 100µM L-glutamate and glycine.Results – characterization of cell death
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3.6  Characterization of cell death
3.6.1  Applied methods for studies on apoptosis and necrosis
Differences in morphology between necrotic and apoptotic cells include cellular appearance
(cellular shrinking vs. swelling), nuclear changes (condensation and DNA fragmentation of
apoptotic cells), cellular membrane changes (translocation of phosphatidylserines vs. lysis of
membranes) and metabolic changes (e.g. activation of caspases during apotosis). Apoptotic
cells shrink and fragment, but remain metabolically intact (e.g. mitochondrial function, cell
membrane integrity). In the following, the principles of the applied methods are briefly
described.
Even though apoptotic cells are beginning to die, their plasma membrane remains intact. For
studies on cell populations, the release of cytosolic lactate dehydrogenase into the cell culture
supernatant indicates the break down of plasma membranes. The mode of cell death,
apoptosis versus necrosis, was determined in part using the combination of two fluorescent
dyes, Sytox and Hoechst 33342. Both dyes stain DNA; however Sytox is membrane non-
permeable and yields green fluorescent chromatin, whereas Hoechst 33342 is membrane
permeable and stains DNA blue. Viable cells display a normal nuclear size with a diffuse
granular substructure and blue fluorescence. Necrotic cells manifest nuclei with strong green
fluorescence and exhibit a typical chromatin pattern. Apoptotic cells exhibit a condensation of
high molecular weight DNA. Hence, apoptotic nuclei show a dense blue staining caused by
the formation of shrunken chromatin or lobular substructures, those being so called apoptotic
bodies. 
Additionally, apoptotic cells undergo endonuclease cleavage of their chromosomal DNA
which leads to fragmentation into low molecular weight oligonucleosomes. This DNA
cleavage leads to a nucleosomal banding pattern in nucleic acid gel electrophoresis analysis.
The subsequent decreasing content of high molecular weight DNA in the apoptotic nuclei is
detected by DNA staining with the fluorochrome propidium iodide and subsequent flow
cytometry. Alive cells produced a pattern where their DNA content is normal diploid (G0 and
G1 phase of the cell cycle) or greater when they begin to enter mitosis (S, G2 and M phase of
the cell cycle) (see fig. 48). The appearance of populations with a DNA content less than the
G1 amount indicates apoptosis. It should be noted that highly fragmented DNA is also foundResults – characterization of cell death
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in the late states of necrosis leading to signals in flow cytometry quite apart from the G1 peak
of the control.
Fig. 48 Flow cytometric profiles of DNA content
L(tk-) wildtype cells were grown for 24 hours in MEM containing 5% FCS. Nuclei were stained with
propidium iodide (50µg/ml). Populations in different phases of the cell cycle are marked: gap0/gap1
phase (G0/G1); synthesis (S) and gap2 / mitose phase (G2)). Apoptotic or necrotic nuclear populations
cause the indicated changes in profile.
Besides nuclear changes, the externalisation of phosphatidylserine (PS) on the plasma
membrane is another feature of apoptosis. During the early stages of apoptosis, PS is
translocated from the inner part to the outer layer of the plasma membrane, thus exposing PS
at the external surface of apoptotic cells, where it can be specifically recognised by
macrophages. This translocation is indicated by the extracellular binding of annexin V, a Ca
2+
dependent phospholipid-binding protein which possesses high affinity for phosphatidylserine.
For the detection, the annexin–V is coupled to fluorochromes such as Alexa 568. Since
annexin V can also detect necrotic cells as a result of the loss of membrane integrity,
apoptotic cells have to be differentiated from these apoptotic cells by the use of propidium
iodide or calcein-AM. This technique allows the concomitant detection of apoptosis and
necrosis at a single-cell level.
3.6.2  Results of cell death studies
Initial studies on the time dependence of LDH release in the induction model indicated a steep
increase in the loss of membrane integrity 12 hours after the induction of NMDA receptorResults – characterization of cell death
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expression (fig. 49). The detected membrane damage is caused either by secondary necrosis
of apoptotic cells or simply accounts for a necrotic way of cell death.
Fig.  49 Loss of membrane integrity after the induction of NMDA receptor expression
L12-G10 cells were exposed to MEM medium containing 5% FCS and 55mM potassium in the
presence and absence of 4µM dexamethasone. LDH release was assayed after 0, 12, 16, 20, 24, 36
and 48 hours.
To look for phenotypic changes after the induction of NMDA receptor expression, L12-G10
cells were cultured in the presence or absence of NMDA receptor antagonist MK801 (10µM).
Integrity of the plasma membrane was examined by the exclusion of the non-permeable,
nuclein acid specific fluorochrome Sytox. Induced cultures developed drastic morphological
changes (see fig. 50). The cells exhibited a certain shrinkage of the cytoplasm and changed
their normal, oblong or angular appearance to almost round cell bodies (fig. 50-G vs. 50-A).
Application of 10µM MK801 prevented cells from these phenotypic changes. 24 hours after
NMDA receptor induction, MK801 treated cultures appeared healthy with similar
morphology compared to uninduced control cells (fig. 50-I vs. 50-A). 
In agreement with the LDH release studies, the expression of NMDA receptors led to an
increased membrane leakage. 24 hours after the induction of NMDA receptors, more than
80% of cells were stained with Sytox (fig. 50-H).Results – characterization of cell death
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Fig. 50
Morphological
changes and plasma
membrane leakage
after induction of
NMDA receptor
expression
L12-G10 cells were
grown in MEM w/o Mg
2+
containing 4µM
dexamethasone, 5%
FCS and 55mM
potassium (identical
medium conditions to
LDH release studies in
the induction model) for
the indicated intervals.
Control cultures were
treated with 10µM
MK801 for 24 hours.
Cultures were stained
with Sytox (final 0.5µM)
after the indicated
intervals and analysed
by light and
fluorescence micros-
copy.Results – characterization of cell death
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This cytotoxicity was mediated by NMDA receptors since it was prevented by the application
of 10µM MK801 (fig. 50-J vs. 50 H) or 100µM ketamine (data not shown). Only a few cells
exhibited a positive Sytox staining 7 and 9 hours after receptor induction (fig. 50-D / F).
Hence, the increase in cytotoxicity occurred between 10 and 24 hours after NMDA receptor
induction. This result confirms the described time course of LDH release (fig. 49). To
examine whether the cellular shrinkage is linked to apoptosis, cells were investigated for
changes in nuclear morphology by a nuclear co-staining with fluorescent dyes Hoechst 33342
(permeable) and Sytox
   (non-permeable). Apoptotic nuclear changes like chromatin
condensation or nuclear DNA fragmentation are characterized by a dense staining of
shrunken, intensely fluorescent nuclei or lobular structures (apoptotic bodies) in the absence
of a nuclear staining with Sytox.
After 7 hours of induction, no significant changes in nuclear morphology were obvious
compared to uninduced cells (fig. 51–E vs. 51–B). Nuclei showed a diffuse, granular
substructure with fine fluorescence spots. Analogous results were obtained after 9 hours of
NMDA receptor induction (fig. 51–H). After 24 hours of differentiation the majority of cells
co-stained with Hoechst 33342 and Sytox (see fig. 51-K and 51-L). Sytox negative nuclei
maintained their granular morphology whereas Sytox positive nuclei exhibited a dense, deep
fluorescence; but regarding their size, these nuclei did not shrink, which is unusual for
apoptosis. Therefore, the deeper staining of these nuclei is rather explained by an easier
access of dye through the damaged plasma membranes than by nuclear apoptosis. Nuclei from
MK801 treated cells maintained their granular structure up to 24 hours of differentiation (fig.
52).
For a further characterization, flow cytometric analysis of propidium iodide stained nuclei
was applied. L12-G10 cells were exposed to induction medium containing 4µM
dexamethasone with or without additional potassium (50mM). After 24 hours, cells were
harvested, stained with propidium iodide (final 50µg/ml) and subjected to flow cytometry. As
control, nuclei from wildtype cells, grown for 24 hours in induction medium, and from L12–
G10 cells, cultured in induction medium lacking dexamethasone, were examined. Both
controls showed normal profiles of DNA content with peaks for nuclei in the G0 / G1 and G2
phase of the cell cycle (see fig. 53). The amount of smaller sized fragments and apoptotic
nuclei was detected to 2.08% for L12–G10 cells and to 6.96% for WT cells (M1 marked
range). For the treatment of L12–G10 cells in induction medium containing 5mM potassium,
the amount of small sized nuclei and nuclear fragments within the M1 marked range slightly
increased to 17.74%.Results – characterization of cell death
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Fig.  51  Nuclear morphology of L12-G10 cells after induction of NMDA receptor
expression
L12-G10 cells were grown in MEM w/o Mg
2+ containing 4µM dexamethasone, 5% FCS and 55mM
potassium (identical medium conditions to LDH release studies) for 0 (A-C), 7 (D-F), 9 (G-I) and 24
hours (J-L). Cultures were co-stained with Hoechst 33342 (final 0.5µg/ml) (B, E, H, K) and Sytox (final
0.5µM) (C, F, I, L) after the indicated intervals and analysed by fluorescence microscopy. A, D, G, J
are the respective phase contrast images.Results – characterization of cell death
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Fig.  52  Nuclear morphology of MK801 treated L12-G10 cells after induction of NMDA
receptor expression 
L12-G10 cells were grown in MEM w/o Mg
2+ containing 4µM dexamethasone, 5% FCS, 1.8mM
calcium, 55mM potassium and 10µM MK801 for 7 (A-C), 9 (D-F) and 24 hours (G-I). Cultures were co-
stained with Hoechst 33342 (final 0.5µg/ml) (B, E, H) and Sytox (final 0.5µM) (C, F, I) after the
indicated intervals and analysed by fluorescence microscopy. A, D, G are the respective phase
contrast images.
Supplement with potassium to a final concentration of 55mM yielded highly fragmented,
small sized DNA (M1 marked range 87.62%). The peak of this population is typical for
necrotic DNA fragmentation. 
Taking together, the data from LDH-release studies and nuclear staining experiments clearly
indicate a NMDA receptor mediated loss of membrane integrity after 10 to 12 hours fromResults – characterization of cell death
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induction of NMDA receptor expression which is not accompanied by nuclear, apoptotic
features like chromatin condensation, DNA fragmentation and the development of apoptotic
bodies.
Fig. 53 Flow cytometry-histograms from propidium iodide stained nuclei
Cells were grown for 24 hours in the indicated medium (GM = growth medium (MEM containing 5%
FCS); IM = induction medium (MEM containing 5% FCS, 4µM dexamethasone in the presence or
absence of additional potassium (50mM))).
Since the development of nuclear changes displays a late event in the programmed cell death
and may be blocked for unknown reasons, the translocation of phosphatidylserines (PS) was
examined. The migration of PS is a very early event in the onset of apoptosis and distinct
from nuclear changes. The binding of Alexa-568 labelled annexin V to L12-G10 cells was
examined after 10 hours of differentiation (induction medium contained 55mM potassium).
Representative images of the annexin V staining are given in fig. 54 and 55. Among the
differentiated, NMDA receptor expressing L12–G10 cells, annexin V positive cells were only
detected in cultures lacking ketamine (see fig. 54). Only a small amount of these cells (<10%)
was annexin V positive. Necrotic cells exhibit a deep fluorescence in annexin V labelling andResults – characterization of cell death
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Fig. 54 Annexin–V staining of L12-G10 cells cultured for 10 hours in MEM containing 5%
FCS, 4µM dexamethasone and 55mM potassium chloride
(A) phase contrast; (B) calcein staining; (C) Hoechst 33342 staining; (D) Annexin V staining. Annexin
V positive cells are marked with solid arrows, necrotic cells with dashed arrows.Results – characterization of cell death
111
Fig. 55 Annexin–V staining of L12-G10 cells cultured for 10 hours in MEM containing 5%
FCS, 4µM dexamethasone, 55mM potassium and 100µM ketamine
(A) phase contrast; (B) calcein-AM staining; (C) Hoechst 33342 staining; (D) Annexin V staining.
lack fluorescence signals resulting from calcein–AM treatment (fig. 54-D and B dashed
arrow). Since these cells were calcein negative, the dense staining of their nuclei (fig. 54-C
dashed arrow) is caused by a greater accumulation of dye through damaged plasma
membranes and not by nuclear condensation. Additionally, the size of these nuclei is
comparable to those of regular, healthy ones. Another population exhibited a positive annexin
V staining accompanied by positive calcein staining (fig 54-D and B solid arrows). Therefore,Results – characterization of cell death
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these cells exhibit two major features of apoptotic cells – phosphatidyl turnover and
membrane integrity. Consistent with the results of the nuclear staining, no changes in the
chromatin pattern of these cells were obvious (fig. 54-C solid arrows). Exposure to the open
channel blocker ketamine (100µM) prevented necrosis and annexin V staining (fig. 55). The
nuclei of ketamine protected cells displayed a normal diffuse, granular staining. Although the
extent of apoptotic PS turnover is very low, the onset of this apoptotic feature is clearly
mediated by NMDA receptor stimulation proofed by the lack of annexin V positive cells in
the ketamine control. Since “apoptotic“ annexin V stained cells lack any nuclear changes, this
confirms the results from nuclear staining and led to the conclusion, that (i) necrosis is the
predominant mode of cell death in the induction model and (ii) that there is some evidence for
the inhibition of nuclear apoptosis by unknown mechanisms.
Fig. 56 Effects of caspase-3 inhibitor Ac-DEVD-CHO on the NMDA receptor mediated
cell death in L12-G10 cells
L12-G10 cells were exposed to MEM medium containing 2µM dexamethasone, 5% FCS in the
absence (control) or presence of 50, 100 and 200µM Ac-DEVD-CHO. LDH release was assayed after
24 hours.
This conclusion is supported by the finding, that the NMDA receptor mediated cell death of
L12-G10 cells is only slightly decreased by application of cell permeable caspase-3 inhibitor
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Ac-DEVD-CHO (acetyl-Asp-Glu-Val-aspartic acid aldehyde) (fig. 56). Compared to control
cells, 200µM Ac-DEVD-CHO decreased the cell death rate to approximately 91 ± 0.7%. This
result corresponds to the results of annexin V staining showing that apoptotic changes of the
plasma membrane are apparent, but only in a small population of stimulated cells (<10%).
Beside the induction model, the shape of cell death was also characterized in the
differentiation model, since pre-expression of NMDA receptors resembles more excitotoxic
processes in neurons. Initial studies characterized the time course of LDH release in the
differentiation model (fig. 57). After stimulation with 30µM L-glu / gly, NR1-1a / 2A
expressing L12-G10 cells showed a steep increase in LDH release, starting 5 min after the
beginning of NMDA receptor stimulation and reaching their maximum cell death rate after 20
min, already. In contrast, NR1-1a / 2B expressing clone L13-E6 exhibited a more delayed cell
death with a maximum cell death rate after 40 to 50 min. This attenuated increase in cell death
time [min]
0 20 40 60 80 100 120
c
e
l
l
 
d
e
a
t
h
 
[
%
]
0
10
20
30
40
50
60
100
L1/2 - G10 (NR1a / NR2A)
L1/3 - E6 (NR1a / NR2B) 
Fig. 57 Loss of membrane integrity after stimulation of pre-expressed NMDA receptors in
the differentiation model
L12-G10 (NR1-1a / NR2A) and L13-E6 (NR1-1a / NR2B) cells were differentiated for NMDA receptor
expression in growth medium containing 4µM dexamethasone and 100µM ketamine for 24 hours.
After removal of the induction medium cells were stimulated in CSS (pH 7.6  for L12-G10 or pH 8.0 for
L13-E6) cont. 1.8mM Ca
2+, 50mM potassium and 30µM L-glu / gly). LDH-release was assayed after
the indicated intervals.Results – characterization of cell death
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could be explained by a reduced calcium permeability of NR1-1a / 2B receptors. In contrast to
the onset of cell death, the final amount of cytotoxicity is comparable in both clones with cell
death rates of 50 to 60% after 90 min of stimulation. Stimulation periods exceeding 3 hours
were not applied to avoid an unspecific cell death caused by growth factor withdrawal.
The early damage of the plasma membrane was confirmed by the nuclear staining with the
non-permeable dye Sytox (fig. 58). 30 min after the beginning of stimulation with 30µM L-
glu / gly, approximately 60% of L12-G10 cells displayed a Sytox positive staining (fig. 58-C),
whereas inhibition of NMDA receptors by 100µM ketamine almost prevented cells from the
loss of plasma membrane integrity (fig. 58-D). Ketamine treated cells maintained their normal
oblong or angular phenotype (fig. 58-B). In contrast, unprotected cells flattened out, showed a
rough surface and the nuclei of necrotic cells were clearly visible in the phase contrast (fig.
58-A and 59-A)). After 90 min of stimulation, NMDA receptor mediated cytotoxicity was
increased to 75% (fig. 58-G) with similar morphological features (fig. 58-E vs. A). Ketamine
treated cultures remained healthy, although the majority of cells changed their appearance to
round cell bodies (fig. 58-H and F).
For the examination of changes in nuclear morphology, a co-staining with Hoechst 33342 and
Sytox was applied (fig. 59). Similar to the results obtained from the induction model, necrotic
L12-G10 cells displayed a dense nuclear staining with Hoechst 33342 dye, although nuclei
did not shrink compared to those of alive, Sytox negative cells (fig. 59-B and C). Ketamine
treated cells maintained the granular substructure of their nuclei up to 90 min of stimulation
(fig. 59-E and K).
Taking together, even the results obtained from the differentiation model lead to the
conclusion, that stimulation of heterologously expressed NMDA receptors in L(tk-) cells
induces a predominant mode of necrotic cell death. 
To investigate whether apoptosis is generally blocked in these cell lines, wildtype L(tk-) cells
were treated with 1µM staurosporine for 8 hours. Staurosporine is an inhibitor of protein
kinase C and a strong inducer of apoptosis in many cell lines. The results of the annexin V
staining are given in fig. 60. The whole population showed a strong blebbing of the cytosol
under maintenance of the membrane integrity (fig. 60-A and B). But only a minority of cells
exhibited a positive annexin V staining (fig. 60-D solid arrows). In contrast to the
investigations on NMDA receptor mediated cell death, the nuclei from annexin V positive
cells exhibited intense fluorescent substructures which are typical for a chromatin
condensation (fig. 60-C) or the formation of apoptotic bodies (fig. 60-G). Interestingly, only aResults – characterization of cell death
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Fig. 58
Morphological
changes and plasma
membrane leakage
after NMDA receptor
stimulation in the
differentiation model
L12-G10 cells were
differentiated for
NMDA receptor
expression in growth
medium cont. 4µM
dexamethasone and
100µM ketamine for
24 hours. After
removal of the
induction medium
cells were stimulated
in CSS (pH 7.8 cont.
1.8mM Ca
2+, 50mM
potassium and 30µM
L-glu / gly) in the
absence (A / E) and
presence (B / F) of
100µM ketamine for
the following intervals:
30 min (A-B) and 90
min (E-F). For the
detection of
membrane leakage,
cultures were stained
with Sytox (final
0,5µM) (C, D, G, H)
and analysed by light
and fluorescence
microscopy.Results – characterization of cell death
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Fig. 59
Nuclear morphology of
differentiated L12-G10
cells after stimulation
of NMDA receptors
L12-G10 cells were
differentiated for NMDA
receptor expression in
growth medium cont.
4µM dexamethasone and
100µM ketamine for 24
hours. After removal of
the induction medium
cells were stimulated in
CSS (pH 7.8 cont. 1.8mM
Ca
2+, 50mM potassium
and 30µM L-glu / gly) in
the absence (A-C and G-
I) and  presence (D-F
and J-L) of 100µM
ketamine for the following
intervals: 30 min (A-F)
and 90 min (G-L).
Cultures were co-stained
with Hoechst 33342 (final
0.5µg/ml) (B, E, H, K)
and Sytox
 (final 0,5µM)
(C, F, I, L) after the
indicated intervals and
analysed by fluorescence
micros-copy. A, D, G and
J are the respective
phase contrast images.
small proportion of the population (<10%) showed a positive annexin V staining accompanied
by the maintenance of plasma membrane integrity. This indicates a general resistance of
L(tk-) cells against apoptotic cell death since even a treatment with 0.5µM staurosporine for
20 hours led not to a significant nuclear condensation or the formation of apoptotic bodies
(data not shown).Results – characterization of cell death
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Fig. 60 Annexin–V staining of staurosporine treated L(tk-) cells 
L(tk-) wildtype cells were cultured for 8 hours in MEM containing 5% FCS, 55mM potassium and 1µM
staurosporine. (A/E) phase contrast; (B/F) calcein-AM staining; (C/G) Hoechst 33342 staining; (D/H)
Annexin V staining. Annexin V positive apoptotic cells are marked with solid arrows, necrotic cells with
dashed arrows.Conclusions
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4. Conclusions
The current study was intended to develop an in vitro test system for NMDA receptor
antagonists. Studies with primary cultures have some limitations in terms of characterizing
antagonistic properties of compounds because there are several subtypes of NMDA receptors
expressed in cultured neurons with different pharmacological properties. Besides, in
toxicological studies investigating neurotoxic effects of compounds, it is useful to have
molecularly defined receptors excluding an interaction with other glutamate receptors or
NMDA receptor subtypes. Therefore, we favoured nonneuronal cell lines expressing
recombinant NMDA receptors. After initial trials with transient expression of recombinant
NMDA receptors in HEK 293 cells we decided to establish a stable expression system which
should represent a more convenient and robust heterologous expression system. 
We succeeded in the establishment of stably transformed mouse fibroblasts [L(tk-)]
expressing recombinant human NMDA receptor subunits NR1-1a / NR2A (clone L12-G10)
or NR1-1a / NR2B (clone L13-E6). The inherent excitotoxicity occurring while expressing
recombinant NMDA receptors in mammalian cells (Anegawa et al., 1995; Cik et al., 1993)
was used to create a cell death based in vitro test system for NMDA receptor ligands. During
routine cell culture, the expression of NMDA receptors is avoided due to the use of a
dexamethasone inducible expression system (Grimwood et al., 1996a). Selection due to
background expression of receptors is prevented by the addition of the NMDA receptor
antagonist ketamine. Our stable cell lines have proved their usefulness for more than 90
passages (∼45 weeks); this is a great advantage compared to transiently transformed cells
which could only be used for several days.
To characterize the expression and functionality of recombinant NMDA receptors in the
obtained cell lines, RT-PCR analysis, Western blot and immunocytochemical analysis of
subunit NR1-1a as well as calcium video imaging was applied. RT-PCR analysis of L12-G10
and L13-E6 cells differentiated for 12 hours with dexamethasone revealed an upregulation of
NMDA receptor mRNA in both clones. By densitometric volume analysis we estimated a 5-
fold increase for NR1-1a transcripts and a 2.3-fold increase for NR2A in L12-G10. For clone
L13-E6, ratios of 4.8 for hNR1-1a and 3.5 for hNR2B were calculated.
These data are consistent with results from immunoblotting of subunit NR1-1a revealing a
maximum of protein amount between 8 and 16 hours of treatment with dexamethasone,
whereas no protein could be detected in uninduced clones and wildtype cells. The size of the
detected 116 kDa protein is consistent with the predicted molecular weight from the deducedConclusions
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amino acid sequence (103.5 kDa) and the size of NR1 subunits detected in rat brain
membranes. Immunofluorescence labelling of subunit NR1-1a in induced clones suggested
high amounts of receptor localized within the plasma membrane. Since it has been reported
that co-expression with NR2 subunits is required for successful surface expression of subunit
NR1 (McIlhinney et al., 1996; McIlhinney et al., 1998) we concluded a localization of hetero-
oligomeric receptors within the plasma membrane. This conclusion was supported by results
from calcium video imaging which indicated a strong increase in [Ca
2+]i after stimulation with
L-glutamate and glycine. Subsequent treatment with open channel blockers ketamine and
MK801 recovered [Ca
2+]i to basal levels. Since single expression of subunit NR1 failed to
form functional receptors in mammalian cells, we have successfully demonstrated the surface
co-expression of the transfected NMDA receptor subunits.
The developed cytotoxicity assay, using the measurement of LDH activity from lysed cells,
represents a valid method with high precision, accuracy and easy performance for the
evaluation of cell death. Other current methods have been described for the quantification of
cell death, e.g. staining with vital dyes like trypan blue or fluorescent dyes like propidium
iodide or Sytox. These approaches are based on the ability of alive cells, with intact cell
membranes, to exclude these dyes and prevent nuclear staining. The disadvantage of these
techniques is the need of multiple, time consuming cell counting. Therefore, results describing
cell death rates under different conditions (e.g. dose response curves) at the same time point
are hardly achieved. Other described cell death assays use the ability of mitochondria to
convert tetrazolium salts like MTT or XTT into coloured formazan product that may be also
measured spectrophotometrically. The disadvantage of these approaches is the need of an
additional incubation period of 1 to 2 hours after treatment of cells, which prolongs assay
time, and the immediate evaluation of cell death after short incubation periods is not possible.
The method described here is suitable for the performance in 96 well or upper scale and offers
an economic method for high throughput screening of compounds either in the induction or
the differentiation model.
The developed cell culture designs were extensively characterized and successfully applied.
For QSAR studies of thienopyridinones, we choose the induction model to evaluate its
applicability. For high affinity compounds, IC50-values obtained by cytotoxicity assays were
well correlated to the Ki-values of binding assays. For the nine compounds active in both
settings, a correlation coefficient of 0.90 (P = 0.001) was observed. The developed test system
even considered compounds binding to plasma albumin which was demonstrated using the
plasma albumin competitor warfarin. It should be noted, that binding to plasma albumin limitsConclusions
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compounds brain penetration in vivo (Rowley et al., 1997b). Therefore, the presence of
plasma albumin binding in the developed test system seems to be an advantage compared to
other routine methods like radioligand binding assays or electrophysiological methods, which
do not consider this critical parameter.
Unfortunately, most low affinity compounds could not be characterized. The high agonist
concentrations provided by the added FCS turned out to represent a disadvantage for
competition assays of compounds with lower potency and poor solubility. Therefore, we
developed an improved model, designated as differentiation model, which provides more
defined experimental settings. This design, also based on the evaluation of cell death rates,
allowed an extensive pharmacological characterization of clones L12-G10 and L13-E6. In
part, we observed distinct pharmacological properties which are reflecting the different
properties of NR1-1a / NR2A and NR1-1a / NR2B receptor assemblies. We demonstrated that
the observed cell death in both cell lines is strictly dependent on the presence of L-glutamate
and even depends on the applied pH. Proton sensitivity of NMDA receptors at the
physiological pH has been established in patch clamp studies in cerebellar neurons (Traynelis
and Cull-Candy, 1990). Now it is clear that proton inhibition is mediated by the absence of
the 5´-insert in the NR1 subunit (Traynelis et al., 1995). Our results emphasize that
experiments at functional NMDA receptors should only be performed under defined pH
conditions (HEPES buffered salt solutions in the absence of CO2 or carbonate buffered cell
culture medium under strict CO2 control). Since this proton inhibition appears in a narrow
range close to physiological pH, the lack of receptor activity is often caused by unsuitable
“acidic“ pH conditions rather than by other reasons. Occurring cell death is triggered under
the presence of glycine site agonists D-serine or glycine, but we failed to demonstrate a clear
dose dependency for these compounds. This failure is probably caused by contamination of
glycine which occurred during washing of the cells with MEM containing 1% BSA (required
for the removal of ketamine to enable receptor activity). Since BSA enhanced adherence of
cultures during the washing procedure, it was an ingredient of washing solutions which we
could not substitute by other high molecular compounds (e.g. dextran). In competition assays,
glycine and D-serine were able to completely abolish cytoprotective effects exerted by
100µM DCKA. The obtained EC50-values indicated an agonist preference of L13-E6 cells
(NR1-1a /NR2B) compared to NR1-1a / NR2A expressing L12-G10 cells. The estimated
concentrations required to abolish 50% of cytoprotection were two to three fold higher with
clone L12-G10. The same preference was evident in assays with the competitive antagonist
(R/S)-CPP where L-glutamate and L-aspartate exhibited a higher potency at L13-E6 cells. InConclusions
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turn, antagonists like (R/S)-CPP, (R/S)-AP5 or DCKA exhibited a 5 fold higher efficacy at
L12-G10 cells. These findings are consistent with results from studies of NMDA receptor
subunits expressed in Xenopus oocytes (Hess et al., 1996) and with the existence of agonist
and antagonist preferring NMDA receptors in vivo. Compared to D-serine, the potency of
glycine was slightly higher at both clones which is also consistent with earlier findings
(Matsui et al., 1995). Efficacy of L-glutamate was 7 to 10 fold higher compared to L-
aspartate. The open channel blocker ketamine did not discriminate between both clones which
is also in accordance to literature. Ifenprodil and haloperidol exhibited cytoprotective effects
only at clone L13-E6 (expressing NR1-1a / NR2B) but failed to reduce cell death at L12-G10
cells (NR1-1a / NR2A) in concentration up to 100µM. This preference (ifenprodil > 670 fold;
haloperidol > 45 fold) is consistent with the finding that these compounds discriminate
subtypes of recombinant heteromeric receptors with a preference for NR2B containing
receptors. Patch clamp studies in Xenopus oocytes revealed a 400 fold NR2B preference for
ifenprodil compared to NR2A (Williams, 1993a). For haloperidol a preference of > 100 has
been described (Ilyin et al., 1996). The reported IC50-values for ifenprodil (0.34µM) and
haloperidol (~3µM) correspond to the estimated IC50-values for ifenprodil (0.15 ± 0.02µM)
and haloperidol (2.2 ± 1.5µM) in our cytotoxicity model. 
Interestingly, the requirement of NR2B subunits overlap with those for stimulation by
polyamines. We have demonstrated, that spermine triggers the function of NR1-1a / NR2B
(L13-E6) receptors resulting in an increased cell death rate. This glycine independent
enhancement of cell death by spermine exhibited a clear dependency on applied proton
concentrations. Increased cell death rates compared to control were obvious at pH levels
which normally inhibit receptor function. At lower proton concentrations spermine failed to
enhance cell death. At NR1-1a / NR2A expressing L12-G10 cells, spermine did not
significantly affect cell death. These results suggest, that (i) spermine specifically affects
NR2B containing receptors and (ii) mediates its positive modulating effect via relief of proton
inhibition. These observations are consistent with the suggested mechanism of spermine
modulation (Traynelis et al., 1995). 
Under these predictions we have evaluated the ability of spermine to abolish the
cytoprotective effects of ifenprodil and haloperidol at clone L13-E6. Spermine affected the
cytoprotection by ifenprodil and haloperidol, but rather in an allosteric than direct competitive
manner. At non-protective concentrations of antagonist, spermine increased the rate of cell
death. In contrast, protective concentration levels remained nearly unaffected. These
experiments were performed under relief of normal proton inhibition (pH 8.0). As previouslyConclusions
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shown, spermine fails to trigger cell death under relief of proton inhibition but enhances cell
death in the presence of non saturated concentrations of ifenprodil and haloperidol although
these experiments were performed at pH 8.0. Hence, we conclude that these allosteric
antagonists partially mediate their cytoprotective effects by facilitating proton inhibition. This
hypothesis is supported by recent reports, which proposed that the allosteric block of NMDA
receptors by ifenprodil is mediated by an increased potency of ambient protons to block the
NMDA receptor (Mott et al., 1998). The authors concluded that ifenprodil causes a larger
fraction of receptors to be protonated and thus inhibited by shifting the IC50 for proton block
of NMDA receptors to more alkaline-values. Hence, spermine reduced cytoprotective effects
of ifenprodil and haloperidol rather due to opposite effects on proton inhibition and not by
direct competition at common binding sites. 
Effects exerted by histamine were obvious at NR1-1a / NR2B expressing clone L13-E6 only,
which is consistent with previous findings (Williams, 1994b). Unexpectedly we observed a
dose dependent inhibition of cell death. Contradictions to earlier studies, which reported
enhanced NMDA receptor function by the application of histamine (Bekkers, 1993)
(Vorobjev et al., 1993) (Zwart et al., 1996), may be caused by distinct pH conditions, since it
has been shown that histamine enhanced the NMDA component of the synaptic currents at
lowered pH (7.2) while at raised pH (7.6) it reduced them (Saybasili et al., 1995). Since we
performed the reported cell toxicity assays under relief of proton inhibition (pH 8.0 for clone
L13-E6), our data support the finding of a histamine mediated inhibition of NR2B containing
NMDA receptors at raised pH levels. 
Although activation of PKC has been reported to enhance NMDA receptor activity (Chen and
Huang, 1991) (Kelso et al., 1992) treatment with PKC activator TPA (100nM) failed to affect
cell death in both clones. But our results may not be in direct contradiction to these
observations, since different splice variants of subunit NR1 exhibit distinct sensitivity to PKC,
and phosphorylation of splice variant NR1-1a exhibits an enhancement of only 3-fold
(Tingley et al., 1993). In turn, a putative phosphorylation may not affect these heterologous
NMDA receptors due to a high basal phosphorylation level which has been reported from
transient expression experiments in Hek 293 cells (Tingley et al., 1993).
To investigate the participation of mitochondrial damage in NMDA receptor mediated
excitotoxicity we used cyclosporin A (CsA) which is a known inhibitor of calcium induced
permeability transition (PT) in mitochondria. Prolonged pre-treatment with CsA reduced cell
death rates in a dose dependent manner. The selective calcineurin inhibitor FK506 failed to
exert cytoprotection after NMDA receptor stimulation which excludes the involvement ofConclusions
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calcineurin inhibition by CsA. Unfortunately, we found that CsA did also affect the
expression of the transfected NMDA receptor subunits. We could demonstrate that prolonged
treatment with CsA reduced the expression of NMDA receptor subunit NR1-1a in our cell
lines by 70%. This finding is in agreement with functional expression of other ion channels in
Xenopus oocytes (Chen et al., 1998) (Helekar et al., 1994). These authors concluded that the
functional expression of ion channels is facilitated by the peptidyl-prolyl isomerase
cyclophilin and that the oligomeric assembly of neurotransmitter-gated ion channels
represents a multi-step process involving the participation of cyclophilins. These
immunophilins, which are present in the cytoplasm, the endoplasmatic reticulum and the
mitochondria, exhibit a peptidyl-prolyl isomerase activity and assist in the folding of
polypeptides similar to classical heat shock proteins (chaperones). Since it has been
suggested, that heterologously expressed NMDA receptor subunits are assembled in the ER
and that co-synthesis of the subunits is necessary for their successful cell surface targeting
(McIlhinney et al., 1998), it is likely that CsA also affects the surface expression of the
transfected NR2 subunits. Brief pre-treatment with 30µM CsA (10min) failed to prevent
cells from undergoing cell death when stimulated under the relief of tonic proton inhibition
(CSS pH 7.6). But cytoprotective effects were evident under partial proton inhibition of
NMDA receptors (CSS pH 7.0). Under these modified conditions, brief pre-treatment with
CsA reduced cell death by approximately 40% compared to control. FK506, which did not
affect the PT, displayed a mean reduction of ~7%. These results exclude a calcineurin
mediated cytoprotection by CsA. But so far, we cannot clearly distinguish between the
assumed inhibition of PT and a reduction of NR1 subunit expression by inhibition of
cyclophilin A. Hence, the participation of mitochondrial damage after stimulation of
heterologously expressed NMDA receptors remains elusive and instead of CsA, the use of
more specific PT inhibitors like bongkrecic acid or inhibitors of mitochondrial calcium
sequestration like ruthenium red or the uncoupler FCCP should be favoured in further
investigations.
Studies on the shape of cell death suggested a predominant necrotic way of cell death due to
early loss of plasma membrane integrity and the failure of nuclear apoptotic features related to
the NMDA receptor stimulation. The lack of apoptosis in our excitotoxicity models is in
contrast to the execution of neuronal glutamate induced cytotoxicity in vivo and in vitro. But
the comparison of neuronal in vitro models (e.g. CGC cells) and heterologous expression
models reveals some crucial differences in calcium metabolism. Due to their function,
neurons have higher abilities to regulate oscillations of intracellular calcium levels and toConclusions
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maintain calcium homeostasis. Ionized calcium as an intracellular second messenger, must be
kept in a narrow concentration range in the resting cell (i. e. 100 – 300nM). Since the calcium
concentration in the extracellular milieu is 1 - 2mM, this results in a very steep concentration
gradient across the plasma membrane. Neurons possess a number of different transmembrane
calcium transporting systems which participate in the control of the free calcium
concentration within the cell. Most of these systems are located in the plasma membrane like
voltage dependent or ligand directed calcium channels (e.g. L-type or NMDA receptor
channels), the calcium pump for the ATP dependent export of calcium (Ca
2+-ATPase) and the
Na
+ dependent Ca
2+ exchanger, who transports three Na
+ ions for one Ca
2+ (inward or
outward depends on the transmembrane potential). Additionally, intracellular organelles are
involved. The ER stores calcium, which can be released into the cytosol by the second
messenger IP3 (second messenger of metabotropic glutamate receptors mGluR1 and 5). Under
pathological conditions, mitochondria possess by far the highest calcium storage capacity in
cells. It has been shown, that the mitochondrial calcium uptake responds dynamically to
changes in cytosolic calcium levels and plays a crucial role in the sequestration of large
calcium loads induced by NMDA receptor activation (Stout et al., 1998b; White and
Reynolds, 1997). Even a privileged access of calcium influx via NMDA receptors to
mitochondria has been described (Peng and Greenamyre, 1998).
Only a few of the described mechanisms such as Ca
2+-ATPase and calcium sequestration by
ER and mitochondria are ubiquitous and also present in the transfected fibroblasts. Since we
have shown that the stimulation of the heterologously expressed NMDA receptors leads to a
steep initial increase in intracellular calcium levels, the lack of an efficient calcium regulation
system in L(tk-) cells (e.g. the Na
+ dependent Ca
2+ exchanger) may lead to an increased
sequestration of calcium by mitochondria, breakdown of mitochondrial membrane potential,
loss of oxidative phosphorylation, lack of ATP synthesis and generation of reactive oxygen
species. The decrease of ATP levels may also be triggered by an increased demand of ATP
for membrane pumps (Ca
2+-ATPase). Results of ATP level determination after stimulation of
the heterologous NMDA receptors confirm the calcium dependent decrease in cytosolic ATP
levels. The ability of some neurons (e.g. CGC cells) to compensate the failure of oxidative
phosphorylation by glycolysis has been shown (Budd and Nicholls, 1996). Interestingly, these
cells predominantly undergo apoptotic excitotoxicity. In the presence of ATP synthase
inhibitor oligomycin glycolysis supports the total cellular ATP demand of CGC cells. The
combination of the complex I inhibitor rotenone with oligomycin allows the proton gradient
at the inner-mitochondrial membrane to decay, preventing mitochondrial calcium loading andConclusions
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reduced cell death. In our cell lines initial experiments with rotenone and oligomycin in the
differentiation model did not lead to cytoprotective effects. After application of oligomycin,
ATP levels in L12-G10 cells rapidly decreased, suggesting that glycolysis in L(tk-) cells is
not sufficient to supply the total cellular ATP demand. Since ATP is required for the
progression of programmed cell death, apoptosis seems to be hindered in our models for two
reasons: (i) lack of efficient mechanisms to maintain calcium homeostasis after stimulation of
heterologous NMDA receptors may lead to an early damage of Ca
2+- sequestering
mitochondria and in consequence to (ii) ATP depletion since the ATP demand of these cells
seems to be mainly supplied by mitochondria. Hence, predominant cell death might switch to
necrosis. Since even staurosporine, which is a strong inductor of apoptosis in a number of cell
lines, failed to induce higher rates of apoptosis, even a general resistance of L(tk-) cells
against apoptosis is likely.
This hypothesis is also supported by the finding, that the murine fibrosarcoma cell line L929,
representing the predecessor cell line of L(tk-) cells, rapidly dies in a necrotic way after
exposure to TNF (Vercammen et al., 1998), which is a common inducer of apoptosis. In L929
cells, TNF seems to mediate its cytotoxicity through an early damage of mitochondria and the
subsequent excessive formation of reactive oxygen intermediates (Schulze-Osthoff et al.,
1992). Since we also assume a rapid damage of mitochondria in our excitotoxicity models,
these findings support our results and lead to the conclusion, that the execution of apoptosis
seems to be hindered due lack of maintenance of cellular ATP levels (Leist et al., 1997).
In summary, we could show that L(tk-) cells stably expressing recombinant human NMDA
receptors inhere pharmacological properties, that correspond with the distinct NMDA receptor
subunit assemblies. In our cell lines, stimulation of heterologous NMDA receptors elicits
necrotic cell death, which was used to establish an efficient in vitro model for the
characterization of NMDA receptor ligands. In this respect, expression of human NMDA
receptor channels from cloned cDNAs in nonneuronal cell line L(tk-) will be useful because a
molecularly defined selective subtype can be studied. The availability of recombinant L12-
G10 and L13-E6 cell lines will facilitate the characterization of NR2B selective and non-
selective antagonists. Furthermore, the cell death based functional assays applied here have
proved to be convenient and pharmacologically valid experimental systems to study human
NMDA receptors, to screen for new ligands or to improve structures of lead compounds in
QSAR studies.Experimental procedures
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5. Experimental procedures
5.1  Transient expression of NMDA receptors in Hek 293 cells
For transfection, the constructs pCIS, pCISNR1-1a, pCISNRε1 and pCISNRε3 were
amplificated in DH5α as host strain and large scale preparations were performed using the
silicia based anion exchanger Nucleobond
®AX according to manufacturers instruction.
The transfection procedure was adapted from standard protocols (Chen and Okayama, 1987).
Confluent cultures of Hek 293 cells were trypsinized in trypsin / EDTA 1x and diluted to
obtain 3 x 10
6 cells per 10 cm cell culture dish. Cells were grown for 40 hours at 5% CO2 in
MEM supplemented with 10% FCS, 2mM L-glutamine, 100 U/ml penicillin, 100 µg/ml
streptomycin and 1% of a non-essential amino acids solution to obtain 50% confluent
cultures. The respective constructs (10 µg per plate) were diluted with water to final volume
of 437µl. Then, 62.5µl 2M CaCl2 and 500µl 2xBBS were added. 2xBBS contains 50mM
BES, 280mM NaCl and 1.5mM Na2HPO4 accurately adjusted to pH 6.95. After 30 min and
the formation of a very fine haze, the precipitate is added to the cell growth medium. The
plates were incubated at 3% CO2 for 24 hours. If indicated, AP5 was present during this
period. Next day, cultures were harvested in trypsin / EDTA and centrifuged. The resulting
cell pellet was resuspended in 5ml PBS. An aliquot was diluted 1:10 in 0.4% trypan blue
(Sigma) in PBS and subjected to a haemocytometer. Using light microscopy, 150 to 200 cells
were counted. Blue staining of chromatin indicated cell death.
5.2 Generation of cell lines stably expressing human NR1-1a /
NR2A and NR1-1a / NR2B
5.2.1 Transfection
For plasmid preparation, the dexamethasone inducible mammalian transfection vectors
pMSGNR1-1a, pMSGNR2A and pMSGNR2B were amplificated in DH5α as host strain and
large scale preparations were performed using the silicia based anion exchanger
Nucleobond
®AX according to manufacturers instruction.
L(tk-) cells were co-transfected with pMSGNR1-1a / pMSGNR2A and pMSGNR1-1a /Experimental procedures
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pMSG-NR2B in a 1:5 ratio (NR1 : NR2), respectively. Transfections were performed using
the calcium phosphate co-precipitation method with 20µg of total DNA. 5x10
5 cells were
plated overnight in a 250ml flask in MEM containing 10% heat inactivated FCS, 2 mM
Glutamax I, 100 U/ml penicillin, 100 µg/ml streptomycin and 0.5 mM sodium pyruvate at 5%
CO2. 30 min prior to transfection, total DNA was precipitated in a final volume of 1ml as
described above (section 5.1). The precipitate was added to the growth medium and the cells
were maintained for 24h at 3% CO2. Next day, cells were rinsed with serum free MEM and
grown for another 24h at 5% CO2 in growth medium containing 100µM ketamine. Two days
after transfection, geneticine in a final concentration of 1mg per ml growth medium was
added for 5 days. Between day 5 and 28 geneticine concentration was increased to 2mg/ml
growth medium.
5.2.2 Cloning
After 4 weeks of selection, pool cultures were cloned using limiting dilution in 96 well plates
(0.3 cells per well). Cloning was performed in growth medium containing 100µM ketamine
and geneticine (2mg/ml). To improve the growth of single cells, 50% of “feeder medium“
were included. “Feeder medium“ was obtained from wildtype L(tk-) cells grown for two days
in growth medium, centrifuged and deep frozen (-70°C) to delete contaminating cells. After
10 to14 days various numbers of clones were obtained. Resulting clones were maintained in
growth medium containing 100µM ketamine and geneticine (2mg/ml).
5.2.3 Screening
For the monitoring of NMDA receptor activity, clone cultures from 96 well plates were
subdivided into 4 wells (96 well plates).Three wells were treated with either growth medium
containing 5% FCS and 1µM dexamethasone or additionally 500µM ketamine or 100µM L-
glutamate and glycine for 24 hours. The fourth well was maintained for further cultivation.
Celltoxicity was determined after 24 hours using the CytoTox 96
® cytotoxicity assay
according to manufacturers instructions. Released LDH was directly measured from 50µl
aliquots of cell culture supernatants. The induction medium was removed and the remaining
cytosolic LDH was released into fresh growth medium (5% FCS) by a freeze-thaw-step at
–70°C for the lysis of surviving cells. Aliquots of 50µl were used for the detection of LDH
activity. The amount of formed red formazan was measured at 490nm in a Dynatech MR5000Experimental procedures
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ELISA-reader (96-well format). Cell death is expressed as ratio of absorption from released
LDH and total LDH (released LDH plus unreleased cytosolic LDH). All absorptions were
corrected for culture medium background caused by phenol red and LDH from FCS.
5.3  Characterization of clones L12-G10 and L13-E6
5.3.1  Reverse-transcription (RT)-PCR analysis
10 to 20x10
6 cells were cultured in growth medium with or without 2 µM dexamethasone for
12 hours. After cell harvesting total cellular RNA was isolated after the guanidinium
thiocyanate method (Chomczynski and Sacchi, 1987) and reverse transcribed into cDNA.
For reverse transcriptase (RT) reaction 5µg of total RNA were denatured in a final volume of
10 µl at 65°C for 10 min and chilled for 5 min on ice. After addition of 30 µl RT reaction
mixture containing RT buffer (BRL Y00121), 14 mM DTT, 0.7 mM dNTPs, 37 units RNasin,
200ng Oligo d(T)12-18 (Gibco) and 200 U reverse transcriptase Superscript plus, cDNA
synthesis was carried out at 37°C for 60 min. After heating to 95°C for 5 min, the resulting
cDNA template was stored at –20°C.
PCR was performed in a total volume of 50µl containing 2 µl template, 10x PCR buffer
(500mM KCl, 100mM TrisCl pH 8.3, 20 mM MgCl2 0.1 % of gelatine), 0.2 mM dNTP and 1
µM of 3`and 5`primers. Amplification was carried out as follows: first cycle denaturation at
94°C for 5 min, addition of 2 U Taq polymerase, annealing at the indicated temperature (see
primers sequence) for 2.5 min and extension at 72°C for 3.5 min; 26 cycles (for ß-actin
priming 22 cycles), denaturation at 94°C for 1 min, annealing at indicated temperature for 2.5
min and extension at 72°C for 3.5 min; last cycle, denaturation at 94°C for 1 min, annealing at
indicated temperature for 2.5 min and extension at 72°C for 10 min. As subunit specific
primers we have used the following oligomers with an annealing temperature of 62°C (5`-
3`):GCAAGTGGGCATCTACAATGG (hNR1-1a-1); CAGCAGGTACAGCAT CACGG
(hNR1-1a-2); TTGTTGAAAATGTGACCCTGCC (hNR2A-1); TGTTATCGT
AGGAATGCTGACG (hNR2A-2); TTCTGACTGCAAATCCTACAACA (hNR2B-1);
ACGGTAGGCCAGCTCGATCT (hNR2B-2). For ß-actin determination, the following
primers were used (5`-3`) GAGGAGCACCCCGTGCTGCTG (ß-actin A) and
CTAGAAGCATTTGCTGTGGACGAT (ß-actin B)  with 60°C as annealing temperature.Experimental procedures
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After amplification, 10 µl of reaction mixture were separated by agarose gel electrophoresis
(3%). Signal intensities were quantified by densitometry (BIO-RAD Gel Doc 1000 system).
5.3.2 Immunoblotting
Western blotting was performed according to standard protocols. 2x10
6 cells, containing
approximately 80µg of total protein, were cultured in growth medium supplemented with
4µM dexamethasone and 100µM ketamine for the indicated intervals. Cells were harvested by
scraping and centrifugation for 10 min at 3,000g. The resulting cell pellet was resuspended in
1ml PBS, recentrifuged at 3,000g and then frozen at –70°C. For Western blot analysis, the
cell pellet was resuspended in 1ml 10mM Tris buffer pH 7.4 containing 1mM EDTA and
1mM PMSF. Membranes were obtained by centrifugation for 15 min at 4°C and 13,000g.
From membrane pellets, receptors were solubilized into 10mM Tris buffer pH 7.4 containing
1mM EDTA, 1mM PMSF and 0.2% Triton X-100 to a final concentration of 4µg total protein
per µl solubilisation buffer. 40 to 60 µg of protein (as indicated) were subjected to
electrophoresis in a 7% SDS-polyacrylamid gel and transferred to a PVDF membrane
(Biorad). Membranes were blocked overnight with blocking buffer (Tris-buffered saline /
0.05% Tween 20 (TBST) containing 5% dried skimmed milk). Anti-NR1 antiboby
(Chemicon) was diluted 1:400 into blocking buffer containing 0.05% sodium azide and
incubated for 90 min. Membranes were washed 6 times with TBST and then incubated with
horseradish peroxidase coupled donkey anti mouse antibody (Chemicon; 1:5000 in blocking
buffer) for one hour. Membranes were washed 8 times and chemiluminescent/fluorescent
detection was performed using the ECL plus kit (Amersham) according to the manufacturers
instructions.
5.3.3 Immunocytochemistry
Cell cultures, grown on FCS coated cover slides in growth medium containing 2µM
dexamethasone and 100µM ketamine for 24 hours, were washed with PBS for 5 min and
permeabilized / fixed with ice cold methanol / acetic acid (90:10) for 5 min. The fluid was
aspirated off and cover slides were allowed to air-dry for 10 min. After a overnight blocking
step with phoshate buffered saline (PBS) containing 1% BSA at 4°C, blocking buffer was
aspirated off and 10µl of primary antiserum (Santa Cruz; diluted 1:500 in blocking buffer)
were placed on the permeabilized cells. After incubation in a moist environment for 1.5 hours,
the primary antiserum was aspirated off and the cells were washed approximately 10 timesExperimental procedures
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with blocking buffer. 10µl secondary antiserum (Cy3-conjugated affinity purified rabbit anti-
goat IgG; Dianova; dilution 1:200 in blocking buffer) were placed on the cells and incubated
for another 1.5 hours. Slides were washed 10 times with PBS and coverslipped on glass slides
with mounting medium. Finally, objects were sealed with clear nail polish. For analysis of
stained cells, confocal laser scanning microscopy (Leica TCS 4D) was applied using a 550 nm
band pass excitation filter and 598 nm band pass emission filters.
5.3.4 Calcium  imaging
The relative increase in [Ca
2+]i was monitored by imaging clones loaded with the calcium
sensitive fluorescent dye fluo-4 acetoxymethyl ester. For NMDA receptor expression, the
cells were plated on FCS coated coverslips for 16 to 20 hours in growth medium containing
4µM dexamethasone and 100µM ketamine to prevent cells from undergoing cell death caused
by NMDA receptor activation. To monitor dynamic changes of [Ca
2+]i, cells were loaded  with
1µM fluo-4 acetoxymethyl ester at 37°C in original medium. After 20 min, cultures were
washed 2 times with MEM w/o FCS, Mg
2+ and phenolred containing 1% BSA and 25mM
HEPES adjusted to pH 6.8 and once with MEM w/o FCS, Mg
2+ and phenolred containing 1%
BSA to remove surplus dye and ketamine. The wash medium was exchanged for a controlled
salt solution (CSS) containing 120mM NaCl, 25mM HEPES, 50mM KCl, 1.8mM CaCl2 and
15mM glucose adjusted to pH 7.8 (relief of proton inhibition ). Cells were allowed to
equilibrate at room temperature for 10 min before agonist exposure. Using the ion quantify
domain of a Leica TCS 4D confocal system equipped with a Leica PL APO 63 x/1.2-0.6 lens,
six cells and background area were marked and images were collected using a 488 nm band
pass excitation filter and 520 nm band pass emission filters (wavelengths). Data were
recorded at 3sec intervals. Relative mean fluorescence levels from defined areas
corresponding to the position of cell bodies were recorded over the time course of the
experiment. Values were corrected for background and arbitrarily set to zero at the beginning
of each experiment.Experimental procedures
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5.4  Cell death based in vitro assays
5.4.1  LDH assay mixture
The following reagents are supplied:
reagents storage
sodium lactate
(60%)
Dissolve 6g sodium lactate in H2O to a final volume of 10ml. -20°C
buffered
substrate
Dilute sodium lactate (60%) 1:20 in 0,1M Tris pH 9.0 fresh
NAD
+ Dissolve NAD
+ in PB 0.5M pH 7.4 to a final conc. of 1%. fresh
INT Dissolve INT in MeOH / H2O (1:1) at 70°C to a final
concentration of 2%.
fresh
BSA Dissolve BSA in H2O to a final conc. of 0.8%. fresh
enzyme buffer Dilute PB 0.1M pH 7.4 1:10 in BSA solution (1%). Dilute the
resulting solution 1:1 with glycerol (87%) and add sodium
azide to a final concentration of 0.01%. The enzyme buffer is
sterile filtered before use.
-20°C
Diaphorase-stock Dissolve lyophilised diaphorase from Clostridium Kluyveri in
enzyme buffer to a final concentration of 1600 U / ml.
-20°C
LDH-stock Dissolve lyophilised LDH from rabbit muscle in enzyme buffer
to a final concentration of 200 U / ml.
-20°C
PB 0.5M pH 7.4 Adjust a 0.5M Na2HPO4 to pH 7.4 with 0.5M KH2PO4. RT
PB 0.1M pH 7.4 Adjust a 0.1M Na2HPO4 to pH 7.4 with 0.1M KH2PO4. RT
Stop solution Dilute 2.222ml acetic acid with H2O to a final volume of 40ml. RT
Blocking solution Dissolve BSA in H2O to a final conc. of 1%. fresh
The following volumes are combined to obtain 1000µl LDH-assay mixture:
reagent volume [µl]
Buffered substrate 333
NAD
+ 111
BSA 111
PB 0.1M pH 7.4 212
INT 222
Diaphorase 11Experimental procedures
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50µl aliquots of cell culture supernatants are transferred to a 96 well flat bottom (enzymatic
assay) plate which was previously blocked overnight with blocking solution (100µl / well).
50µl of LDH-assay mixture are added and the plate is incubated at 25°C for 30 min under
light protection. After 30 min, 50µl of stop solution are added to each well. Large bubbles are
removed with a syringe needle and the absorbance at 490nm is recorded in a common ELISA-
reader (Dynatech MR5000). To obtain a suitable total LDH activity < 10mU / 50µl cell
culture supernatant, 15x10
3 L(tk-) cells were seeded and the incubations were performed in a
final volume of 200µl / well.
5.4.2 Induction  model
15 x 10
3 cells per well were seeded in a 96 well plate which was previously coated with heat
inactivated FCS for 30 min. Cells were grown overnight in growth medium at 5% CO2.
Stocks of DMSO, methanol or ethanol dissolved compounds were regarded as sterile.
Hydrophilic compounds were dissolved in PBS and sterile filtered. Stock solutions were
diluted 1:100 in induction medium (MEM w/o Mg
2+  and phenolred containing 5% FCS,
50mM KCl, 2 mM Glutamax I, 100 U/ml ampicillin, 100 µg/ml streptomycin, 0.5 mM
sodium pyruvate and 4µM dexamethasone). As FCS contains saturating concentrations of
glutamate and glycine, addition of agonists was not necessary. To avoid variations in agonist
concentration, always the same FCS batch was used. Receptor expression was induced by
replacing growth medium with antagonist containing induction medium (200µl per well). 96
well plates were incubated at 37°C and 5% CO2. Every concentration of antagonists was
incubated as triplicate. As positive control, cultures were treated with induction medium
containing 1% solvent (n = 6). For background subtraction, 200µl of induction medium were
incubated in blank wells (n = 6). After 20 to 24 hours, plates were carefully agitated and 50µl
aliquots of each well were transferred to assay plates (released LDH). Residual medium was
removed from wells and cytosolic LDH of surviving cells was released into blank induction
medium containing 0.1 % Triton X 100. 50µl samples of each well were transferred to assay
plates and determined as described above. Data were corrected for cell culture medium
background. Cell death rate (CD) was calculated as follows:
CD (%) = ALDH rel/( ALDH rel+ ALDH cyt)*100Experimental procedures
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Cell death rates in % to control were fitted to a four parameter logistic function using Sigma
Plot. From the resulting dose response curve, the concentration displaying 50% of the
observed cytoprotective effect was calculated (IC50). To prevent measurement of non-specific
toxicity, the applicable concentration range of each compound was determined prior to LDH
assays by trypan blue exclusion of non-dexamethasone treated cells. After 24 hours of
incubation, 50µl of 0.04% trypan-blue in PBS were added and dye exclusion was checked
using light microscopy. Only non-toxic inhibitor concentrations were used.
5.4.3 Differentiation  model
15x10
3 cells per well were seeded in a 96 well plate which were previously coated with heat
inactivated FCS. Cultures were grown overnight in growth medium at 37°C / 5% CO2. To
induce receptor expression, the growth medium was exchanged for growth medium
containing 4µM dexamethasone and 100µM ketamine (alternative seeding of 20x10
3 cells /
well in growth medium containing 4µM dexamethasone and 100µM ketamine is possible).
After 20 to 24 hours, ketamine was removed from cultures. Wells were washed twice with
100µl MEM w/o FCS containing 1% BSA and 25mM HEPES (adjusted to pH 6.8) and once
with MEM w/o FCS containing 1% BSA. Incubations were carried out in a controlled salt
solution (CSS). 100ml CSS were prepared as described:
ingredient added volume [ml] final concentration [mM]
sterile glucose solution (40%) 0.676 15
sterile normal saline solution 77.922 120
1M HEPES solution 2.5 25
1M KCl solution 5 50
1M CaCl2 solution 0.18 1.8
H2O 13.722 –
10 mM dexamethasone in DMSO 0.04 0.004
Ligands applied in constant concentrations (e.g. agonists like L-glu and glycine or D-serine),
were added from concentrated stock solutions and pH was adjusted to 7.6 for clone L12-G10
or 8.0 for clone L13-E6, respectively, to abolish proton inhibition. The wash medium was
removed and 200µl CSS containing the indicated concentrations of test compounds (diluted
1:100 from concentrated stocks) were added. Test compounds were incubated as triplicatesExperimental procedures
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for 90 min at 37°C. Total LDH activity was determined in sister well cultures treated with
lysis medium (CSS containing 0.1 % Triton-X-100; n = 6). Plates were carefully agitated and
50 µl supernatant of each well were transferred to assay plates and measured as mentioned
above. Data were corrected for background controls (CSS and lysis medium; n = 3) and cell
death was calculated as absorbance ratio of records from released LDH and total LDH:
CD (%) = ALDH rel / ALDH total*100
For curve fitting, estimation of IC50-values and exclusion of unspecific cell death see section
5.4.2.
5.5  Inhibition of cell death by cyclosporin A
Cytotoxicity assays were performed using the differentiation model (see previous section).
Pre-treatment with compounds was performed as follows: Cell cultures were differentiated in
growth medium, containing 4µM dexamethasone and 100µM ketamine (induction medium)
for 20 hours minus the indicated pre-treatment interval. The induction medium was removed
and immunophilin ligand containing induction medium was incubated for the indicated time.
Stock solutions of compounds were prepared by dissolving CsA in ethanol and FK506 in
DMSO. Stocks were diluted 1:100 in fresh induction medium and if present during
stimulation 1:100 in CSS. Control cultures were exposed to the respective solvent diluted
1:100 in induction medium or CSS.
For immunoblotting, 25x10
6 L12-G10 cells were seeded overnight in growth medium. Next
day, growth medium was exchanged for induction medium followed by 6 hours of CsA pre-
treatment. Control cultures were exposed to induction medium containing corresponding
amounts of ethanol. Pre-treated cultures were washed three times with 20ml PBS and scraped
off into 10ml PBS. Cell suspensions were centrifuged at 500g for 10 min. The supernatant
was discarded and the pellets were shock frozen in nitrogen and stored at –70°C. For
sonification lysis, cell pellets were resuspend in 2ml of ice cold PBS containing 1mM PMSF
and 1mM EDTA. Cells were homogenized in a BANDELEIN SONOPULS HD200 sonifier
(30% efficacy; 3 x 3 sec on; 10 sec off) and chilled on ice. Homogenates were centrifuged for
20 min at 500g at 4°C. Supernatants were subjected to density centrifugation. The density
fraction consisted of 3ml sucrose (25% in PBS) containing 1mM PMSF and 1mM EDTA and
was carefully overlayed with supernatants. The density centrifugation was carried out in aExperimental procedures
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Beckman Ultracentrifuge using a Beckman SW 55 Ti rotor at 150,000g for 30 min at 4°C
with low deceleration. The supernatants were discarded and the pelleted plasma membranes
were resuspend in 50µl of hypotonic buffer (10mM Tris; 1mM EDTA; 1mMPMSF). 10µl
aliquots were used for detection of protein amount (BIO-RAD protein assay according to
manufacturer’s instruction). For solubilization, 0.8µl Triton-X-100 (10%) were added to the
residual volume and chilled on ice for at least 15 min. Non dissolved ingredients were
separated by centrifugation (4°C; 14000g; 15 min). Supernatant (37.5µl) was diluted 1:2 with
standard loading buffer, boiled for 10 min and stored at –20°C. Under consideration of protein
amounts, sample volumes containing 8, 4, 2, 1 µg protein were subjected to gel
electrophoresis in a 7% SDS-polyacrylamid gel and transferred to a PVDF membrane
(Amersham). Membranes were blocked overnight with blocking buffer (Tris-buffered saline
(TBS) containing 5% dried skimmed milk). Anti-NR1 antiboby (Chemicon) was diluted
1:400 into blocking buffer containing 0,05% sodium azide and incubated for 90 min.
Membranes were washed 6 times with TBST and then incubated with horseradish peroxidase
coupled donkey anti mouse antibody (Chemicon; 1:5000 in blocking buffer) for one hour.
Membranes were washed 8 times and chemiluminescent/fluorescent detection was performed
using the ECL plus kit (Amersham) according to the manufacturers instructions.
For calcium imaging 6x10
5 cells were seeded on poly-L-lysin (1mg / ml) coated cover slides
(32mm diameter) in induction medium for 15 hours, followed by pre-treatment with 30µM
CsA for 5 hours. Calcium imaging was performed as described in section 1.1.4 using an Zeiss
Axiovert S 100 video imaging system equipped with 488nm (excitation) and 520nm
(emission) band pass filters. Data were obtained and transformed using ATTOFLUOR ratio
vision software.
For the determination of intracellular ATP levels, differentiated L12-G10 cells were
stimulated in CSS pH 7.6 containing 100µM L-glu / gly, 1% BSA and 1.8 or 0.1mM Ca
2+,
respectively (n = 3). Differentiated L12-G10 cells cultured in CSS pH 7.6 (1% BSA) w/o L-
glu / gly were used as control. ATP samples (trial and control; n = 3) were taken prior to
stimulation and after 10, 20 and 30 min. The medium was removed from cell cultures and
ATP was released into 200µl of ice cold ATP releasing buffer (Sigma). 80µl of each sample
were immediately frozen in nitrogen and stored at –20°C to avoid ATP decay caused by
ATPases. ATP content of the samples was determined using a luciferase based
bioluminescence assay (CLS II ATP bioluminescence kit Boehringer Mannheim). Samples
were thawed on ice water for 10 min, agitated and centrifuged for 2 min at 4°C and 14000g.
50µl of each sample were added to 50µl of ice cold ATP assay mixture. The 96 wellExperimental procedures
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luminescence plate was gently agitated and the developed bioluminescence was assayed in a
Microplate Luminometer LB 96V (EG&G BERTHOLD). The obtained relative light units
(RLU; integration interval = 6sec) are direct proportional to the amount of ATP within the
samples. Although the consumption of ATP by luciferase is regarded as low, a timed
dependent decay of approximately 2% RLU / min was observed (linear plot!). Therefore, to
shorten run time, the number of samples within one run was limited to the samples of one
stimulation interval (run time < 1 min). Results were expressed as RLU in % to control
samples.
5.6  Characterization of cell death
5.6.1  Plasma membrane damage and morphological characterization
Necrosis (plasma membrane damage) was calculated using the described LDH assay (see
section 5.4.1). To distinguish morphologically apoptotic, necrotic and living cells, cultures
were stained with a mixture of the membrane permeable chromatin dye Hoechst 33342 (stock
50mg / ml DMSO; working solution 50µg / ml DMSO; 0.5µg/ml final; staining all nuclei)
and the membrane nonpermeable dye Sytox (stock 250µM in DMSO; working solution 50µM
in DMSO; 0.5µM final). Cells stained with different fluorescent probes were imaged in a
Leica DM-IRB microscope equipped with a video camera. Blue Hoechst 33342 fluorescence
was excited with UV and green Sytox fluorescence with blue band pass filters.
5.6.2 Flow  cytometry
L12-G10 cells were cultured in MEM containing 5% FCS, 4µM dexamethasone, 5mM or
55mM potassium. After 24 hours, cells were harvested into the original medium using a cell
rubber. After centrifugation, the resulting pellet were lysed in 0.1% Triton-X-100 / 0.1%
sodium citrate and stained with propidium iodide (final 50µg/ml) for 6 hours. Nuclei were
then subjected to flow cytometry (FACS Calibur; Becton Dickinson). Using CELL Quest
software, 5000 events were gated. As control, nuclei from WT cells, grown for 24 hours in
growth medium containing 5% FCS and 4µM dexamethasone, and from L12–G10 cells,
cultured in MEM lacking dexamethasone, were examined.Experimental procedures
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5.6.3 Phosphatidyl  serine  translocation
Surface phosphatidylserine (PS) expression was analysed by annexin V-staining and confocal
microscopy (TCS-4D UV/VIS confocal scanning system; Leica AG). For NMDA receptor
expression, the L12-G10 cells were plated on poly-L-lysine coated coverslips in induction
medium containing 5% FCS and 4µM dexamethasone in the presence and absence of 100µM
ketamine. After 10 hours of differentiation, cells were analysed for PS translocation. L(tk-)
wildtype cells, exposed to 1µM staurosporine in growth medium, were assayed after 8 hours.
Incubation medium was removed and cells were rinsed with annexin-V binding buffer
(containing 1% BSA, 140mM NaCl, 2.5mM CaCl2 and 10mM HEPES adjusted to 7.4).
Buffer was removed and a 1:100 dilution of labelled annexin-V was added. After 5 min, cells
were gently rinsed with annexin binding buffer. To ensure that the red fluorescence signals
from Alexa 568 labelled annexin–V results from the binding to translocated PS, a co–staining
with calcein-AM was performed. The accumulation of this fluorochrome in the cytoplasm
depends on the activity of esterases. Calcein is not enriched in the cytoplasm if the plasma
membrane is damaged. To examine whether the phosphatidyl turnover is accompanied by
nuclear changes, an additional staining with Hoechst 33342 was applied. Cultures were
loaded with Hoechst 33342 (0.5µg / ml) and calcein-AM (1µM final) for 2 min before
observation. Cells were imaged under phase contrast optics and with three fluorescent filter
sets (red fluorescence, Alexa-568 labelled annexin V; green fluorescence, calcein-AM; blue
fluorescence, Hoechst 33342). Experimental procedures
138
6. Materials
The following materials were used (alphabetical order):
materials purchased from
(R/S)-AP5; ketamine hydrochloride; DCKA; (R/S)-CPP;
ifenprodil; haloperidol; (+)-MK801 hydrogen maleate; D-
serine; L-glutamate hydrochloride
RBI distributed by BIOTREND Chemikalien
GmBH Köln
Ac-DEVD-CHO BACHEM Biochemica GmbH, Heidelberg
Acrylamid solution BIO-RAD
Albumine from bovine serum (BSA) fraction V FLUKA Chemie AG, Switzerland
Annexin–V (Alexa 568 labelled) Boehringer Mannheim, Germany
ATP Bioluminescence Assay Kit CLS II Boehringer Mannheim, Germany
ATP Releasing Reagent for Somatic Cells (FL-SAR) SIGMA-Aldrich, Deisenhofen, Germany
BES (N,N-bis[2-Hydroxyethyl]-2-aminoethanesulfonic
acid)
SIGMA-Aldrich, Deisenhofen, Germany
Calcein-AM Molecular Probes, Leiden, Netherlands
Cell culture materials Greiner GmbH, Frickenhausen, Germany
Cy3 conjugated rabbit anti goat polyclonal IgG Dianova, Hamburg, Germany
Cyclosporin A ALEXIS
Cyto Tox 96™ Promega, Heidelberg, Germany
Dexamethasone FLUKA Chemie AG, Switzerland
Diaphorase, Clostridium kluyveri Calbiochem, Bad Soden, Germany
dNTPs; DTT GIBCO BRL Life Technologies
Donkey anti mouse IgG
(horseradish peroxidase conjugated)
CHEMICON International Inc., Canada
ECL-Plus Kit Amersham Buchler GmbH, Germany
Fluo-4-AM Molecular Probes, Leiden, Netherlands
Fetal calf serum (FCS) Boehringer Mannheim, Germany
Geneticin (G418) GIBCO BRL Life Technologies
Glutamax I (100x); sterile filtered GIBCO BRL Life Technologies
Glycine SIGMA-Aldrich, Deisenhofen, Germany
Goat anti-NR1 polyclonal IgG (C-terminal) SANTA CRUZ Biotechnology Inc.,
HEPES (4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic
acid)
FLUKA Chemie AG, Switzerland
Hoechst 33342 Molecular Probes, Leiden, Netherlands
Human embryonal kidney cells (Hek 293) (American
Type Culture Collection CRL 1573)
Generous gift from
Prof. Dr. H. Betz (Max Planck Inst. for Brain
Research, Frankfurt, Germany)
INT (Iodonitrotetrazolium chloride) FLUKA Chemie AG, SwitzerlandMaterials
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L(tk-) cells (American Type Culture Collection CCL1.3) Generous gift from
Prof. Dr. Engels (Dept. of Organic.
Chemistry, University of Frankfurt,
Germany)
Lactate dehydrogenase from rabbit muscle Calbiochem, Bad Soden, Germany
L-Glutamine (200mM) SIGMA-Aldrich, Deisenhofen, Germany
L-Lactic acid sodium salt FLUKA Chemie AG, Switzerland
MEM non essential amino acid solution (100x); sterile
filtered
SIGMA-Aldrich, Deisenhofen, Germany
MEM with Earle´s salts w/o L-glutamine GIBCO BRL Life Technologies
MEM with Earle´s salts w/o L-glutamine, Mg
2+  and
phenolred
GIBCO BRL Life Technologies
Mouse anti-NR1 monoclonal IgG (N-terminal) CHEMICON International Inc., Canada
NAD
+ (ß-Nicotinamide adenine dinucleotide from yeast) SIGMA-Aldrich, Deisenhofen, Germany
Nucleobond AX Macherey und Nagel, Düren, Germany
Oligo d(T)12-18 GIBCO BRL Life Technologies
PBS (Buffer substance Dulbecco´s powder) SERVA, Heidelberg, Germany
pCIS vectors and respective rodent cDNAs Generous gift from
Prof. Dr. F. A. Stevenson (Dept. of
Pharmaceutical Chemistry, School of
Pharmacy, London, UK)
Penicillin-Streptomycin (10,000 IU/ml-10,000µg/ml) GIBCO BRL Life Technologies
PMSF FLUKA Chemie AG, Switzerland
pMSG vectors and respective human cDNAs Generous gift from
Dr. P.J. Whiting (Merck, Sharp and Dohme
Research Laboratories, UK)
Poly-L-lysine SIGMA-Aldrich, Deisenhofen, Germany
Primer specific for transfected hNRs GIBCO BRL Life Technologies
Protein assay BIO-RAD
PVDF-Membrane BIO-RAD
RNasin GIBCO BRL Life Technologies
SDS MERCK, Darmstadt, Germany
Sodium pyruvate 100mM solution; sterile filtered SIGMA-Aldrich, Deisenhofen, Germany
Superscript Plus GIBCO BRL Life Technologies
Sytox Molecular Probes, Leiden, Netherlands
Tacrolimus (FK 506) ALEXIS
Tris SIGMA-Aldrich, Deisenhofen, Germany
Triton X-100 FLUKA Chemie AG, Switzerland
Trypsin-EDTA-solution (10x); sterile filtered SIGMA-Aldrich, Deisenhofen, Germany
All other not further specified chemicals were obtained from Merck Darmstadt, Germany.Zusammenfassung – German summary
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7. Zusammenfassung (German summary)
Das Ziel der vorliegenden Arbeit war die Etablierung eines funktionellen in vitro Testsytems
für NMDA-Rezeptor Antagonisten. Primäre neuronale Zellkulturen weisen ein sehr
komplexes Expressionsmuster einer Vielzahl von Ionenkanälen und unterschiedlichen
Glutamatrezeptoren auf. So werden neben metabotropen (G-Protein gekoppelten)
Glutamatrezeptoren und ionotropen AMPA- und Kainatrezeptoren auch verschiedene
NMDA-Rezeptorsubtypen mit unterschiedlichem pharmakologischen Eigenschaften
exprimiert. Im Vergleich dazu ermöglicht ein heterologes Expressionssytem die
pharmakologische Charakterisierung von NMDA-Rezeptorantagonisten an molekular
definierten Rezeptoren. Hinsichtlich der Entwicklung eines „Screening“ fähigen Testsystems
stellt die fehlende Proliferation der isolierten Neurone eine weitere Limitierung dar. Aufgrund
dieser Tatsachen wurde die heterologe Expression von rekombinanten NMDA-
Rezeptoruntereinheiten in eukaryotischen Zelllinien favorisiert.
Zu Beginn der Entwicklung wurden transiente Co-Expressionen der Untereinheiten NR1-1a
(Ratte), NRε1 (NR2A; Maus) und NRε3 (NR2C; Maus) in Hek 293 Zellen durchgeführt
(Abschnitt 3.1). In den hierfür verwendeten pCIS-Konstrukten steht die Expression der
transfizierten cDNAs unter der Kontrolle des konstitutiv aktiven hCMV Promotors. Da
funktionelle NMDA-Rezeptoren Heteromultimere aus Subtypen der NR1- und NR2-Familie
darstellen, wurde die NR1-1a Untereinheit mit den Untereinheiten NRε1 bzw. NRε3 im
Verhältnis 1:3 co-transfiziert. Die Kombination aus NR1-1a / NRε1 führte nach 24 Stunden
zu einer signifikant erhöhten Zelltodrate (28,2 ± 3,7 %). Die Zelltodrate der Transfektion der
Untereinheiten NR1-1a / NRε3 (8,7 ± 2,1 %) unterschied sich dagegen nicht signifikant von
der Zelltodrate der mit dem pCIS Kontrollvektor transfizierten Kulturen (7,3 ± 2,5 %). Der
kompetitive NMDA-Rezeptorantagonist (R/S)-AP5 (150µM) reduzierte die Zelltodrate der
NR1-1a / NRε1 Transfektion auf 16,5 ± 1,5 %. Diese Ergebnisse sind in guter
Übereinstimmung mit Resultaten aus anderen Untersuchungen. Cik et al. (1993) berichteten
eine 24 Stunden Mortalität von 21,7 % für die Co-Expression von pCISNR1-1a / pCISNRε1
in Hek 293 Zellen. (R/S)-AP5 (200µM) reduzierte die Zelltodrate auf 8,3 %. Anegawa et al.
(1995) fanden nach 48 Stunden eine Mortalität von 57,9 % für die Co-Expression der
Untereinheiten NR1-1a (Ratte) und NR2A (Ratte) sowie eine im Vergleich zur Kontrolle
unveränderte Mortalität für die Co-Expression der Untereinheiten NR1-1a (Ratte) / NR2C
(Ratte).
Der unter der Co-Expression von NR1-1a / NR2A beobachtete Mortalitätsanstieg scheintZusammenfassung – German summary
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durch die Aktivierung von funktionellen NMDA-Rezeptoren durch im Zellkulturmedium
enthaltenes Glutamat und Glycin hervorgerufen zu sein, da der kompetitive
Glutamatantagonist AP5 die Zelltodrate signifikant reduzierte. Das Fehlen einer gesteigerten
Mortalitätsrate unter der Co-Expression der Untereinheiten NR1-1a / NR2C kann in der
geringeren Calcium-Permeabilität dieses NMDA-Rezeptorsubtyps begründet liegen (Monyer
et al., 1992).
Nach diesen ersten transienten Expressionsstudien wurde die Etablierung eines stabilen
heterologen Expressionssytems angestrebt. Für die stabile Expression der humanen cDNAs
der NMDA-Rezeptoruntereinheiten NR1-1a, NR2A und NR2B wurde die Maus-Fibroblasten
Zelllinie L(tk-) verwendet. Da sowohl für die Co-Expression von NR1-1a / NR2A als auch
für NR1-1a / NR2B eine erhöhte Zellmortalität beschrieben ist (Anegawa et al., 1995), mußte
ein induzierbares Expressionssystem gewählt werden. In den für die Transfektion
verwendeten Vektoren steht die Expression der transfizierten cDNAs unter der Kontrolle
eines Dexamethasone induzierbaren MMTV-Promotors (Grimwood et al., 1996a). Durch
Zusatz von Dexamethasone wird die Expression der NMDA-Rezeptoruntereinheiten und ein
damit verbundener Zelltod induziert, während unter normalen Zellkulturbedingungen in der
Abwesenheit von Dexamethasone ein normales Wachstum der Zellkulturen gewährleistet ist
(Selektion durch Hintergrundexpression wurde durch Zusatz des nicht kompetitiven NMDA-
Rezeptorantagonisten Ketamin (100µM) verhindert). Die Erhöhung der Zellmortalität unter
der Expression von funktionellen NMDA-Rezeptoren stellt das Prinzip des entwickelten
Testsystems dar, da in der Gegenwart von NMDA-Rezeptorantagonisten eine Erhöhung der
Zelltodrate unterdrückt werden kann. Die Co-Transfektionen wurden in einem Vektor-
Verhältnis von 1:5 (NR1 : NR2) durchgeführt. Nach vierwöchiger Selektionierung mit
Geneticin (2mg/ml) und anschließender Klonierung durch limitierende Verdünnung wurden
verschiedene Zelllinien erhalten, die für funktionelle Experimente in einem Zeitraum von
mehr als 90 Passagen (~ 45 Wochen) verwendet werden können. Nach Screening-Versuchen
mit verschiedenen NMDA-Rezeptorantagonisten (Abschnitt 3.2.3) wurden die Klone L12-
G10 (NR1-1a / NR2A) und L13-E6 (NR1-1a / NR2B) zur molekularbiologischen
Charakterisierung herangezogen. Die RT-PCR Analyse (Abschnitt 3.3.1) des Klones L12-
G10 ergab für ein Differenzierungsintervall von 12 Stunden mit 2µM Dexamethasone einen
5-fachen Anstieg der mRNA für die Untereinheit NR1-1a und einen 2,3-fachen Anstieg für
NR2A. Analoge Ergebnisse wurden für den Klon L13-E6 erhalten, der einen 4,8-fachen
Anstieg der NR1-1a mRNA und einen 3,5-fachen Anstieg der NR2B mRNA zeigte. Diese
Ergebnisse zur Transkription der transfizierten Untereinheiten sind in Übereinstimmung mitZusammenfassung – German summary
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Untersuchungen zum immunologischen Nachweis der exprimierten NR1-1a Untereinheit. Die
Westernblot-Analyse von Zelllysaten ergab ein Maximum an NR1-1a Protein zwischen 8 und
16 Stunden nach Induktion mit Dexamethasone. NR1-1a Protein konnte dagegen weder in
L(tk-) Wildtyp Zellen noch in nicht induzierten Klonen nachgewiesen werden (Abschnitt
3.3.2). Die Größe des 116 kDa Proteins ist in Übereinstimmung mit dem detektierten Protein
aus Rattenhirn Membranhomogenaten und dem aus der Aminosäuresequenz unter
Vernachlässigung der Glykosilierung abgeleiteten Molekulargewicht von 103,5 kDa. Die
immunozytochemische Untersuchung der Lokalisation der NR1-1a Untereinheit mittels
confocaler Lasermikroskopie ergab den Nachweis größerer Mengen an NR1-1a
Rezeptorprotein innerhalb der Zytoplasma Membran (Abschnitt 3.3.3). Da gezeigt werden
konnte, dass die Co-Expression der NR2 Untereinheit für eine erfolgreiche
Oberflächenexpression der NR1-Untereinheit notwendig ist (McIlhinney et al., 1996), kann
aus diesen Ergebnissen auf eine Co-Lokalisation der transfizierten NMDA-
Rezeptoruntereinheiten innerhalb der Zytoplasma Membran geschlossen werden. Diese
Schlußfolgerung wurde durch Ergebnisse aus Calcium Video-Imaging Untersuchungen
bestätigt (Abschnitt 3.3.4). Hierfür wurden beide Klone für 16 bis 20 Stunden mit
Dexamethasone und Ketamin behandelt. Nach Beladung der Zellen mit dem Calcium
sensitiven Fluorochrome Fluo-4, der Entfernung von Ketamin und anschließender Stimulation
mit L-Glutamat und Glycin konnte in beiden Klonen ein starker Anstieg der intrazellulären
Ca
2+-Konzentration ([Ca
2+]i) festgestellt werden. Die anschließende Zugabe der nicht
kompetitiven Antagonisten Ketamin oder MK801 führte zum Absinken der [Ca
2+]i auf ein
basales Niveau. Da die alleinige Expression der NR1 Untereinheit in eukaryotischen Zellen
nicht zur Ausbildung funktioneller Ionenkanäle führt, kann anhand dieser Ergebnisse
ebenfalls auf eine funktionelle Co-Lokalisation der transfizierten cDNAs an der
Zelloberfläche geschlossen werden.
Zur Bestimmung der auftretenden Exzitotoxizität nach Induktion der NMDA-
Rezeptorexpression wurde eine Methode etabliert, die die Freisetzung von Lactat-
Dehydrogenase (LDH) aus lysierten, nekrotischen Zellen nutzt (Abschnitt 3.4.1). Die
Aktivität der von lysierten Zellen abgegebenen LDH kann direkt aus dem Zellkulturmedium
bestimmt werden. Der hierfür selbst entwickelte „Assay-Mix“ enthält ca. 1 % Natrium-L-
Lactat, 0,1 % NAD
+, 0,08 % Albumin, 18 U / ml Diaphorase und 0,4 %
Iodnitrotetrazoliumchlorid (INT). Das Prinzip der Methode stellt eine gekoppelte
Enzymreaktion dar: Die die Reaktionsgeschwindigkeit limitierende LDH-Aktivität katalysiert
die Reduktion von NAD
+ zu NADH + H
+, welches als Substrat für die Reduktion desZusammenfassung – German summary
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farblosen INT zum Rot gefärbten Formazan dient. Die Menge an gebildeten Formazan ist
direkt proportional zur eingesetzten LDH-Aktivität und kann im 96-well-Format bei 490nm
photometrisch bestimmt werden. Die Reaktion folgt bei 25°C einer klassischen Michaelis-
Menten Kinetik mit einer pseudo Michaelis-Konstanten von ca. 17mU LDH / 50µl. Die zu
bestimmenden Proben sollten deshalb weniger als 10mU LDH / 50µl Zellkulturmedium
enthalten. Die hohe Präzision und Richtigkeit der Methode wurde in einem Meßbereich von 0
bis 7,5 mU LDH / ml Zellkulturmedium mit Variationskoeffizienten von < 4 % sowie relative
Fehlern < 3 % belegt.
Zur Testung von NMDA-Rezeptorliganden wurden zwei verschiedene Versuchsdesigns
entwickelt und charakterisiert (Abschnitt 3.4.2). Bei dem als Induktionsmodell bezeichneten
Verfahren werden über Nacht 15 x 10
3 Zellen pro well angesetzt. Am nächsten Tag erfolgt die
Induktion der NMDA-Rezeptorexpression unter Zugabe von Dexamethasone und
gleichzeitigem Zusatz der zu testenden Rezeptorantagonisten. Die Stimulation der
rekombinanten Rezeptoren erfolgt durch die im zugesetzten foetalen Kälberserum (5% FKS)
enthaltenen Co-Agonisten Glutamat und Glycin. Die Zelltodrate wird nach 20 bis 24 Stunden
unter Verwendung des entwickelten „LDH Assays“ bestimmt. 
Um die Anwendbarkeit dieser Methode zu zeigen, wurde für eine Serie von Thieno[2,3-
b]pyridinonen (C. Noe, Institut für Pharmazeutische Chemie, Universität Wien) auf ihre
Zytoprotektivität getestet (Abschnitt 3.4.3). Diese Verbindungen stellen Bioisostere zu L-
701,324 dar, einem hochaffinen Glycin-Antagonisten mit in vivo Aktivität. Die Affinität der
einzelnen Verbindungen zur Glycin-Bindungsstelle von NMDA-Rezeptoren aus
Hippocampus-Membranen der Ratte wurde durch [
3H]-Glycin Bindungsstudien
charakterisiert (M. Berger, Institut für Hirnforschung, Universität Wien). Aufgrund der
Verfügbarkeit von Ki-Werten stellt diese Verbindungsklasse somit ein geeignetes Test-Set zur
Überprüfung der Anwendbarkeit der entwickelten Methode in QSAR-Studien dar. Für die
neun hochaffinen Substanzen, die mit beiden Methoden charakterisiert werden konnten, ergab
sich eine gute Korrelation zwischen den ermittelten IC50-Werten im Exzitotoxizitätsmodell (4
bis 90 µM) und den Ki-Werten der Bindungsexperimente (1 bis 290 nM) (Korrelations-
koeffizient = 0,90; P = 0,001). Unter Verwendung des Albumin-Kompetitors Warfarin konnte
gezeigt werden, dass die entwickelte Zellkulturmethode im Gegensatz zu den
Bindungsexperimenten auch die für Glycin-Antagonisten typische und als problematisch zu
bewertende Bindung zu Plasmaalbumin berücksichtigt. Da eine hohe Bindungrate an
Plasmaalbumin in vivo die Penetration der Verbindungen ins ZNS behindert und somit die
zentrale Bioverfügbarkeit herabsetzt (Rowly et al., 1997b), stellt die Berücksichtigung diesesZusammenfassung – German summary
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Parameters sicherlich einen Vorteil gegenüber anderen Routinemethoden wie Radioligand-
Bindungsstudien oder elektrophysiologische Untersuchungen dar.
Aufgrund des durch FKS verursachten hohen Glycingehaltes und der geringen Löslichkeit der
Verbindungen im Inkubationsmedium, konnten Substanzen mit „niederer“ Affinität nicht
charakterisiert werden. Deshalb wurde ein Test-Design entwickelt, dass die Charakterisierung
von Agonisten und Antagonisten unter definierteren Bedingungen erlaubt. Bei diesem als
Differenzierungsmodell bezeichneten Design (Abschnitt 3.4.2) werden die Zellkulturen für 20
bis 24 Stunden mit Dexamethasone in der Gegenwart von Ketamin differenziert. Nach
anschließender Entfernung des Ketamin werden die zu untersuchenden Substanzen in einer
kontrollierten Salzlösung unter definierten Bedingungen (variierbarer pH-Wert und Agonist-
Konzentrationen) für 60 bis 90 Minuten bei 37°C inkubiert und anschließend die Zelltodrate
bestimmt. Aufgrund des wesentlich verkürzten Test-Intervalls kann sowohl auf sterile
Bedingungen als auch auf den Zusatz von FKS verzichtet werden. Dieses Design erlaubte
eine umfassende pharmakologische Charakterisierung der Klone L12-G10 und L13-E6. Die
hier ermittelten pharmakologischen Profile der beiden Klone reflektieren die
unterschiedlichen Eigenschaften der exprimierten Rezeptoren (NR1-1a / NR2A gegenüber
NR1-1a / NR2B). 
Es konnte eine Abhängigkeit der Rezeptoraktivität vom pH-Wert des verwendeten
Inkubationsmediums gezeigt werden (Abschnitt 3.4.5.1). Protonen inhibieren die maximale
Zelltodrate mit IC50-Werten nahe des physiologischen pH-Wertes von 7,4. Für Klon L12-G10
wurde ein IC50 von pH 7,2 ermittelt, während Klon L13-E6 eine noch größere Sensitivität für
Protonen mit einem IC50 von pH 7,5 aufzeigt. Diese Ergebnisse sind in guter
Übereinstimmung mit elektrophysiologischen Untersuchungen zur Inhibition von NMDA-
Rezeptoren durch Protonen (Traynelis et al., 1995). Für die in Xenopus Oozyten exprimierten
NR1-1a / NR2A-Rezeptoren wurde ein IC50 von pH 7,2 berichtet, während NR1-1a / NR2B
Rezeptoren mit einem IC50 von pH 7,3 bestimmt wurden. Aufgrund der gezeigten Sensitivität
gegenüber Protonen sollten funktionelle Experimente an NMDA-Rezeptoren nur unter strikter
Kontrolle des pH-Wertes durchgeführt werden.
Es konnte weiterhin gezeigt werden, dass der in beiden Zelllinien auftretende Zelltod von der
applizierten Dosis an Glutamat abhängig ist (Abschnitt 3.4.5.3). Für die Zelllinie L12-G10
wurde unter sättigenden Glycinkonzentrationen ein EC50 von 3,4µM (3,7µM; 3,1µM)
ermittelt. Für Klon L13-E6 ergab sich ein EC50 von 2,7µM (2,8µM; 2,6µM). Der auftretende
Zelltod wurde durch den Zusatz von Glycin oder D-Serin verstärkt, jedoch konnte keine
klassische Dosis-Wirkungsbeziehung für diese Substanzen gezeigt werden. Dies liegtZusammenfassung – German summary
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wahrscheinlich in Glycin Kontaminationen begründet, die durch das Waschen der
Zellkulturen mit 1% BSA enthaltendem MEM-Medium hervorgerufen werden (Auswaschen
von Ketamin zur Aktivierung der exprimierten NMDA-Rezeptoren). BSA wurde zur
Verstärkung der Zelladherenz zugesetzt und konnte nicht durch andere Polymere wie z.B.
Dextran ersetzt werden. Dagegen konnten in Kompetitionsversuchen mit dem Glycin-
Antagonisten DCKA (100µM) klassische Dosis-Wirkungskurven beobachtet werden. Der
Vergleich der hierfür erhaltenen EC50-Werte für Glycin und D-Serin weist auf eine Präferenz
des Klons L13-E6 (NR1-1a / NR2B) für Agonisten an der Glycin-Bindungstelle hin, da die
EC50-Werte für Klon L12-G10 (NR1-1a / NR2A) um Faktor 2 bis 3 höher liegen. Ebenso war
in Kompetitionsversuchen mit dem Glutamat-Antagonisten (R/S)-CPP eine Präferenz für
Agonisten an der Glutamat-Bindungsstelle evident. L-Glutamat und L-Aspartat zeigten
hierbei eine wesentlich höhere Wirksamkeit an Klon L13-E6 als an Klon L12-G10 (s.
Abschnitt 3.4.5 Tab.7). Dagegen zeigen die ermittelten IC50-Werte für den Glutamat-
Antagonisten (R/S)-AP5 und den Glycin-Antagonisten DCKA eine ca. 7-fach höhere
Effizienz an L12-G10 Zellen an. Der offene Kanalblocker Ketamin diskriminiert dagegen
nicht zwischen beiden Klonen. Diese Ergebnisse sind in Übereinstimmung mit Patch-Clamp
Studien an NMDA-Rezeptor exprimierenden Xenopus Oozyten (Hess et al., 1996) und der
Existenz von Agonist oder Antagonist bevorzugenden NMDA-Rezeptoren in vivo. 
Im Vergleich zu D-Serin war die Wirksamkeit von Glycin an beiden Klonen leicht erhöht,
was ebenfalls mit früheren Beobachtungen übereinstimmt (Matsui et al., 1995). Die Effizienz
von L-Glutamat ist im Vergleich zu L-Aspartat 7- bis 10-fach höher.
Die NR2B selektiven allosterischen Antagonisten Ifenprodil und Haloperidol zeigten
zytoprotektive Effekte an Klon L13-E6 (NR1-1a / NR2B) (IC50  Ifenprodil = 0,15 ± 0,02 µM;
IC50 Haloperidol = 2,2 ± 1,5 µM), blieben aber in der Testung an Klon L12-G10 (NR1-1a /
NR2A) in Konzentrationen bis zu 100µM ohne Effekt (Abschnitt 3.4.5.5). Diese Ergebnisse
bestätigen frühere Studien, die eine NR2B-Selektivität für Ifenprodil (Williams et al., 1993a)
und Haloperidol (Ilyin et al., 1996) beobachteten. Die berichteten IC50-Werte für Ifenprodil
(0,34µM) und Haloperidol (3µM) stimmen mit den ermittelten IC50-Werten überein.
Für das positiv modulatorische Polyamin Spermin (300µM) konnte ebenfalls eine Selektivität
zugunsten des Klons L13-E6 gezeigt werden (Abschnitt 3.4.5.2). Das Ausmaß dieser
glycinunabhängigen Verstärkung der Zelltodrate durch Spermin war abhängig vom pH-Wert
des Inkubationsmediums und stieg mit steigender Inhibition durch Protonen an. An L12-G10
Zellen blieb Spermin dagegen ohne signifikanten Effekt. Diese Ergebnissen bestätigen, dass
Polyamin-Effekte nur an solchen Rezeptoren auftreten, an denen neben bestimmten NR1-Zusammenfassung – German summary
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Speißvarianten wie NR1-1a (Abwesenheit von Exon 5!) die Untereinheit NR2B beteiligt ist.
Die pH-Wert Abhängigkeit des beobachteten Effektes weist darauf hin, dass der
glycinunabhängige positiv modulatorische Effekt der Polyamine über eine Aufhebung der
Inhibition durch Protonen vermittelt wird. Somit sind diese Beobachtungen in
Übereinstimmung mit dem von Traynelis (1995) vorgeschlagenen Mechanismus zur
glycinunabhängigen Stimulation von NMDA-Rezeptoren durch Polyamine.
Obwohl für die NR2B selektiven Verbindungen Ifenprodil und Haloperidol bereits früher eine
Interaktion mit der Polyamin-Bindungstelle des NMDA-Rezeptors diskutiert wurde, zeigen
diese Verbindungen auch in der Abwesenheit von Spermin starke zytoprotektive Wirkung
(s.o.). Eine zusätzliche Kompetition um die Polyamin-Bindungstelle scheint allerdings nicht
vorzuliegen, da unter Zusatz von 300µM Spermin die Dosis-Wirkungskurve nicht parallel
verschoben wird. Die Zelltodrate wird lediglich bei nicht voll inhibierenden Konzentrationen
an Ifenprodil oder Haloperidol erhöht. Somit scheint eine allosterische Interaktion dieser
Verbindungen wahrscheinlicher zu sein. Die diskutierten Experimente wurden bei einem pH-
Wert von 8,0 durchgeführt wurden, bei dem normalerweise keine Inhibition durch Protonen
mehr vorliegt. Da Spermin seinen positiv modulatorischen Effekt normalerweise über eine
Aufhebung der Inhibition durch Protonen vermittelt, könnte die teilweise Aufhebung der
zytoprotektiven Effekte von Ifenprodil und Haloperidol durch Spermin darauf hinweisen, dass
die Zytoprotektivität dieser Verbindungen in einer Erleichterung der Inhibition durch
Protonen begründet liegt. Diese Interpretation der Ergebnisse ist in Übereinstimmung mit dem
von Mott et al. (1998) vorgeschlagenem Mechanismus zur allosterischen Blockade von
NMDA-Rezeptoren durch Phenylethanolamine. 
In Übereinstimmung mit früheren Beobachtungen (Williams et al., 1993b) traten Histamin-
Effekte nur an dem NR1-1a / NR2B exprimierenden Klon L13-E6 auf (Abschnitt 3.4.5.6).
Anstatt einer Erhöhung der NMDA-Rezeptoraktivität (Bekkers, 1993; Vorobjev et al., 1993;
Zwart et al., 1996) wurde jedoch eine dosisabhängige Inhibition des Zelltodes beobachtet.
Diese Unterschiede könnten auf unterschiedliche pH-Bedingungen zurückzuführen sein.
Saybasili et al. (1995) beobachteten für Histamin bei pH-Werten um pH 7,2 eine Verstärkung
von NMDA induzierten Strömen, während bei einem erhöhten pH-Werten von 7,6 eine
Reduktion der Ströme auftrat. Die Behandlung der Klone L12-G10 bzw. L13-E6 mit dem
Protein Kinase C (PKC) Aktivator TPA (100nM) bei gleichzeitiger Stimulation der NMDA-
Rezeptoren führte nicht zu einer erhöhten Mortalität (Abschnitt 3.4.5.6), obwohl
elektrophysiologische Untersuchungen eine Verstärkung der NMDA-Rezeptoraktivität durch
Phosphorylierung der beteiligten NR1 Untereinheit zeigten (Chen et al., 1991; Kelso et al.,Zusammenfassung – German summary
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1992). Es muß dabei aber berücksichtigt werden, dass verschiedene Spleißvarianten eine
unterschiedliche Sensitivität gegenüber der PKC aufweisen (Tingley et al., 1993) und die
Untereinheit NR1-1a nur eine dreifache Erhöhung der Spitzenströme aufzeigte. Andererseits
kann bereits ein hohes basales Phosphorylierungsniveau vorliegen, vergleichbar dem der in
Hek 293 Zellen exprimierten Rezeptoren (Tingley et al., 1993).
Für Untersuchungen zur Ca
2+ induzierten mitochondrialen Schädigung als Ursache für den
NMDA-Rezeptor vermittelten Zelltod wurde Cyclosporin A (CsA) verwendet. CsA ist ein
Inhibitor der sogenannten „permeability transition pore“ (PTP), einer Ca
2+ induzierbaren Pore
innerhalb der inneren mitochondrialen Membran. Die Induktion dieser PTP führt zu einer
Depolarisation der inneren mitochondrialen Membran und mit dem Verlust des
Membranpotentials ∆ψ zu einer Entkopplung der mitochondrialen Atmungskette und zum
Abfallen der intrazellulären ATP-Spiegel. Eine mehrstündige Vorbehandlung mit CsA führte
nach anschließender Stimulation zu einer signifikanten Reduktion der Zellmortalität um
maximal 40 bis 60% (IC50 ~ 7µM) (Abschnitt 3.5). Da CsA ebenfalls die NMDA-Rezeptor
regulierende Ca
2+/Calmodulin abhängige Ser/Thr-Phosphatase Calcineurin inhibiert, wurde
der selektive Calcineurin Inhibitor FK506 (Tacrolimus) auf seine zytoprotektiven
Eigenschaften getestet. Für eine mehrstündige Vorbehandlung mit FK506 konnten keine
signifikanten zytoprotektiven Effekt gezeigt werden. Deshalb kann der zytoprotektive Effekt
von CsA nicht durch Inhibition von Calcineurin vermittelt sein. Überraschenderweise wurde
aber festgestellt, dass CsA mit der Expression der transfizierten NMDA-
Rezeptoruntereinheiten interagiert. Eine sechsstündige Vorbehandlung der NMDA-Rezeptor
induzierten Zellen mit 30µM CsA reduzierte die Menge an NR1-1a Protein um ~70%. Dieser
Effekt könnte mit einer CsA vermittelten Inhibition der Peptidyl-Prolyl-Isomerase-Aktivität
von Cyclophilinen zusammenhängen (Chen et al., 1998; Helekar et al., 1994). Diese im
Zytoplasma, im ER und in Mitochondrien vorkommenden Immunophiline sind an der Faltung
von Polypeptiden ähnlich den klassischen „heat shock“ Proteinen (Chaperone) beteiligt. Da
gezeigt werden konnte, dass heterolog exprimierte NMDA-Rezeptoren innerhalb des ER
assembliert werden und zur Oberflächenexpression eine Co-Synthese von NR1 und NR2
Untereinheiten notwendig ist (McIlhinney et al., 1998), kann somit auch von einer
Beeinflussung der Oberflächenexpression der transfizierten NR2 Untereinheiten ausgegangen
werden. Calcium Video Imaging Studien belegten den Verlust funktioneller NMDA-
Rezeptoren nach mehrstündiger Vorbehandlung mit 30µM CsA. Im Gegensatz zur
mehrstündigen Präinkubation von 30µM CsA führte ein kurzes Vorbehandlungsintervall von
10 min bei pH 7,6 zu keinem zytoprotektiven Effekt. Dagegen konnte bei eingeschränkterZusammenfassung – German summary
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Rezeptoraktivität (pH 7,0) die Zelltodrate um 40% gesenkt werden (FK506 ohne signifikanten
Effekt!). Insofern kann eine zusätzliche Beeinflussung der PTP durch CsA nicht
ausgeschlossen werden. Um die Beteiligung einer mitochondrialen Schädigung nach
Stimulation heterolog exprimierter NMDA-Rezeptoren eingehender zu charakterisieren,
sollten in zukünftigen Studien selektivere PTP-Inhibitoren wie Bongkrekische Säure oder
Inhibitoren der mitochondrialen Ca
2+-Speicherung wie „ruthenium red“ oder FCCP
Verwendung  finden. Nach Untersuchungen zur Charakterisierung des vorherrschenden
Zelltodtyps kann auf einen vorwiegend nekrotischen Zelltod geschlossen werden. Der
auftretende Zelltod ist in beiden Modellen durch einen raschen Verlust der Integrität der
Zytoplasma Membran gekennzeichnet (Abschnitt 3.6.2). Die für apoptotische Prozesse
charakteristischen nukleären Veränderungen des Chromatins wie Kondensation und DNA-
Fragmentierung konnten weder mit FACS-Analysen noch mit fluoreszenzmikroskopischen
Methoden beobachtet werden.
Das fehlende Auftreten von Apoptose in den entwickelten Exzitotoxizitätsmodellen steht in
Kontrast zur neuronalen Glutamat induzierbaren Zytotoxizität in vivo und in vitro. Als
Ursache hierfür sind Unterschiede im Ca
2+-Metabolismus (z.B. das Fehlen wichtiger Ca
2+-
Transporter wie dem Na
+ abhängigen Ca
2+-Austauscher) zu sehen. Der Mangel an einer
effizienten Ca
2+-Regulation kann zu einer verstärkten Ca
2+-Speicherung innerhalb der
Mitochondrien, dem Zusammenbruch von ∆ψ, dem Verlust der oxidativen Phosphorylierung
mit anschließendem Abfall der ATP-Spiegel und Generierung reaktiver Sauerstoffspezies
(Peroxiden und Superoxidradikalen) führen. Dieser Abfall der ATP-Spiegel kann durch einen
erhöhten ATP-Bedarf für Membranpumpen (z.B. Ca
2+-ATPase) noch verstärkt werden. Der
gemessene Ca
2+ abhängige Abfall der ATP-Spiegel während der Stimulation der heterolog
exprimierten NMDA-Rezeptoren (Abschnitt 3.5) weist auf eine solche mitochondriale
Schädigung hin. Da eine Aufrechterhaltung der intrazellulären ATP-Spiegel als
Voraussetzung für Entwicklung apoptotischer Prozesse angesehen wird (Nicotera et al., 1998;
Leist et al., 1999), erklärt dies die nach Stimulation der heterologen NMDA-Rezeptoren rasch
eintretende Nekrose. 
Zusammenfassend kann gesagt werden, dass das Ziel der Etablierung eines funktionellen in
vitro Testsystems zur Charakterisierung von NMDA-Rezeptorliganden erreicht wurde. Die
mit humanen NMDA-Rezeptoruntereinheiten stabil transfizierten Zelllinien wurden
molekularbiologisch eingehend charakterisiert und die Funktionalität der exprimierten
Rezeptoren mit verschiedenen Methoden belegt. Auf der Basis der nach Stimulation der
ligandgesteuerten Ionenkanäle rasch auftretenden Nekrose wurden zwei eingehendZusammenfassung – German summary
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untersuchte in vitro Modelle entwickelt, die der pharmakologischen Charakterisierung der
vorgestellten Zelllinien dienten. Es konnte gezeigt werden, dass die unterschiedlichen
pharmakologischen Profile der Zelllinien in der jeweiligen molekularen Zusammensetzung
der exprimierten heteromultimeren Rezeptoren begründet liegen. 
Abschließend bleibt festzuhalten, dass die hier vorgestellten, auf exzitotoxischen Prozessen
basierenden Modelle im Vergleich zu elektrophysiologischen Methoden und Radioligand-
Bindungsstudien experimentell sehr einfache, aber zugleich pharmakologisch valide
Testsysteme darstellen, die der weiteren Untersuchung humaner NMDA-Rezeptoren, dem
Screening neuer NMDA-Rezeptorliganden sowie der Verbesserung von Leitstrukturen in
QSAR-Studien dienen können.References
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